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Chapter 1
1.1 Dementia
Dementia is the overall-embracing term for clinical syndromes that are related to decline 
in mental abilities, and is caused by a broad spectrum of neurodegenerative brain diseases. 
The most common forms of dementia are Alzheimer’s disease (AD), vascular dementia 
(VaD), frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB) (figure 1). 
These diseases are characterized in general by symptoms of cognitive decline, often 
accompanied by impairment in language and executive skills, and changes in behavior 
[1].	Dementia	in	 its	sporadic	form,	typically	affects	people	aged	≥60	years.	 In	2010,	the	
prevalence of dementia has been estimated to be 4.7% worldwide, and is predicted to 
double every 20 years [2]. Different dementia disorders have in common the irreversible 
damage and loss of neurons. The underlying cause of this neuronal loss is different in 
each dementia disorder, and symptoms therefore also differ slightly between distinct 
dementia types. However, symptoms also often display large overlap and patients can 
suffer from mixed dementia (more than one dementia disorder).
 
1.1.1 Dementia disorders
Alzheimer’s disease (AD)
AD is the most common form of dementia and accounts for about 60-80% of cases. The 
first clinical signs of AD are loss of short term memory and disturbances in attention 
and spatial orientation, which are followed by impairment in language and changes 
in personality [3]. Symptoms get gradually more severe and patients may suffer from 
restlessness, disorientation and hallucinations. In patients with late stage AD, motor 
functions such as talking, walking and swallowing will be severely impaired, leading 
ultimately to death. AD was first described in 1907 by the German psychiatrist and 
pathologist Alois Alzheimer, who had discovered the accumulation of senile plaques 
in the brains of patients who suffered from mental decline, language and behavioral 
impairment [4]. Since then, extracellular plaques, mainly formed by the protein 
amyloid-β	 (Aβ),	 together	 with	 intracellular	 neurofibrillary	 tangles	 (NFTs),	 consisting	 of	
the hyperphosphorylated tau protein, are recognized as the key hallmarks in AD, and are 
used for postmortem identification and staging of the disease. Both structures appear 
primarily in the entorhinal cortex and the hippocampus of the brain, which are the sites 
of memory formation [5]. AD pathology is described in more detail in subchapter 1.2, and 
AD diagnosis in subchapter 1.3 and 1.4.
13
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Vascular dementia (VaD)
VaD is less common as a sole cause of dementia (~20% of dementia cases worldwide), 
and often patients with AD also display brain abnormalities that are typical for VaD 
[6, 7]. The National Institute of Neurological Disorders and Stroke and the Association 
Internationale pour la Recherche et  l’Enseignement en Neurosciences (NINDS-AIREN) 
criteria were formulated in 2003, and are used to identify VaD cases [7]. VaD can be 
distinguished clinically from AD by differences in the onset of memory impairment, which 
is initially mild in VaD patients, whereas in AD memory loss is one of the first symptoms 
[8]. Furthermore, VaD is more characterized by impairment of executive functions such 
as planning and sequencing, performance on unstructured tasks, attention and language 
production [9]. However, it remains difficult to distinguish AD and VaD based on clinical 
investigations only, since symptoms often do overlap. Sporadic VaD develops due to 
infarcts in the brain that are caused by atherosclerosis in the vascular system. Primarily, 
the frontal lobe of the cortex is affected [10]. Also white matter lesions are a common 
feature of VaD [11]. A rather rare familial variant of VaD exists, which is called “cerebral 
autosomal dominant arteriopathy with subcortical infarts and leukoenephalopathy” 
(CADASIL) and is caused by mutations in the Notch 3 gene [12].
Figure 1: Prevalence of the most common dementias
Diagram	of	the	prevalence	of	Alzheimer’s	disease	(blue),	vascular	dementia	(purple),	dementia	with	Lewy	
bodies	(green)	and	frontotemporal	dementia	(red).	Dementia	disorders	have	much	overlap	in	their	clinical	
manifestations,	 which	 makes	 exact	 differentiation	 difficult.	 The	 percentages	 are	 therefore	 estimated	
numbers.	Other	causes	of	dementia	are	for	simplicity	not	depicted	in	this	figure.
14
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Dementia with Lewy bodies (DLB)
DLB accounts for 10-15% of dementia cases at autopsy and is thought to be the third most 
common type of dementia after AD and VaD [13]. This dementia disorder is recognized by 
a complex combination of symptoms such as cognitive impairment, autonomic and motor 
disturbances and behavioral changes [14]. Other typical clinical symptoms in DLB are 
visual hallucinations that are associated with deficits in cortical acetylcholine [15, 16]. The 
pathological hallmarks of DLB are neuronal Lewy bodies, which are inclusions containing 
aggregates	of	α-synuclein.	These	Lewy	bodies	are	also	a	hallmark	of	Parkinson’s	disease.	
A correct diagnosis of DLB is of particular importance, since patients have responded well 
to a treatment with cholinesterase inhibitors, but do suffer from severe side effects of 
other neuroleptic drugs [17]. 
Frontotemporal dementia (FTD)
Symptoms of FTD are often recognized at a younger age (45-65 years) than in AD, 
and FTD is in this age group the second most common dementia type (~20%) [18]. In 
general, neurons of the frontal and temporal lobe, hence the name FTD, are affected 
[19]. Patients in the early disease stage suffer primarily of changes in personality and 
behavior, and language problems [20]. However, the clinical symptoms of FTD can display 
heterogeneous phenotypes and FTD is subdivided into three clinically-based syndromes: 
The behavioral variant (bvFTD) with progressive behavioral impairment and decline in 
executive function, the non-fluent variant of primary progressive aphasia (PPA) with 
expressive or motor speech deficits, and the semantic variant of PPA (also called semantic 
dementia) with loss of object knowledge [18]. Of these FTD syndromes, bvFTD accounts 
for ~70% of all FTD cases. Symptoms of FTD and other neurodegenerative diseases often 
overlap with each other, for instance 10-30% of patients who were clinically diagnosed 
with FTD, are found to have AD pathology at autopsy [21]. Neuropathologically, FTD is 
characterized by protein aggregates in the brain, which again differentiate FTD cases into 
several subtypes, which however do not correspond to the clinical FTD syndromes. The 
most common neuropathological subtypes are FTD-tau with intracellular tau aggregates, 
FTD-TDP with inclusions containing the TAR DNA-binding protein (TDP-43), and FTD-FUS 
with aggregates of the protein fused-in-sarcoma (FUS). Most cases of FTD are sporadic, 
but a considerable number (~25%) has familial FTD that can be caused by different 
mutations [22]. These include mutations in the MAPT gene encoding the tau protein, the 
gene encoding progranulin and C9ORF72 repeat expansions. Rarely, also mutations of the 
TDP-43 gene appear, although these mutations are more common in familial amyotrophic 
lateral sclerosis (ALS) [21].
1.1.2 Mild cognitive impairment (MCI)
MCI is a general term that indicates a subtle but measurable memory disorder, thus 
subjects with MCI suffer from memory problems that are greater than normally expected 
with aging but do not show other symptoms of dementia [23]. In literature several terms 
of MCI are handled, for instance amnestic versus non-amnestic or single versus multi-
domain MCI [24]. However, general criteria to identify MCI cases were formulated in 2011 
by the NIA-AA (see subchapter 1.3.1) [25]. The annual rate of MCI patients that progress 
to AD (MCI due to AD, in short MCI-AD) is 10-15% [26-28], but subjects with MCI might 
15
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also progress to another dementia type or remain stable. Two studies even showed that 
more than one-third of MCI patients may return to normal cognition [29, 30]. Based on 
only clinical assessments, the identification of MCI-AD remains a major challenge, but is 
of great importance, since therapeutic interventions that are currently developed and 
tested in AD might be more beneficial when applied as early as possible. 
1.2 AD pathology
In the Netherlands, dementia was one of the most important causes of death in 2014, of 
which AD comprised 25% [31]. The prevalence of AD increases exponentially with age [2]. 
The majority of AD patients have sporadic AD and most of them develop the disease above 
the age of 65 years. A small percentage (<1%) are familial AD cases that mostly develop 
AD with early-onset [32]. Usually, patients with familial AD carry inherited mutations that 
affect	 the	 synthesis	 of	 the	protein	 amyloid-β	 (Aβ).	 The	mutations	 are	 identified	 in	 the	
gene	encoding	the	Aβ	precursor	protein	(APP)	[33],	or	in	the	genes	encoding	the	enzymes	
presenilin 1 and 2 (PSEN1, PSEN2) [34, 35]. The knowledge that comes from familial AD 
together	 with	 the	 observation	 that	 Aβ	 and	 its	 aggregates	 are	 the	 major	 components	
of senile plaques that are prominently present in AD brains, led to the idea that the 
accumulation	of	Aβ	in	the	brain	initiates	the	development	of	AD,	an	idea	also	referred	to	
as	the	“amyloid	cascade	hypothesis”	[36,	37].	According	to	this	hypothesis,	Aβ	aggregates	
cause stress in the brain which leads to neuronal dysfunction and death and subsequently 
to dementia [38]. There is evidence that the formation of NFTs is a downstream event 
which	is	induced	by	Aβ,	but	the	exact	underlying	molecular	link	has	not	yet	been	identified.	
Furthermore, anti-amyloid clinical trials have not yet proven successful therapies against 
AD, which raises question marks to the validity of the amyloid cascade hypothesis and 
Aβ	as	the	only	inducer	of	AD	[39].	Nonetheless,	Aβ	and	the	tau	protein	compose	the	key	
neuropathological hallmarks of AD and are the best studied proteins with respect to this 
disease. A third protein, apolipoprotein E (ApoE), has got much attention as important 
genetic risk factor for AD (see for more details subchapter 1.2.3).
1.2.1 Amyloid-β
Aβ	 is	 produced	 by	 several	 cell	 types	 in	 the	 brain,	 but	 in	 particular	 by	 neurons	 [40-42].	
The protein is produced by cleavage from the transmembrane protein APP, a process 
which involves several enzymes and produces several by-products (reviewed in [43]). The 
enzymes	designated	 as	 secretases	 cleave	APP	 in	 two	distinct	 pathways	 (figure	 2).	 In	 the	
non-amyloidogenic	pathway,	APP	is	cleaved	by	α-secretase,	which	results	in	the	production	
of	the	extracellular	soluble	APP-α	(APPsα)	and	the	membrane	bound	C-terminal	fragment	
(CTF	 or	 C)83.	 Next,	 C83	 is	 further	 cleaved	 by	 γ-secretase,	 which	 results	 in	 the	 soluble	
fragment	p3	and	the	intracellular	fragment	C59.	In	this	pathway	no	Aβ	protein	is	produced.	
In	the	amyloidogenic	pathway,	APP	is	first	processed	by	the	enzyme	β-secretase	(or	beta-
site	APP	cleaving	enzyme	1;	BACE1)	and	 then	γ-secretase,	of	which	 the	endproducts	are	
intracellularly	 C59,	 and	 extracellularly	 soluble	 APP-β	 (APPsβ)	 and	 Aβ.	 Aβ	 is	 produced	 in	
different	isoforms	that	vary	in	length	between	39-43	amino	acids.	While	Aβ40	is	the	most	
common	isoform,	Aβ42	is	more	susceptible	to	aggregation	[44].	The	aggregation	process	of	
Aβ	is	rather	complex,	and	aggregates	of	all	kinds	of	sizes	and	shapes	exist	in	the	brain.	Aβ	
16
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monomers	aggregate	with	each	other	and	form	dimers,	oligomers,	protofibrils	and	fibrils.	
Different	kinds	of	oligomers	have	been	reported	such	as	 the	globular-shaped	Aβ-derived	
diffusible	ligands	(ADDLs)	[45]	or	the	somewhat	larger	doughnut-shaped	annular	protofibrils	
[46].	Plaques,	a	high	order	aggregate	that	consists	mainly	of	Aβ	fibrils,	were	first	thought	
to	 be	 the	malefactor	 that	 causes	 brain	 deterioration	 in	 AD.	 But	 in	more	 recent	 studies,	
it	was	observed	that	Aβ	oligomers	affected	neuronal	synapses	by	 impairing	potentiation,	
which	leads	to	neurotoxicity	and	subsequently	cell	death	[47,	48].	Aβ	might	affect	synapses	
by	binding	to	different	receptors	such	as	the	α7	acetylcholine	receptor	[49],	the	receptor	
for	advanced	glycation	endproducts	(RAGE)	[50],	the	neurotrophin	receptor	P75	[51]	and	
others.	Furthermore,	Aβ	interacts	with	a	variety	of	proteins,	for	instance	with	tau	[52]	or	
ApoE	[53],	and	these	interactions	might	contribute	to	AD	development.
1.2.2 Tau protein
Tau belongs to the family of microtubule-associated proteins (MAPs) and is expressed in 
neurons. MAPs regulate microtubule stability in the cell, which is important for diverse 
cellular processes such as cell morphogenesis, cell division and intracellular trafficking 
[55]. Trafficking is regulated by the tight binding of MAPs to microtubules, which interferes 
with the movement of motor proteins such as dynein or kinesin and causes detachment 
of transported cargo from microtubules [56]. Tau is enriched in axons and therefore 
Figure 2: Amyloid Precursor Protein synthesis
The	 transmembrane	 protein	 amyloid	 precursor	 protein	 (APP)	 is	 cleaved	 by	 α-secretase	 or	 β-secretase.	
A)	α-secretase	cleaves	APP	and	produces	 the	 fragments	soluble	APPα	(APPsα)	and	C-terminal	 fragment	
C83.	γ-secretase	subsequently	cleaves	C83	to	produce	the	non-pathological	p3	and	C59	fragments.	This	
pathway is also called the non-amyloidogenic pathway. B)	 In	 the	 amyloidogenic	 pathway,	 β-secretase	
cleaves	 APP	 into	 soluble	 APPβ	 (APPsβ)	 and	 C99.	 C99	 is	 then	 cleaved	 by	 γ-secretase	 and	 the	 resulting	
proteins	are	C59	and	the	different	Aβ	isoforms	(Reprinted	by	permission	from	Macmillan	Publishers	Ltd:	
Nature Reviews Neurology, adapted from [54], copyright 2010).
A B
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involved in regulation of axonal transport [56]. Several serine and threonine amino acids 
of tau can be phosphorylated, such as threonine 181, and hyperphosphorylation at these 
sites causes the protein to detach from microtubules. The destabilized microtubules then 
cause dysfunction of axonal transport [57], and hyperphosphorylated tau associates into 
intracellular paired helical filaments that form NFTs [58]. It is still under debate whether 
it is the loss of normal function of the tau protein or the formation of NFTs within brain 
cells that contributes more to AD development. The accumulation of NFTs, however, can 
be used for postmortem staging of AD. NFTs follow a pattern with six stages, called Braak 
stages [5]. First, the medial temporal lobe is affected, in particular the entorhinal cortex 
(Braak I and II), then NFTs are found in limbic regions such as the hippocampus (Braak III 
and IV), and later NFTs spread to the neocortex (Braak V and VI) [59]. NFTs correlate with 
the severity of cognitive decline and are used for the neuropathological diagnosis of AD 
[60].
1.2.3 Risk factor Apolipoprotein E
ApoE,	 more	 specifically	 the	 ɛ4	 allele,	 is	 the	 most	 important	 genetic	 risk	 factor	 for	
developing AD. The three most common isoforms of ApoE are ApoE2, ApoE3 and 
ApoE4. They differ from each other by two amino acids and contain either an arginine 
or a cysteine at positions 112 and 158. ApoE2 (Cys112, Cys158) is considered protective 
against AD [61]. With 5-10% coincidence, ApoE2 is also the least common variant. ApoE3 
(Cys112, Arg158) is the most frequent variant, and is carried by 60-70% of the population. 
ApoE4	(Arg112,	Arg158)	is	found	in	15-20%	of	people,	but	at	least	one	ɛ4	allele	is	present	
in	up	to	65%	of	AD	cases	[62].	Carriers	with	one	copy	of	the	ɛ4	allele	have	a	3.7	fold	and	
carriers	with	an	ɛ4/ɛ4	genotype	even	a	12	fold	increased	risk	to	develop	AD	compared	to	
those	carrying	the	ɛ3	allele	[63].	Carrying	the	ɛ4	genotype	decreases	the	age	at	onset	of	
AD approximately eight years in heterozygous carriers until up to 15 years in homozygous 
carriers [64]. Furthermore, the ApoE4 genotype dose-dependently predicts the rate 
of cognitive decline in AD patients, with homozygous ApoE4 carriers showing a faster 
decline than heterozygous ApoE4 carriers [65]. In the brain, ApoE is secreted in high-
density lipoprotein (HDL)-like particles that contain phopholipids and cholesterol [66]. 
ApoE is thus involved in lipid transport, but also in the uptake of lipoprotein particles via 
ApoE receptors [66]. Receptor binding, however, differs between the different isoforms 
of ApoE, which is caused by the different amino acids of the three isoforms that lead 
to a different conformation of the ApoE protein. In ApoE4, Arg112 forms a salt bridge 
with Glu109, which results in exposure of residue Arg61 away from the four-helix bundle 
of the N-terminus. In contrast, in ApoE3 this side chain is buried [67]. In ApoE4, Arg61 
is therefore free to interact with other residues such as Glu255, which might lead to a 
close interaction between the C-terminal and N-terminal domain [68]. The residue on 
position 158 determines the interaction of ApoE with the low-density lipoprotein (LDL) 
receptor [69]. Arg158 forms a salt bridge with Asp154 in ApoE3 and E4. In ApoE2, an 
alternative salt bridge is formed between Asp154 and Arg150, which is situated in the 
LDL receptor binding region. This causes ApoE2 to have less affinity for the LDL receptor 
than ApoE3 and E4. These structural differences of the ApoE isoforms are also important 
for finding an explanation of the AD risk that ApoE4 composes. It has been suggested 
that the most important reason that ApoE isoforms affect the risk of AD is the differential 
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influence	on	Aβ	clearance	and	thus	its	accumulation	in	the	brain.	Several	studies	showed	
that	ApoE4	increases	Aβ	accumulation	and	decreases	Aβ	clearance	compared	to	ApoE3	
and	 E2	 [70-73].	 How	 exactly	 the	 ApoE	 structure	 influences	 Aβ	 clearance	 is	 still	 under	
debate.	For	instance,	ApoE4	forms	less	stable	interactions	with	Aβ	than	E2	and	E3	[53],	
which	might	influence	Aβ	clearance	and	accumulation.	On	the	other	hand,	Aβ	competes	
with ApoE for the same LDL receptor-related protein 1 (LRP1), and since ApoE2 is less 
efficient	 in	LDL	receptor	binding,	more	Aβ	 is	 taken	up	by	this	receptor	 for	clearance	or	
breakdown	[74].	Possibly	both	mechanisms	play	an	 important	 role	 in	Aβ	clearance	and	
thus AD development.
1.3 Diagnosis of Alzheimer’s disease
1.3.1 Clinical diagnosis
The golden standard for diagnosing AD is the pathological identification of its two hallmarks, 
plaques and NFTs, during autopsy. But in alive patients, diagnosis is mainly based on clinical 
criteria. In 1984, the National Institute of Neurological and Communicative Disorders and 
Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) 
published consensus criteria for the clinical diagnosis of AD [75], which were updated in 
2011 and are designated the NIA-AA criteria (after the National Institute on Aging and 
the Alzheimer’s Association) [76]. According to these criteria, AD patients are divided 
in having probable AD (having a well-documented decline and thus increased certainty 
of actually having AD) or possible AD (having a sudden onset of cognitive impairment 
or signs of a mixed pathology). To establish a clinical diagnosis, standard assessments, 
such as clinical, neuropsychological, and behavioral tests, also including assessment of 
the family history of a patient are applied. A commonly applied neuropsychological test 
to measure cognitive impairment is the Mini-mental state exam (MMSE) [77]. This is a 
questionnaire in which a maximal score of 30 points can be achieved. A patient with a 
score >27 points is considered cognitively normal, but scores <24 points are assigned to 
mild	(19-24	points),	moderate	(10-18	points)	or	severe	(≤9	points)	cognitive	impairment	
[78]. The Clinical dementia rating (CDR) score is another measure, to determine severity 
of cognitive impairment [79]. It is based on a five-point scale and divides patients into 
normal (CDR = 0), very mild (CDR = 0.5), mild (CDR = 1), moderate (CDR = 2) and severe 
(CDR = 3) cases. Both, MMSE score and CDR rating are also used in other dementia 
disorders, but are only to a limited degree able to differentiate AD from other dementias 
such as DLB [80] or VaD [81]. Therefore, biomarkers that reflect pathological changes 
in the brain, have been included in the NIA-AA criteria to increase the certainty of an 
established, clinical AD diagnosis.  
1.3.2 Biomarkers for AD diagnosis
The imaging techniques positron emission tomography (PET) and magnetic resonance 
imaging (MRI), and biochemical markers that are quantified in body fluids, are currently 
in use to support the clinical AD diagnosis. The most commonly applied PET scan 
makes use of Pittsburg Compound-B (PIB), which labels amyloid deposits [82]. PIB-PET 
differentiates AD patients from controls with high sensitivity (96%), but is not a very 
good progression marker for AD. By using 18fluorodeoxyglucose (FDG) as a tracer, PET also 
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visualizes the hypoperfusion patterns in the brain. By indicating frontotemporal rather 
than tempoparietal hypometabolism, FDG PET can be used to differentiate AD from FTD 
[83]. DLB can also be differentiated from AD when prominent occipital hypometabolism is 
detected [84]. Recently, a tracer that is able to visualize tau has been developed (18F T807) 
and has shown promising results as a biomarker in differentiating between MCI, AD and 
control cases [85]. Limitations of PET in general are its relatively expensiveness and poor 
availability, although due to its application in cancer, the availability is quickly increasing 
[86]. Another drawback of PET techniques is the use of radioactive tracers, although at 
levels that are below significant known risk [86]. As PET, MRI is an imaging technique 
and can be divided into structural MRI and functional MRI. Structural MRI is applied to 
visualize the degree of atrophy, especially in the entorhinal cortex and the hippocampus 
[86]. Reduced entorhinal and hippocampal volumes are already detected in mild AD and 
even in subjects who were initially asymptomatic but later progressed to AD [87, 88]. 
The most important strength of structural MRI is that volumes correlate to neuronal 
counts at autopsy and thus to cognitive decline [89-91]. A drawback is that it does not 
detect histopathological hallmarks, and is therefore downstream from the molecular 
pathology [86]. Functional MRI has been developed to detect changes in the brain such 
as neuronal activity. This is done by measuring changes in blood flow, blood volume 
and the oxyhemoglobin/deoxyhemoglobin ratio, and generating the blood oxygen level-
dependent (BOLD) signal [86]. Functional MRI detects brain dysfunctions caused by AD 
such as decreased hippocampal activity that are detected when subjects perform cognitive 
tasks in the MRI scanner [92]. The technique is well-suited as a marker of progression in AD 
[86]. In MCI or in genetically at-risk subjects, however, inconclusive results are obtained, 
and more longitudinal studies are needed to clarify these discrepancies. An important 
drawback is also that it is difficult for patients with severe AD to perform tasks in the 
MRI scanner, since it is difficult to keep them from moving [86]. Yet, MRI is a non-invasive 
technique well-accepted by patients, and is often applied in the clinic to contribute to the 
formulation of the AD diagnosis. Biochemical markers in body fluids can be specifically 
detected by methods such as enzyme-linked immunosorbent assay (ELISA). The preferred 
body fluid to measure biochemical markers in AD is cerebrospinal fluid (CSF), which is in 
close contact to the brain and may best reflect pathological, brain-specific changes on 
the	molecular	level.	Currently,	the	proteins	Aβ42, total tau (t-tau) and phosphorylated tau 
(p-tau) are used as CSF biomarkers (see for more details subchapter 1.4.1). Using CSF to 
measure biomarkers for support of the clinical AD diagnosis is also commonly applied. A 
drawback remains, however, the patients’ complaints after lumbar puncture, which are 
mostly headache (19%), back pain (17%) and typical postlumbar puncture headache (9%), 
as has been reported recently [93]. Serum could be a less-invasive, more easy accessible 
alternative as biomarker source instead of CSF. Yet, the current protein biomarkers cannot 
be	used	 in	 serum,	 since	 serum	 levels	of	Aβ42, t-tau and p-tau are equal in AD patients 
compared to controls or results have been inconclusive (reviewed in [94]). The blood-
brain-barrier (BBB) might hinder the detection of pathological changes that occur in the 
brain. Nonetheless, serum remains an attractive source for the investigation of novel 
biomarkers.
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The currently available CSF and imaging biomarkers add in a qualitative and quantitative 
aspect to support the clinical AD diagnosis. These markers were therefore incorporated 
in the NIA-AA criteria [76]. Efforts are now undertaken to standardize measurements and 
analysis. The aim of these efforts are to reduce inter-laboratory differences such as the 
handling of significant cut-off levels [95], which are most advanced for CSF biomarkers 
[76]. However, the search for better biomarkers also continues. Novel biomarkers are 
of particular importance for identifying pre-symptomatic or preclinical AD and MCI, as 
disease progression marker, and as specific marker in differential diagnosis of AD and 
other dementia disorders.
1.4 Novel CSF biomarkers for AD diagnosis
Biochemical markers typically reflect the pathological events that are going on during 
development and progression of a disease. In AD, such events are mainly the formation of 
amyloid plaques and NFTs, but also processes such as inflammation, neuronal dysfunction and 
loss are involved, and can lead to the identification of interesting markers. Since many analytes 
may have low concentrations in CSF, especially in the early stages of AD, an important issue 
to identify novel biomarkers is also the development of sensitive assays to 
detect them. Novel biochemical markers can be single proteins or metabolites, but also 
protein complexes or RNA molecules such as microRNAs (miRNAs) can be studied. 
1.4.1 Proteins as biomarkers
The	 most	 important	 protein	 biomarkers	 for	 AD	 are	 Aβ42, t-tau and p-tau that are 
quantified	in	CSF.	Decreased	levels	of	Aβ42 in CSF reflect amyloid deposition in the brain, 
and increased t-tau and p-tau CSF levels are an indication of neurodegeneration [96, 97]. 
When combined, these proteins have a sensitivity and specificity of 80-95% to differentiate 
between	AD	and	non-demented	 controls	 [98].	 Furthermore,	Aβ42 and t-tau are able to 
identify MCI patients that will later-on progress to AD with a sensitivity and specificity of 
~89% [99]. Despite the good differentiation between AD patients and healthy controls, 
these three biomarkers have limited diagnostic power in the differentiation of AD from 
other types of dementia such as VaD or DLB that closely resemble AD pathology and have 
also	altered	levels	of	Aβ	and	tau.	Furthermore,	Aβ42 and t-tau do not correlate well with 
disease severity [100]. 
In the past years, many more proteins were identified in CSF, e.g. by proteomics or 
multiplexing immunoassay panels, that have biomarker potential for AD either alone 
or in combination with each other or the traditional CSF biomarkers. Examples are 
BACE1, Visinin-like protein-1 (reviewed in [101]) or the recently investigated neurogranin 
[102]. Yet their addition to the known biomarkers only slightly improves the accuracy of 
diagnosing AD. The differentiation of AD from other dementias and the prediction of the 
severity and progression of AD remain challenges and therefore other ways to find CSF 
biomarkers are explored. 
A	 rather	 new	 approach	 is	 the	 quantification	 of	 protein	 complexes.	 For	 instance,	 Aβ	
forms	 complexes	 with	 many	 proteins	 such	 as	 αB-crystallin	 [103]	 or	 ApoE	 [53]	 and	
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quantification of such complexes could lead to novel and perhaps more specific 
biomarkers	 than	 an	 individual	 protein.	 Furthermore,	Aβ	oligomers	 are	 currently	 in	 the	
center	of	interest	as	novel	AD	CSF	biomarkers.	Oligomers,	as	the	most	toxic	Aβ	species	in	
the AD brain, might correlate with the severity of the disease and might be specific for 
AD compared to other neurodegenerative diseases. Recent studies indicated increased 
levels	 of	 Aβ	 oligomers	 in	 CSF	 from	 AD	 patients	 versus	 controls	 [104-107].	 However,	
this is in contrast to other studies that did not identify differences in oligomer levels 
[108, 109]. Discrepancies might be inflicted by differences in the detection methods 
for	 oligomers,	 for	 instance	 different	 Aβ	 antibodies	 might	 detect	 different	 species 
of oligomers.
1.4.2 MicroRNAs as biomarkers
MiRNAs are a novel class of regulatory RNA molecules. They circulate in body fluids and 
are relatively stable. As such they compose an interesting target to study as potential 
disease biomarkers. This has been done primarily in different cancers, but currently also 
in neurodegenerative disorders. More than three decades ago, the first miRNA, lin-4, 
has been discovered in Caenorhabditis elegans, which inhibited the translation of the 
lin-14 mRNA by complementary sequence interaction with its 3’ untranslated region 
(UTR) [110]. Since then, many more miRNAs have been identified, constituting today the 
largest group of non-coding RNAs with more than 28,000 known sequences from various 
organisms (http://www.mirbase.org; status release 21, June 2014). 
Most miRNAs are synthesized from intergenic or intronic DNA regions in the nucleus 
(figure 3). First, a long hairpin structure, called primary miRNA (pri-miRNA) is formed. 
After cleavage by the endonuclease Drosha, a 60-100 nucleotide long hairpin pre-miRNA 
is generated, which is then shuttled out of the nucleus into the cytoplasm by Exportin-5. 
There, a second endonuclease, called Dicer, cuts the hairpin loop of the pre-miRNA, which 
results in a duplex of two single strands. The two single strands, which are approximately 
22 nucleotides long, are subsequently divided into a functional guide strand (the mature 
miRNA) and a passenger strand (miRNA*), which is usually degraded. The guide strand 
binds in a semi-complementary manner to mRNAs for post-transcriptional regulation. They 
most often interact with the 3’UTR of mRNAs, but can also bind to the 5’UTR or the coding 
sequence [111, 112]. Mature miRNAs are not the actual functional entity that causes the 
posttranscriptional regulation. They work in conjuncture with different proteins and form 
the so called RNA-induced silencing complex (RISC), including argonaute (Ago) proteins 
and TAR RNA-binding proteins (TRBPs) [113]. RISC is guided by the mature miRNA and 
either inhibits translation or causes the breakdown of an mRNA, in both cases inhibiting 
the translation of the encoded protein.
All kinds of processes are influenced by the action of miRNAs, and in the brain, it has been 
reported that miRNAs play roles in early development and maturation and later in synaptic 
plasticity (reviewed in [115]). Altered miRNA expression has been observed in several 
neurodegenerative diseases including AD [116-118], and with the help of transfection 
studies the protein targets that are regulated by these miRNAs were identified. For 
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instance, levels of the miR-29 gene family (miR29a, -b and -c) are altered in AD, and miR-
29 targets BACE1 [118]. Another example of a widely studied deregulated miRNA in AD 
is miR-146a, which is involved in inflammation and targets complement factor H and the 
NF-κB	pathway	[119,	120].	Alterations	of	miRNAs	are	also	detected	 in	biofluids	such	as	
blood [121-123] and CSF [121, 124]. miRNAs have been observed to be very stable in body 
fluids. Although their primary function is intracellular, they can be released by cells either 
by passive leakage due to cell lysis or cell death, or by active transport via microvesicles 
or exosomes [125]. MiRNAs can be protected from degradation by such microvesicles, but 
they can also be protected by the association with proteins such as Ago2, nucleophosmin 
Figure 3: Biogenesis of miRNAs
(i) According to the standard miRNA 
biogenesis pathway, pri-miRNAs are 
transcribed by RNA polymerase II. (ii) 
The endonuclease Drosha together with 
the protein DGCR8 (DiGeorge syndrome 
critical region gene 8) removes the 
7-methylguanosine cap and the 3’poly (A) 
tail, which results in the pre-miRNA. (iii) 
The pre-miRNA is then transported into the 
cytoplasm by Exportin-5 and the guanosine 
5’-triphosphate(GTP)-binding protein Ran 
(Ran-GTP). (iv) In the cytoplasm, the pre-
miRNA is processed by Dicer together 
with the RNA-binding protein TRBP 
(transactivation response RNA binding 
protein). The resulting miRNA-miRNA* 
duplex is loaded into an argonaute (Ago) 
protein and upon discarding the miRNA 
passenger strand, the RNA-induced silencing 
complex (RISC) is formed. The mature 
miRNA targets complementary sequences 
in mRNAs, usually in the 3’UTR region of the 
mRNAs. The presence of RISC either inhibits 
translation of the mRNA or causes mRNA 
degradation.
(adapted from [114]. Reprinted with 
permission from AAAS.) 
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1 or lipoprotein complexes [126, 127]. A large quantity of circulating miRNAs are well-
detected by profiling techniques such as quantitative polymerase chain reaction, 
microarrays or next generation sequencing. Circulating miRNAs therefore comprise an 
interesting novel research area for the identification of potential AD biomarkers.
1.5 Outline of thesis
This thesis is devoted to the study of novel biofluid-based markers for AD, and its 
differentiation from other dementia types. Several approaches have been undertaken to 
identify novel biomarkers for AD, which are divided in three main parts, focusing on the 
methods to study and detect biomarkers (Part I), on potential novel protein biomarkers 
in CSF and serum (Part II) and on miRNAs as a novel group of biomarkers in CSF (Part III).
Part I: Methods and Techniques to study AD biomarkers
Chapter 2:
One	of	the	most	important	known	biomarkers	for	AD	is	Aβ.	In	this	chapter	it	is	reviewed,	
how this protein is handled and studied by various methods. Methods for quantification 
of	 Aβ	 (aggregates)	 as	 a	 biomarker	 form	 an	 essential	 part	 of	 this	 chapter,	 reviewing	
traditional as well as novel attempts. 
Chapter 3:
The detection of several interesting biomarkers is often hampered by low concentrations 
in body fluids such as CSF. This chapter describes the attempts to develop a new assay 
(also referred to as Bio-barcode assay), which is based on ELISA and the use of nucleotide 
sequences to amplify the signal for the detection of low abundant proteins.   
Part II: Protein biomarkers for AD
Chapter 4:
In	this	chapter,	Aβ	in	complex	with	ApoE	is	investigated	as	potential	novel	serum	biomarker	
for	AD.	For	this	purpose	an	ELISA	is	developed	and	validated	to	specifically	measure	Aβ/
ApoE	complexes.	Levels	of	Aβ/ApoE	complexes	are	compared	between	patients	with	AD,	
FTD, DLB and VaD, and controls.
Chapter 5:
Multipanel studies are often used to identify promising new biomarkers in CSF. In one 
of such a study, NrCAM, a protein involved in neuronal adhesion, was identified. In this 
chapter we aim to confirm previous results and investigate whether NrCAM indeed has 
potential as CSF biomarker in differentiating AD from non-demented controls, FTD and 
DLB patients.
Part III: MicroRNA biomarkers for AD
Chapter 6:
In this chapter we investigate the levels of several miRNAs in hippocampus extracts of 
AD patients with different Braak stages and of controls. Those miRNAs are also measured 
in CSF and if detectable, investigated for their suitability as CSF biomarkers in AD 
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compared to controls. Furthermore, we describe various pitfalls (most importantly blood 
contamination) that may influence miRNA levels and their quantification in CSF.
Chapter 7:
This study is a small scale follow-up study on the previous chapter, in which four miRNAs 
are investigated that had been identified in previous studies as differentially expressed 
in CSF of AD patients versus controls. We additionally test whether they are influenced 
by blood contamination. MiRNA miR-29a showed potential as CSF biomarker when AD 
patients are compared to controls.
Chapter 8:
In this third chapter a large, multicenter study is performed. All miRNAs that were 
successfully detected in CSF as described in the two previous chapters, are now investigated 
in CSF of several patient groups: AD, non-demented controls, FTD, DLB and MCI-AD. We 
therefore not only aim to repeat previous findings in AD patients and controls, but also 
extend the study towards three new, and in literature scarcely tested patient groups for 
miRNA expression.
Chapter 9:
This chapter is a summary of all the previous chapters and critically reviews the most 
important findings. It further indicates several future directions in biomarker research.
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Abstract
Amyloid-β	 protein	 (Aβ)	 accumulation	 is	 one	 of	 the	 major	 hallmarks	 of	
Alzheimer’s	 disease	 and	 plays	 a	 crucial	 role	 in	 its	 pathogenesis.	 Aβ	 aggregates	
into fibrils, but rather than these end-products of the aggregation process, 
intermediate species, referred to as oligomers, have been identified as 
the	 most	 neurotoxic	 Aβ	 aggregates.	 To	 characterize	 the	 different	 Aβ	 species 
and to study the aggregation process, a wide range of techniques has been applied over 
the	past	years.	These	techniques	aim	to	visualize	the	different	Aβ	species	and	study	their	
structure,	 to	 separate	 them	and	 to	 quantify	 the	 aggregated	Aβ	 forms	by	 immunology-
based methods. In this review we provide an overview and discussion of the most 
important techniques used for these aims. Often a combination of techniques will be 
appropriate to obtain the most optimal information.
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2.1 Introduction
Alzheimer’s Disease (AD) is the most common cause of dementia in elderly worldwide. 
An estimated amount of 20-30 million people are affected [128]. Characteristic symptoms 
comprise memory loss, cognitive decline and mood changes [129]. AD is characterized 
by neuronal degeneration and cell loss in the hippocampus and various cortical areas. 
Central	 in	AD	pathology	 is	 the	amyloid-β	 (Aβ)	protein,	which	polymerizes	and	deposits	
extracellularly in the form of cerebral senile plaques and cerebral amyloid angiopathy 
(CAA)	 [130].	 In	 the	non-amyloidogenic	pathway,	 the	amyloid-β	precursor	protein	 (APP)	
is	cleaved	by	α-	and	γ-secretase,	whereas	Aβ	is	produced	in	the	amyloidogenic	pathway	
when	 APP	 is	 cleaved	 by	 β-secretase	 instead	 of	 α-secretase	 [131].	 Several	 Aβ	 isoforms	
exist	in	the	brain.	The	main	isoforms	are	Aβ40	and	Aβ42, differing only by two amino acids 
at	the	C-terminus	of	the	protein,	of	which	the	former	one	is	most	prevalent,	but	Aβ42 is 
more	prone	to	aggregate	[132].	The	aggregation	pathway	of	Aβ	(figure	1)	is	very	similar	to	
that of other amyloidogenic proteins and can be modeled as follows [44, 133]. Monomers 
attach to each other to form larger complexes, ranging from dimers to heptamers. These 
heptameric paranuclei then grow into larger oligomers that eventually form protofibrils. 
Finally,	protofibrils	grow	into	mature	fibrils.	This	process	of	Aβ	aggregation	is	dependent	
on several factors, including concentration, pH and temperature [134]. 
Many different prefibrillar multimers have been described, which are collectively termed 
oligomers. This term refers to complexes roughly ranging from dimers to 24-mers, with 
a heterogeneity in quaternary structures (for an overview see [135-138]). Usually a few 
different oligomeric species are discriminated. Low molecular weight (LMW) oligomers 
are	defined	as	oligomers	consisting	of	less	than	8	Aβ	subunits.	The	high	molecular	weight	
(HMW)	oligomers	may	contain	Aβ	aggregates	from	~42	kDa	up	to	1	mDa.	Oligomers	are	
referred to with different defining terms, based on their morphology, but also on the 
origin	of	different	Aβ-isoforms	[139].	For	example,	oligomers	are	defined	as	“Aβ-derived	
diffusible	 ligands	 (ADDLs)”	 [45],	 which	 comprises	 a	 heterogeneous	 collection	 of	 Aβ	
oligomers, from LMW up to aggregates larger than 1 mDa [140]. Their common feature 
is their globular shape. Another subgroup often mentioned are the “annular oligomers”, 
which have an outer, somewhat larger diameter than ADDLs (8-12 nm) and are doughnut 
shaped [46, 141]. An even larger form are the spherical intermediates with a diameter of 
15-35	nm	and	a	molecular	weight	of	650	kDa.	These	round-shaped,	Aβ40-derived species 
already	display	an	ordered	β-sheet	conformation	 [142].	Although	protofibrils	are	often	
regarded as species distinct from oligomers, by definition these are also HMW oligomers. 
Protofibrils	 are	more	 ordered	 than	 smaller	 oligomers,	 contain	 predominantly	 β-sheets	
and can be visualized by electron microscopy (EM) and atomic force microscopy (AFM). 
They are regarded as intermediates in the fibrillization process and are the precursors to 
fibrils, or – alternatively – may disassemble into smaller oligomers [44, 137]. However, 
they should not be confused with protofilaments, which are the substructures of fibrils 
and appear as a twisted thread [140]. Protofibrils in contrast, consist of a heterogeneous 
group of oligomers and can be annular or linear (5 nm in diameter and less than 200 
nm in length). Finally, fibrils are the end product of the aggregation process. These are 
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insoluble, filamentous structures longer than 1 µm and with a diameter of 8-12 nm. For 
a more detailed overview of these subspecies we recommend an article by Jan et al. 
(2010)	 [140].	A	 current	 and	widely	 accepted	opinion	 is	 that	 oligomeric	Aβ	 is	 the	most	
neurotoxic	species	 in	the	spectrum	of	Aβ	aggregation	forms	[143].	Several	studies	have	
been	conducted	on	the	toxicity	levels	of	different	Aβ	oligomers.	One	important	neurotoxic	
oligomer	is	the	56	kDa	species,	also	referred	to	as	Aβ*56.	These	oligomers	were	derived	
from the brains from transgenic mice and were demonstrated to correlate with memory 
deficits and induce transient memory impairment [144]. Also it was shown that dimers 
derived from AD brains are potent neurotoxic species and impair synaptic plasticity and 
memory [145]. In another study, highly toxic 10-15 nm synthetic spherical oligomers 
were produced, as the end products of a distinct assembly pathway that does not lead to 
fibrils. These oligomers were termed amylospheroids (ASPDs) [141]. Native ASPDs have 
also been isolated from patient brains and were shown to cause neurodegeneration in 
vitro [146].
With	the	recognition	that	Aβ	aggregation	plays	a	crucial	role	 in	AD	pathogenesis,	many	
techniques to analyze this aggregation process have been employed. These techniques 
include various microscopic techniques that enable visualization and structural 
determination	(chapter	1),	separation	techniques	to	analyze	and	obtain	Aβ	species	of	a	
certain size (chapter 2), spectroscopic techniques to follow the aggregation process and 
determine protein shape (chapter 3) and immunology-based methods for quantification of 
Aβ	(chapter	4).	Many	of	the	studies	we	refer	to	are	based	on	synthetic	Aβ;	if	brain-derived	
Aβ	was	used,	this	is	specifically	indicated.	The	aim	of	this	review	is	to	provide	an	overview	
of	all	 the	different	 techniques	 that	are	currently	 in	use	 to	analyze	Aβ	aggregates,	 their	
specific applications, and advantages and disadvantages. This is of importance, because 
the	 analysis	 of	 Aβ	 aggregates	 may	 be	 more	 difficult	 than	 analysis	 of	 non-aggregating	
proteins.	Since	Aβ	aggregates	often	exist	as	a	dynamic	mixture	of	species	with	a	broad	
range in sizes, that are unstable, may disassemble or assemble during analysis, and since 
the concentration of each particular aggregate in vivo is usually very low, this all may 
hamper	discrimination	of	 the	 various	 types	of	Aβ	 assembly	 and	 their	 specific	 analysis.	
From	this	overview	we	conclude	that	a	thorough	characterization	and	quantification	of	Aβ	
aggregates requires a combination of different techniques to obtain an accurate analysis. 
To illustrate this, we provide some successful examples of combined techniques in the 
concluding section.
2.2 Techniques to determine morphology and structural 
conformation
Different	 aggregation	 states	 of	 Aβ	 can	 be	 visualized	 by	 using	microscopic	 techniques.	
Numerous studies have been performed using light microscopy, EM and AFM (for an 
overview on microscopic techniques to visualize amyloid plaques and fibrillogenesis, 
see	 Harris	 (2005)	 [147]).	 Here,	 we	 will	 consider	 aggregation	 forms	 of	 Aβ	 and 
its appearance using high-resolution microscopic techniques. Note that none 
of the microscopic techniques described here are useful for determination of 
sample concentration. 
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2.2.1 Electron Microscopy 
EM	has	been	used	to	study	plaque	morphology	and	to	obtain	structural	information	on	Aβ	
fibrils.	Although	not	specifically	for	Aβ,	already	in	1967	amyloid-laden	tissue	of	the	liver	
and the spleen was visualized under the electron microscope to differentiate between 
amyloid	 fibrils,	 protofibrils	 and	 subfibrillar	 structures	 [148].	 Later,	 Aβ40	 and	 Aβ42 were 
visualized by using the electron microscope, as a mesh of fibers with diameters between 
6 and 10 nm. Here, a difference between short, curly fibrils, that were termed protofibrils, 
and mature fibrils could be made according to their length [149]. By using transmission 
electron microscopy (TEM), it was possible to identify small pseudo-spherical structures 
with	 a	 diameter	 ranging	 from	 9-25	 nm,	 in	 Aβ40 preparations incubated for less than a 
day [150]. Protofibrils with diameters of ~8.5 nm developed within an incubation period 
of two days. Finally, after two days of incubation, long mature fibrils with a diameter of 
up to 10.5 nm could be detected. The TEM images also revealed structural diversity in 
the fibrils. Fibrils either formed coiled structures or multistranded ribbons of two, three, 
four or more strands which might have formed by parallel association and annealing of 
protofibrils. 
EM is a very useful technique for visualizing fibrils and protofibrils and their structural 
morphologies, but EM is not suitable for detecting and differentiating small, LMW 
oligomeric	species.	Usually,	synthetic	Aβ	mixtures	are	studied	at	an	initial	concentration	
of	 approximately	 200	 μM	 [151]	 to	 allow	 Aβ	 to	 aggregate	 and	 measure	 it	 at	 different	
incubation times to test the influence of different conditions, such as buffer solutions, pH 
Figure 1: A proposed pathway for  aggregation 
of amyloidogenic proteins. ([44] Copyright 
2011 National Academy of Sciences, U.S.A. 
Reproduced with permission.)
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or temperature on aggregation and morphology. Important disadvantages of EM are the 
need for expensive equipment and highly specialized operators and the fact that only small 
sample	volumes	of	3-10	μl	can	be	studied,	which	may	lead	to	selection	bias.	Furthermore,	
during the preparation and visualization protocols, unintended changes to the peptides 
may occur, such as breakdown or altered aggregation. To prevent this, formaldehyde 
or glutaraldehyde in combination with osmium tetroxide can be used for fixation. It 
should be noted that only highly pure glutaraldehyde should be used and that, due to its 
crosslinking activities, it might change the aggregation of structures. Samples can also be 
prepared in solution and imaged with cryoEM, a transmission EM variant that makes use 
of very low (cryogenic) temperatures by which the structure of proteins remains better 
preserved. 
2.2.2 Atomic Force Microscopy
AFM (Box 1) can produce high resolution images in the nanometer range by scanning 
the surface of a sample and drawing a topographical map. The major advantage of AFM 
compared to EM is the ability to visualize biological material in solution and thus under 
physiological conditions (figure 2). This way, the natural appearance of these structures 
are conserved during the scanning process and, by applying time-lapse AFM, even 
structural changes in one sample can be followed [152]. 
Figure 2: Atomic Force Microscopy images 
Aβ40-fibril	seeds	were	attached	to	a	mica	surface	and	non-fibrillar	Aβ40 in solution was added. The growth 
of the fibrils was imaged by time-lapse atomic force microscopy at time points t = 5, 45, 75, 155, 200 
minutes. (Reprinted from [162], Copyright 2011 with permission from Elsevier.)
35
2
Methods for analysis of Amyloid-β aggregates
Box 1) Atomic Force Microscopy: To visualize structures in the nanometer range, AFM uses a flexible 
scanning needle (cantilever)  with a very fine tip, whereby feature resolution is dependent on size and 
shape of the tip [153]. For soft sample surfaces, silicon cantilevers  with a sharp carbon nanotube tip 
attached, were developed. These probes access narrow and deep features [154], whereby differences in 
heights are depicted in the AFM image in different shades of gray: Dark color resembles features beneath 
the	surface	and	white	color	 represents	structures	 lying	above	the	surface.	To	visualize	Aβ	 fibrils,	multi-
walled carbon nanotube (MWNT) probes were quite successful  and can reach even higher resolution than 
silicon probes [153]. In order to measure biomolecules with AFM, the tapping mode is applied. Here the 
cantilever with the tip oscillates up and down with an amplitude of about 100-200 nm, making it possible 
for the loosely attached molecules to move and interact with each other. The surface to which biomolecules 
are attached, is most often hydrophilic mica [45, 155-158], but also hydrophobic, highly ordered pyrolytic 
graphite (HOPG) [155, 156, 159]  is used. Dependent on the properties of these substrates, information 
about behavior of molecules in such environments can be obtained. The substrates  are mounted on a 
hydrophobic teflon disk and both are submerged in a fluidic chamber filled with a buffer solution. The 
electrolyte concentration and pH of this buffer solution can be adjusted according to the sample, to rule 
out unwanted electrostatic interactions between the AFM tip and the sample, that could cause incorrect 
measurements of the heights of the imaged biomolecule [160, 161].
Source:
h t t p : / / c o m m o n s .w i k i m e d i a .
o r g / w i k i / F i l e : At o m i c _ fo r c e _
microscope_block_diagram_v2.svg
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AFM	can	be	used	to	visualize	Aβ40	and	Aβ42 in different aggregation states, such as ADDLs, 
subfibrillar assemblies and protofibrils [163]. Over time, formation of oligomers were 
visualized that, after longer incubation, changed into larger structures, resembling 
protofibrils. Upon extended incubation, these protofibrils converted into two types of 
fibrils: Type-1 fibrils with nodules, that appear in a periodic pattern along the fibrils 
(“nodular fibrils”), and type-2 fibrils without these nodules (“smooth fibrils”) [155].
Using	 AFM,	 deposition	 of	 Aβ42	 in	 diffuse	 plaques,	 as	 the	 initial	 step	 in	 the	 amyloid	
cascade hypothesis [164, 165], was mimicked [166]. Aggregation was most efficient when 
soluble	Aβ42	was	added	to	fixed	Aβ42	oligomers	on	the	template,	which	indicated	that	Aβ42 
contributes	more	to	amyloid	plaque	growth	than	Aβ40. 
Time-lapse AFM allows to visualize single fibrils and fibril elongation over several hours 
[162].	 This	 method	 can	 be	 useful	 in	 studies	 testing	 Aβ-inhibitors.	 Accordingly,	 the	
technique can also deliver information on the fibril-nucleating ability and structural 
incorporation	of	other	molecules	into	Aβ	aggregates.	
Compared	to	EM,	AFM	is	able	to	clearly	distinguish	between	Aβ	oligomers,	protofibrils	and	
fibrils and has superior resolution [167]. AFM has enabled detailed structure analysis of 
Aβ	aggregates,	made	it	possible	to	follow	the	fibrillization	pathway	[155]	and	contributed	
to	 the	understanding	of	Aβ	behavior	 in vivo.	 To	measure	Aβ,	 concentrations	 as	 low	as	
2.5	 μM	 can	 be	 used,	 but	 higher	 concentrations	 of	 50-100	 μM	 are	more	 often	 applied	
[151].	However,	AFM	also	enables	visualization	of	only	small	sample	volumes	(~5-50	μl),	
requires the availability of very expensive equipment, and specialized operators. 
2.2.3 Circular Dichroism
Only few techniques are available to study structural properties of proteins. In studying 
structure	 of	 Aβ	 aggregates,	 fancy	 techniques	 based	 on	 nuclear	 magnetic	 resonance	
spectroscopy [142, 168-171] and mass spectrometry [172, 173] are currently in use, but 
mainly	 to	 study	 Aβ-peptides	 or	 fragments.	 An	 often	 used	 and	 validated	 technique	 for	
analyzing secondary and tertiary structure and conformation of proteins and complex 
molecules	is	circular	dichroism	(CD),	and	many	studies	have	been	performed	on	Aβ.
Structural asymmetry causes light to polarize in different angles and these differences 
are detected by CD spectroscopy. The CD spectrum in the far-UV region (190-250 
nm)	 indicates	 the	 presence	 of	 α-helices,	 β-sheets,	 β-turns	 or	 random	 coils	 within	
proteins (figure 3). CD has been used to monitor changes in secondary structure and 
to	 define	 the	 conformational	 state	 of	 Aβ40	 and	 Aβ42.	 It	 was	 demonstrated	 that	 Aβ	
fibrils	 predominantly	 adopt	 a	 β-sheet	 conformation	 [174],	 whereas	 other	 amyloid	
peptides or fragments display also other secondary structures [175]. During the 
aggregation	 process,	 Aβ	 undergoes	 conformational	 changes	 from	 random	 coil	
and	 α-helix	 to	 β-sheet	 structure.	 In	 CD	 this	 is	 recognized	 as	 a	 drop	 in	 the	 signal	 at	 
218	nm	in	time,	indicating	formation	of	β-sheets	[176].	At	the	same	time	an	increase	in	
signal	at	195	nm	is	observed,	indicating	the	disappearance	of	α-helices	(figure	4A)	[177].	
By plotting the absolute CD signal at 215 nm against time, a sigmoid curve is obtained 
37
2
Methods for analysis of Amyloid-β aggregates
Figure 4: CD spectroscopy kinetic study of 
Aβ42 
A) Overlaid CD spectra recorded at 45 
min time intervals. The light grey curve 
represents the spectrum recorded after 1h, 
the black curve represents the spectrum 
recorded after 12 h (see arrows). B) A 
sigmoidal curve representing the formation 
of	 β-sheets	 over	 time	 is	 obtained,	 	 when	
absolute CD signal at 215 nm is plotted 
against time.  ([177] Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with 
permission.)
Figure 3: Determination of secondary 
structure by CD spectroscopy
Typical	spectra	representing	α-helix,	β-sheet	
and random coil conformations are detected 
in the far-UV spectral region at a wavelength 
of 190-250 nm. (http://employees.
csbsju.edu/hjakubowski/classes/ch331/
protstructure/olcompseqconform.html)
38
Chapter 2
with a lag phase, an exponential growth phase and a plateau phase in the aggregation 
process (figure 4B). This kind of curve is also observed in dynamic light scattering studies 
and Thioflavin T assays. 
Besides monitoring the aggregation process, CD is also often used to study the 
conformational stability of molecules upon environmental changes, such as ionic strength, 
temperature	and	the	concentration	of	Aβ	[177].	For	instance,	pH	affects	Aβ	conformation;	
at	pH	5.5,	both	Aβ39	and	Aβ42	adapted	predominantly	a	β-sheet	formation	[178],	whereas	
at	 lower	or	higher	pH,	both	peptides	display	predominantly	α-helices.	Furthermore,	CD	
analysis	 demonstrated	 that	when	Aβ40 was in contact with the surface of hydrophobic 
membranes	or	lipid	vesicles,	it	displayed	β-sheet	formation	[179].	In	contrast,	when	the	
peptide was incorporated into membranes, it was stabilized by lipid surrounding into an 
α-helical	conformation.	
Changes	 in	 the	 amino	 acid	 composition	 of	 Aβ	 may	 strongly	 affect	 its	 conformation.	
When valine 18 is replaced by alanine, or glutamic acid 22 by glutamine, the propensity 
of	 Aβ	 to	 form	 an	 α-helix	 is	 increased,	 which	 indicates	 that	 there	 is	 a	 reduction	 in	
aggregation.	 Indeed,	 CD	 spectroscopy	 confirmed	 the	 formation	 of	more	 α-helices	 and	
reduced	 formation	of	β-sheets.	 Furthermore,	CD	 studies	demonstrated	 that	 the	GxxxG	
motif,	which	appears	three	times	within	the	Aβ25-37 sequence, may be responsible for the 
conformational	changes	in	Aβ	that	promotes	oligomerization,	but	less	fibrillization,	and	
thus neurotoxicity [180]. Replacement of one glycine of the GxxxG motif into a leucine 
residue results in a conformational change over time, from predominantly random coil 
into	 a	 primarily	 β-sheet	 formation,	 which	 increased	 the	 rate	 of	 fibril	 formation	 and	
decreased the concentration of small soluble and neurotoxic oligomers [181]. 
CD	 spectroscopy	 can	be	 a	useful	 tool	 to	 follow	Aβ	aggregation	 and	determine	optimal	
conditions for obtaining synthetic monomers, oligomers and fibrils. The effects of 
solvents	 (e.g.	NaOH,	HCl	 or	H2O)	on	Aβ40 conformation has been studied by CD [182]. 
For	instance,	Aβ40 dissolved in water, gradually changed form from random coils into an 
α-helix	structure,	whereas,	when	Aβ	was	dissolved	in	NaOH	almost	50%	of	Aβ40	adopted	
a	β-sheet	structure.	In	another	study	the	effect	of	hexafluoroisopropanol	(HFIP)	on	Aβ40 
and	 Aβ42	 was	 investigated	 [134].	 This	 reagent	 is	 known	 to	 break-down	 β-sheets,	 and	
is	 therefore	 often	 used	 to	 force	 synthetic	 Aβ	 into	 its	monomeric	 state	 [175,	 183].	 CD	
analysis	 confirmed	 that	 HFIP	 was	 able	 to	 keep	 Aβ	 in	 an	 unaggregated	 form,	 since	 CD	
spectra	indicated	that	the	peptides	almost	completely	were	in	an	α-helix	or	random	coil	
form,	with	very	little	β-sheets.
In summary, CD is a very useful technique for the identification of the secondary protein 
structure that is most abundant in a sample. The most important advantage is the real-time 
monitoring of the conformation of proteins in aqueous solutions. However, determining 
the	structure	of	different	Aβ	aggregates	in	one	solution	can	be	difficult,	because	solutions	
with	Aβ40	or	Aβ42 often contain different stages of aggregation and may contain mixtures 
of	secondary	conformations.	In	particular	Aβ	oligomers	comprise	different	conformational	
states	of	Aβ	and	CD	spectroscopy	can	only	determine	the	dominant	secondary	structures	
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in that solution [134]. To do measurements, only a small volume of sample is required 
(less	than	100	μl),	but	a	relatively	large	amount	of	material	(1	mg	protein	per	titration)	
must be present in the sample [184]. Experiments can take 10 minutes or up to 3 hours, 
dependent on the number of records [184]. Another drawback is that CD analysis is not 
compatible with a number of frequently used buffer components that absorb UV light 
in the far-UV region (e.g. high concentrations of DTT, histidine, imidazole), and thus can 
interfere with measurements. Transparent solvents such as phosphate, Tris and borate 
buffer do not interfere, however [185].
2.3 Techniques to determine molecular weight
Techniques	 to	 separate	 Aβ	 species	 by	 size	 are	 ubiquitously	 used	 both	 for	 analytical	
and fractionation purposes. However, the influence of the conditions during sample 
pretreatment and the experiment can be substantial and can affect the composition of 
Aβ	species	that	are	present.
2.3.1 Polyacrylamide Gel Electrophoresis
An	often	used,	reasonably	simple,	inexpensive	technique	to	separate	proteins	in	a	complex	
sample based on molecular weight is Polyacrylamide Gel Electrophoresis (PAGE) [186, 
187]. The most widely used variant of electrophoresis is SDS-PAGE [188]. SDS causes 
denaturation	of	secondary	and	non-disulfide-linked	tertiary	structures.	Moreover,	protein	
complexes	 can	 be	 disassembled	 in	 SDS-PAGE	 by	 addition	 of	 a	 reducing	 agent,	 such	 as	
dithiothreitol	(DTT)	or	β-mercaptoethanol,	which	breaks	up	disulfide	bonds.	SDS-PAGE	is	
most	often	followed	by	Western	blotting,	which	increases	both	specificity	and	sensitivity	
of	the	detection.	To	visualize	pure	synthetic	Aβ	protein,	a	range	of	concentrations	has	been	
applied	to	the	gel,	from	around	1	ng	[189]	up	to	1	µg	[190],	depending	on	antibody	quality,	
sensitivity	of	the	analysis	method	and	homogeneity	of	the	Aβ	species.	To	determine	Aβ	in	
brain	lysate	a	total	protein	amount	of	0,5	–	50	µg	is	used,	in	a	typical	volume	of	25-40	μl.	
To perform an SDS-PAGE and Western blot experiment about 1 to 1.5 days are required.
PAGE	techniques	have	been	helpful	in	the	past	to	identify	brain-derived	Aβ	as	a	pathological	
protein	in	AD	[191]	and	to	elucidate	the	aggregation	properties	of	synthetic	Aβ	[192].	Until	
2005,	 SDS-PAGE	 was	 the	 most	 commonly	 used	 method	 to	 detect	 and	 characterize	 Aβ	
oligomers	(figure	5)	[193].	However	critical	notes	can	be	placed	on	the	protein	stability	in	
PAGE.	It	has	been	shown	that	conditions	in	SDS-PAGE	electrophoresis	cause	disassembly	of	
the	larger	oligomers	into	smaller	ones.	Oligomers	of	around	50	kDa	and	up,	obtained	after	
size exclusion chromatography (SEC; see par. 2.2), appeared mainly in the form of monomers 
to	tetramers	on	immunoblot	after	SDS-PAGE	separation	[194,	195].	Furthermore,	samples	
that	were	boiled	in	denaturing,	reducing	sample	buffer	and	analyzed	by	western	blotting	
almost exclusively consisted of monomers and dimers, which seem to be heat-stable, in 
contrast to the heat-instable high molecular weight oligomers. Also, in another study, 
monomeric	Aβ,	ADDLs	and	fibrils	were	prepared	and	analyzed	by	SDS-PAGE	[189],	resulting	
in	practically	the	same	band	pattern	for	all	three	samples,	corresponding	with	monomers,	
dimers	and	tetramers.	This	indicates	that	the	ADDLs	and	fibrils	are	SDS-instable	species.	
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To	avoid	denaturing	effects,	polyacrylamide	gels	can	also	be	prepared	without	SDS	(native	
PAGE	[196]).	A	disadvantage	of	 this	application	 is	 that	besides	molecular	weight,	protein	
conformation	and	charge	also	affect	 the	migration	process,	complicating	exact	molecular	
weight	 determination.	 Although	 native	 PAGE	 has	 been	 used	 to	 study	 Aβ	 aggregation,	 it	
seems inevitable to combine this technique with other techniques like SEC or microscopic 
techniques,	 because	 of	 the	 inherent	 limited	molecular	weight	 information	 derived	 from	
native	PAGE	[132,	163,	197].	
Another	method	to	avoid	disassembly	of	Aβ	oligomers	in	gel	is	stabilization	by	chemical	
crosslinking. This probably enables more reliable results in SDS-PAGE, because oligomers 
become	SDS-	and	thermostable.	A	technique	to	crosslink	Aβ	is	Photo-Induced	Crosslinking	
of Unmodified Proteins (PICUP) [198, 199], which uses visible light and a tris-bipyridyl 
Ru(II) complex to form covalent bonds between polypeptide chains. 
To	 study	 smaller	 and	 larger	 Aβ	 oligomers	 simultaneously,	 a	 gradient	 PAGE	 gel	 can	 be	
used. Gradient gels can be of additional value to separate proteins with closely related 
sizes	 like	Aβ	monomers	 and	 dimers,	 by	 enhancing	 the	 resolution	 in	 a	 certain	 range	 of	
molecular weights. Using this type of gel, a striking ladder-like pattern of oligomers could 
be visualized [195]. In addition, buffer composition in SDS-PAGE significantly affects 
separation	of	Aβ	peptides.	This	characteristic	can	also	be	used	to	enhance	Aβ	separation.	
Small	complexes	of	synthetic	Aβ40	and	Aβ42 (from mono- to tetramer) were readily visible 
on	a	16.5%	Tris-Tricine	gel,	whereas	high	molecular	staining	corresponding	to	fibrillar	Aβ	
were only visible on a 16% SDS-PAGE Tris-Glycine gel [200]. These results are in agreement 
with the property of Tris-Tricine gels to increase the resolution of proteins with molecular 
weight between 5-20 kDa relative to Tris-glycine systems [201]. 
In summary, the advantage of PAGE is its simplicity, and it is a rapid, inexpensive and 
reproducible	 technique	 to	 visualize	 the	 different	 forms	 of	 Aβ	 present	 in	 a	 sample.	
However, a major disadvantage is the influence of the denaturing and reducing 
conditions used in the assay, and as a result analysis of SDS-labile protein complexes 
Figure 5: Overview of biophysical 
methods used for detection and 
characterization  of amyloidogenic 
oligomers. Data are derived from 
publications in the first six months 
of 2004. ([193] Reproduced with 
permission.)
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may yield unreliable data. This may be counteracted by using native PAGE or by applying 
crosslinking techniques. Besides, additional assays, e.g. SEC (paragraph 2.2) or quasi-
elastic light scattering (paragraph 2.3), can be used to verify the molecular weight of the 
Aβ	molecules.
2.3.2 Size Exclusion Chromatography
SEC is another method to separate molecules by size. [202, 203], also referred to as 
gel filtration/permeation chromatography. The principle of SEC is separation over a gel 
filtration column, which consists of porous particles. Molecules will flow through the 
column with different retention times, based on their size. Larger molecules will only 
be able to pass through the inter-particle space, whereas smaller particles can also pass 
through	the	pores	inside	the	particles.	For	Aβ	chromatography	most	often	Superdex	75	
or 200 columns are used, depending on the desired fractionation range [163, 189, 204, 
205]. However, columns containing matrixes of different material and other particle sizes 
have also been used [189, 206, 207]. With flow rates of 0,5-1 ml/min an experiment can 
be conducted within one hour (sample preparation and column calibration excluded). 
However,	 rather	high	amounts	of	Aβ	are	needed,	namely	volumes	between	100-500	μl	
with concentrations of 1-2 mg/ml.
SEC	 has	 generally	 been	 applied	 in	 two	 ways.	 First,	 for	 analytic	 purposes,	 the	 Aβ	 size	
distribution	of	a	sample	can	be	determined.	For	instance,	the	protofibrillar	Aβ	intermediate	
was for the first time extensively studied, after it appeared over time as a second peak in 
the	analysis	of	chromatographed	synthetic	Aβ	[149].	Also	the	presence	of	Aβ	oligomers	in	
brain homogenates and body fluids could be demonstrated by using SEC, both in humans 
[207, 208] and transgenic mice [144]. Second, SEC has been used for preparative purposes 
to	obtain	a	sample	enriched	 for	oligomeric	Aβ	of	a	certain	size.	Both	naturally	 isolated	
[209], cell derived and synthetically derived oligomers [210], obtained by SEC, have been 
used to investigate their toxicity and to study aggregation pathways in vitro [211-213]. 
SEC offers an advantage in comparison with SDS-PAGE, because the separation of proteins 
is conducted under non-denaturing conditions and therefore is supposed to present 
a more realistic picture of the sample content. Furthermore, buffer conditions in SEC 
resemble physiological conditions much better than in SDS-PAGE, because there is no 
need for detergents or reducing reagents. This advantage results in a better reflection of 
natural conditions for oligomers.
It cannot be excluded, however, that during SEC oligomers and aggregates are dissociated 
to a certain extent (or, alternatively, stimulated to aggregate) because of dilution, change 
of solvent conditions or adsorption to the surface of the stationary phase particles [214]. 
In	 addition,	 Aβ	 collected	 after	 SEC	 can	 be	 prone	 to	 aggregate	 at	 high	 concentrations.	
Another	possibility	is	that	Aβ	might	stick	to	tube	walls	during	storage,	which	is	especially	a	
problem	for	Aβ	samples	with	low	concentration.	It	has	already	been	shown	that	different	
tube	materials	 can	 bind	 Aβ	 in	 cerebrospinal	 fluid	 (CSF)	 samples,	 thereby	 lowering	 the	
measurable concentration [215]. Another disadvantage of the method is the relatively 
low sample recovery, due to dilution effects inherent to the procedure and proteins 
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sticking to the stationary phase [214]. Furthermore, interactions between proteins and 
the column material will result in inaccurate molar mass calculations [216]. In addition, 
molecular mass determination in SEC may be inaccurate since elution of proteins is not 
only dependent on molecular weight but also on protein conformation, and proteins are 
compared to molecular weight standards. 
Resolution of SEC is lower than that of SDS-PAGE, and usually not as optimal as desired for 
Aβ	research	[139],	since	small	oligomers	are	not	resolved.	Therefore,	SEC	is	particularly	
suitable for coarse separation of small oligomers from the larger oligomers or (proto)
fibrils [139, 149, 217]. The problem of poor resolution may be partly solved by applying 
two columns with different particle sizes in tandem, resulting in a better resolution of 
small	Aβ	forms	(mono-	to	hexamers)	[194].	Also	the	use	of	a	 light	scattering	method	in	
combination with SEC, offers an advantage in determining the molar mass of particles 
(see paragraph 2.3). 
In	short,	SEC	can	be	successfully	applied	for	analysis	and	fractionation	of	Aβ	oligomers.	
There are however a few downsides, like low resolution of small oligomers, interactions 
of proteins with the stationary phase and possible influence of the buffer on oligomer 
content.
2.3.3 Light Scattering
Light scattering techniques use laser light and a photodetector to measure the intensity 
of light reflected by particles in solution [218]. Multi Angle Laser Light Scattering (MALLS) 
is	a	form	of	static	or	classic	light	scattering	that	has	been	used	to	study	Aβ	aggregation.	
The scattering of the laser light is measured at multiple different angles and from this the 
average molecular weight of particles in suspension can be calculated.
An often used combination of techniques is SEC-MALLS: proteins are separated by 
SEC and subsequently the molecular mass is determined by MALLS, e.g to identify the 
different	Aβ	forms	present	 in	an	ADDL	solution,	namely	monomers	and	high	molecular	
weight oligomers [189]. Another study investigated the potentials of a combination of 
MALLS with asymmetric flow field-flow fractionation (a separation technique in which the 
sample flows between two plates and a perpendicular force is applied to elute proteins 
through	 a	membrane	 in	 the	 bottom	 plate)	 to	 study	 Aβ	 aggregation	 [219].	 Preliminary	
results showed that this combination provides clear insight into the time-dependent 
aggregation	 process.	 Over	 24	 hours	 Aβ	 retention	 times	 increase,	 indicating	 a	 larger	
hydrodynamic radius (RH) – a computational parameter related to the size of a molecule 
– of eluting species. Furthermore, the peak broadens which indicates that a wider range 
of	Aβ	species	is	present.	
Another variant of the light scattering techniques is Dynamic Light Scattering (DLS), also 
called Quasielastic Light Scattering or Photon Correlation Spectroscopy [218, 220]. The 
difference between static light scattering and dynamic light scattering is that in the static 
version the average intensity over time is calculated, whereas in DLS the fluctuations in 
light intensity are detected. These fluctuations are caused by movement of the particles, 
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and therefore regarded as diffusion coefficients [214, 221]. Usually DLS data are converted 
from the diffusion coefficient into the RH of the particles. Both MALLS and DLS have been 
combined	to	study	the	effect	of	low	pH	on	Aβ40 protofibril formation [222]. Furthermore, 
DLS	has	 been	used	 to	 study	 the	 interfering	 effect	 of	Aβ42 C-terminal fragments on the 
oligomerization	of	full	 length	Aβ	[223].	However,	DLS	is	more	often	used	to	gain	kinetic	
information about the fibrillization process, for instance the growth rate of fibrils under 
various conditions [224, 225]. 
Even though light scattering techniques are quite sensitive [226], the resolution is 
rather poor and to differentiate between two particles, a difference in molecular 
weight of about a factor 8 is required [214]. Furthermore, small amounts of 
monomers	 and	 oligomers	 are	 difficult	 to	 detect	 among	 larger	 Aβ	 species	 [227],	
since light scattering detection provides an average picture of oligomers/aggregates 
present in the sample. To detect smaller oligomers, the technique can be combined 
with SEC [149]. Because this combination is often used in-line, the input for LS, 
in terms of sample volume and concentration, is usually similar to the output of SEC.
2.3.4 Analytical Ultracentrifugation
In Sedimentation Velocity (SV) and Sedimentation equilibrium (SE) molecules are 
separated from each other by ultracentrifugation at very high speed up to 60,000 
rpm. Movements of these molecules and sedimentation speed are analyzed. In SV, 
movements and sedimentation in the centrifuge are dependent on the molecular 
weight and shape of a molecule, which is expressed as the sedimentation coefficient. 
For instance, molecules sediment faster, when they have a larger mass, whereas 
molecules with small masses will need more time to settle. The more conventional 
method SE is closely related to SV, but depends solely on the molecular weight 
of a molecule. The big advantage of SV compared to SE is, that performance 
time, which is needed to analyze molecules and their aggregation forms, is much faster 
in SV (mostly between 1-24 hours) than in SE (several days). 
With	respect	to	the	different	forms	of	Aβ,	both	techniques	are	useful	 in	detecting	and	
quantifying the amount of aggregates [228]. This was illustrated in a study in which a 
pharmacological	inhibitor	of	Aβ	aggregation	was	tested	on	Aβ42 labeled by a fluorophore 
[229].	Aggregation	of	Aβ42 was measured after 5 hours, 1, 2 and 5 days by SV and the 
sedimentation	coefficient	increased	over	time,	resembling	the	growth	of	Aβ	aggregates.	
The added test compound was able to reduce the sedimentation coefficient and thus 
the	size	of	aggregates.	 In	a	sample	with	mixed	Aβ	forms,	rotor	velocity	can	be	used	to	
separate	different	species.	For	 instance,	when	3	mg/ml	of	Aβ40	and	Aβ42 was dissolved 
in PBS, it was possible to differentiate between three types of species [230]. At 3,000 
rpm insoluble, large aggregates were measured with sedimentation coefficients of 
~50,000 S and molecular masses of ~1010 Da. After increasing rotor velocity to 30,000 
rpm, soluble aggregates with sedimentation coefficients of ~30 S and masses of ~106 Da 
sedimented. Remaining material, that did not sediment at this high speed, was identified 
as	monomeric	Aβ.
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SV and SE are also able to analyze effects of different conditions like solvents and pH 
on	 the	 aggregation	 and	 hydrodynamic	 behavior	 of	 Aβ.	 SE	was	 used	 to	 investigate	 the	
effect	of	pH	on	Aβ	aggregation	[216].	At	pH	3,	the	average	molecular	mass	of	Aβ40 was 
938,000	Da.	At	pH	5	no	such	Aβ40 aggregates could be detected and at pH 7, the average 
molecular	mass	was	12,100	Da.	The	results	by	SE	could	show,	that	aggregation	of	Aβ	is	
pH-dependent. 
Recently, different fluorescent dyes were tested to measure amyloid oligomers by SV 
[231]. The dyes were attached in different ways to the amyloidogenic proteins apoC-II 
and huntingtin. These fluorescence-detection systems in general increased the sensitivity 
to subnanomolar concentrations. Furthermore, the range of concentrations could be 
extended spanning 10-10 to 105 M.
Compared to other separation techniques such as SEC or SDS-PAGE, SE and SV are not 
prone to errors in molecular mass calculations since, for example, no stationary phase 
or gel matrix is used, that could nonspecifically bind proteins [216]. Furthermore, higher 
resolutions can be achieved and a broad size range of molecules can be identified in one 
experiment. Also monomers and dimers are distinguished easily and with high accuracy 
[232]. The techniques enable the study of samples over a wide range of pH, ionic strength 
and temperatures. Therefore application of SE and SV is in particular useful for analysis of 
complex heterogeneous mixtures of molecules [233]. However, the techniques are limited 
by the absence of a direct relationship between sedimentation coefficient and the size 
of aggregates, in particular for fibrils [234]. Other disadvantages are the relatively long 
running	time,	in	particular	for	SE	and	for	small	proteins	like	small	Aβ	aggregates,	and	the	
high concentrations that are needed (absorbance at OD280 in the range of 0.1-1.5). Both 
factors	might	enable	Aβ	aggregation	processes	during	the	ultracentrifuge	run.	Usually	the	
temperature during an SV or SE experiment is 20°C, but to slow down or prevent unwanted 
aggregation processes, the temperature could be decreased to 4°C [235]. It also should 
be noted that SE is not suited to analyze large amyloid fibrils, because they sediment too 
quickly and can therefore not form an equilibrium concentration gradient [235]. Both, SV 
and SE experiments require an expensive ultra-centrifuge (usually optimaTM XL-A or XL-I) 
and equipment to measure sedimentation speed.
2.4 Techniques to determine kinetic characteristics based 
on spectroscopy
Spectroscopic	techniques	are	usually	applied	to	gain	information	about	the	kinetics	of	Aβ	
aggregation. In real-time the fibrillization state of a sample can be investigated. Turbidity, 
Congo Red and Thioflavin T assays are unsuitable to detect small oligomers, but can be 
used to show the presence of protofibrils and fibrils. Techniques based on Fluorescence 
Microscopy are also able to detect LMW oligomers.
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2.4.1 Turbidity
It	 is	possible	 to	study	the	kinetics	of	Aβ	aggregation	by	the	relatively	simple	technique	
of turbidity measurement, usually performed at 400-420 nm. The sample can be applied 
to a microplate well or a cuvette, depending on the type of spectrophotometer used. 
For the latter, a larger sample volume (up to 1 ml) is required. The technique is not 
very sensitive, concentrations of around 50 µM are generally used [236, 237]. Also, the 
method	is	not	optimally	suited	to	study	Aβ	oligomerization	[238].	Turbidity	only	detects	
fibrillary aggregates [149, 239], because protofibrils are too small to reflect light of 400 
nm. This is also evident when the technique is compared to a Thioflavin T (ThT) assay 
which is believed to allow detection of both protofibrils and fibrils (see paragraph 3.2). 
It has previously been concluded that the curves generated in turbidity measurements 
display a significantly shorter lag time than those in ThT measurements, which indicates 
that turbidity can only be measured later in the aggregation cascade and therefore 
reflects larger species [200]. Differences in ThT and turbidity signals were also observed 
in aggregation studies with superoxide dismutase 1, an amyloidogenic protein that 
pathologically aggregates in amyotrophic lateral sclerosis. While Thioflavin T dye showed 
an increasing signal over time, no turbidity was measured, indicating that no insoluble 
particles (fibrils) were formed. 
Turbidimetric assays have especially been used to study the aggregation kinetics of 
Aβ	 [239-241].	 In	 one	 study	 the	 aggregation	 of	 the	 highly	 toxic	 Aβ25-35 was investigated 
and	it	was	demonstrated	that	Aβ	aggregates	that	were	shifted	in	pH	from	3	to	7.4	were	
significantly reduced in turbidity [242]. Also, this technique can be used in a simple way 
to	take	a	rapid	look	at	the	effect	of	certain	compounds	on	Aβ	fibrillization	[237].	It	was	
for instance recently used to demonstrate that the addition of both Cu2+ and Zn2+	to	Aβ	
increases turbidity and thus its aggregation [236]. 
Advantages of the technique are its simplicity and the requirement for a standard 
spectrophotometer. However, disadvantages of turbidity measurements are that protein 
concentrations	need	to	be	relatively	high	to	be	measured.	Furthermore,	it	is	not	suitable	to	
detect	oligomers	or	even	protofibrils	and	it	is	not	applicable	for	quantification	studies.	The	
assay	might	however	be	more	advantageous	for	analysis	of	non-amyloidogenic	aggregating	
proteins	(e.g.	TDP-43),	for	which	no	alternatives,	like	the	amyloid-staining	compound	ThT,	
are available.
2.4.2 Thioflavin T and Congo Red Assays
Many	 extrinsic	 fluorescent	 probes	 have	 been	 developed	 that	 bind	 amyloid	 proteins.	
Fluorescent dyes that bind non-covalently to amyloid proteins are known for more than 
100	years	[243].	Some	other,	newer	dyes	like	tetramethylrhodamine,	fluorescein	or	Cy3/Cy5	
(different	colours	available)	use	covalent	bond	formation	between	the	dye	and	a	specific	
chemical	group	in	the	structure	of	Aβ,	usually	the	ε-amino	group	of	a	lysine,	the	α-amino	
group of the N-terminus or the thiol group of cystein [244-246]. We will focus in this paper 
on	the	two	most	important	and	widely	used	probes;	Congo	Red	(CR)	and	Thioflavin	T	(ThT),	
which bind non-covalently to amyloid. Both undergo absorbance spectrum changes upon 
binding	to	amyloid	proteins,	for	instance	Aβ,	huntingtin,	α-synuclein	and	prion	protein	[247].	
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CR is mainly used as a histological staining dye to demonstrate the presence of amyloid 
aggregates in the brain [248]. Besides in histochemistry, CR is also applied in in vitro 
aggregation studies. In steady-state fluorescence assays, spectral data measured in 
a spectrophotometer can provide information about the aggregation state of amyloid 
proteins [244]. Upon binding to amyloid proteins, the absorption maximum of CR shifts 
under crossed polarization from a wavelength of 490 nm to 540 nm [247]. 
Figure 6: Application of thioflavin T to 
quantify formation of prefibrillar Aβ 
aggregates 
A)	 Aβ42 fibril formation leads to a high 
Thioflavin T fluorescence (and open 
circles in C). B) Fibrils are absent after 
Aβ42 preincubation with prefoldin; the 
corresponding Thioflavin T fluorescence 
is	 reduced	 compared	 to	 fibrillar	Aβ	but	
is still present and represents prefibrillar 
Aβ	 (and	 closed	 circles	 in	 C). Key: A.U. 
= Arbitrary Units. ([262] Copyright 
John Wiley and Sons. Reproduced with 
permission.)
A
C
B
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Binding of CR is mainly limited to fibrils, but it may also to a lesser degree bind oligomers 
and protofibrils [249]. A point of attention is the fact that CR has been shown to be able 
to	 inhibit	Aβ	aggregation,	plaque	formation	and	toxicity,	e.g.	 towards	cultures	 from	rat	
hippocampal neurons [250, 251], human macrophages [252] and pericytes [253]. This 
might be caused by a stabilization of the monomeric species [254]. However, at low 
concentrations of CR, fibril formation has been shown to be enhanced [255]. 
Another ubiquitously used fluorescent amyloid binding dye is Thioflavin T (ThT). This 
dye is, similar to CR, widely applied to identify amyloid deposits in postmortem brain 
tissue [256, 257] and as a probe to quantify protein aggregation in vitro [258, 259]. ThT 
also undergoes an absorbance spectrum shift. Free, unbound ThT has an excitation and 
emission maximum of respectively 385 and 445 nm, and these are elevated to respectively 
450 and 482 nm upon amyloid binding [259]. It was first believed that ThT binds only 
β-sheets	in	protein	structures	[259],	however	recent	evidence	shows	that	ThT	supposedly	
also	binds	similarly	shaped,	non	β-sheet	containing	cavities	inside	molecules	[260].
ThT assays can be used to study the influence of external factors on the fibrillization, 
for instance in the search for aggregation inhibitors. However, the technique should be 
used with caution in the presence of exogenous polyphenols, because their intrinsic 
fluorescence can cause significant absorption in the spectral range of ThT, thereby 
significantly biasing the results [261]. 
It	has	been	well	established	that	ThT	and	CR	both	bind	Aβ	fibrils,	but	whether	these	dyes	
also	bind	smaller	oligomeric	Aβ	is	still	under	debate.	By	measuring	fluorescence	intensity,	
it has been shown that ThT is able to bind fibrils and protofibrils, but not monomeric 
and	 dimeric	 Aβ	 [227].	 Another	 indication	 that	 ThT	 is	 able	 to	 bind	 HMW	 oligomers	
and	protofibrils	was	 found	when	 the	 aggregation	of	Aβ	was	 reduced	by	 the	molecular	
chaperone prefoldin [262]. In this experiment, electron microscopy revealed the absence 
of mature fibrils in these samples, but both particles smaller than fibrils (that on SDS-
PAGE were found to be high molecular weight oligomers) and protofibrils were visible 
that likely generated the ThT signal (figure 6). In addition, in other studies it was also 
found	that	CR	and	ThT	may	bind	to	oligomeric	Aβ	[263].	ThT	however	shows	a	relatively	
low binding affinity. In addition, the binding characteristics of ThT and CR to amyloid 
proteins and their specificity are not fully understood [247]. The current status of today’s 
research of their binding characteristics is extensively discussed in a recent review by 
Groenning (2009) [264]. 
 
In summary, extrinsic fluorophores have proven to be useful tools to investigate the 
molecular mechanisms involved in protein fibrillization in a high-throughput screening 
way and to quantify amyloid aggregation over time [265]. The methods are fast, since it is 
relatively simple to withdraw only a few microliters of sample from an incubation mixture 
of	between	0,5	-	50	µM	of	Aβ	and	measure	those	at	different	time	points	[206,	262,	263].	
Nevertheless, as mentioned above, the specificity of both CR and ThT and the protein 
structure they bind to are still relatively unclear, but in general the usefulness in studying 
smaller oligomers seems to be limited.
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2.4.3 Fluorescence Microscopy
By attaching a fluorescent label (such as Hilyte FluorTM	 or	 Alexa-fluor	 488)	 to	 Aβ,	
aggregation	 of	 Aβ	 can	 be	 studied	 by	 fluorescence	 microscopy	 (FM).	 Diffusion	 of	 the	
fluorescent molecules in solution can be tracked and the RH, can be calculated [266]. 
An	 advanced	 application	 that	 uses	 a	 fluorescent	 label	 to	 study	 Aβ	 polymerization	 is	
fluorescence correlation spectroscopy (FCS). For an extensive description of the technique 
and its applications we refer to a review by Krichevsky and Bonnet (2002) [267]. In short, 
this technique is based on fluctuations of fluorescent intensity that are measured with 
a confocal laser microscope. These fluctuations can be detected in a confocal volume 
of only 1 femtoliter. Fluorescent particles in this volume are excited by the laser and 
every single photon is recorded. Furthermore, because the technique is based on single-
molecule detection, the fluorophores are diluted to such an extent that only a few are 
present in the confocal volume at the same time. This enables the detector to measure 
between sub-nanomolar to micromolar concentrations of fluorophores, and only 20 µl 
of sample is required. Fluctuations in fluorescent signal, which are caused by diffusion 
of particles in and out of the confocal volume, can be quantified by the autocorrelation 
of	 time	 and	 fluorescent	 intensity	 [268].	 The	 residence	 time	 (τD)	 of	 a	molecule	 in	 the	
confocal volume is in proportion with its RH. FCS has been used to study the aggregation 
and	 the	 composition	 of	 samples	 of	 synthetic	 Aβ	 [245,	 269-271].	 Usually	 a	 very	 low	
concentration	 of	 labeled	 Aβ	 is	 co-incubated	 with	 a	 higher	 concentration	 of	 unlabeled	
Aβ	 and	 the	peptide	mixture	 is	 allowed	 to	 aggregate.	Observed	differences	 in	 diffusion	
time and fluorescence intensity allow estimation of the size of the oligomers. The effect 
of	 fluorophore	 conjugation	 on	 the	morphology	 and	 function	 of	 Aβ	 oligomers	 has	 also	
been	studied	[246].	When	labeled	Aβ	was	incubated	to	aggregate,	the	N-terminally	bound	
fluorophore was shown to cause atypical oligomer and fibril formation. Thus, in order 
to	 retain	 the	oligomeric	 structure	of	unlabeled	Aβ	oligomers,	 it	 is	 advised	 to	 label	 the	
proteins after the aggregation process. Both strategies are described in figure 7. Another 
option	 is	mixing	a	 small	amount	of	 labeled	Aβ	with	a	 large	concentration	of	unlabeled	
protein, but this option was not investigated [246]. In one recent article, FCS was used in 
combination with EM and toxicity assays, to identify and investigate different pathways 
that	 lead	 to	 fibril	 formation	 and	 the	 formation	of	 highly	 toxic,	 spherical	 Aβ	oligomers,	
termed amylospheroids [141]. In this study, FCS provided information regarding the mass 
and distribution of aggregates in the sample. Furthermore, EM gave insight into the 
morphology of the aggregates.
 
A relatively novel fluorescence-based technique, using fluorescent nanocrystals, 
also	 called	 quantum	dots	 (QD),	 has	 been	 employed	 to	 image	 the	 aggregation	of	Aβ	 in	
time [200]. QDs consist of semiconductor material (cadmium mixed with selenium or 
tellurium) surrounded by a shell of zinc sulfide and belong to the category of fluorophores. 
Compared to conventional fluorophores they are very small, with sizes in the nanometer 
range (15-20 nm), which is close to the average protein size. QDs can fluoresce without 
the involvement of electronic transitions. To fluoresce, QDs make use of the formation of 
excitons that have much longer lifetimes than conventional fluorophores, which enables 
studies over time. Furthermore, dependent on the size and the energy of the exciton, 
different colors are generated, a property useful in multiplex assays using different colors 
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for visualization. QDs are functionalized with chemical groups, that can be activated and 
are	able	 to	bind	 to	chemical	groups	of	proteins.	To	couple	Aβ,	QDs	 functionalized	with	
polyethylene glycol and amine groups were used [272]. By using a fluorescence microscope, 
tiny spots were observed of which the relative fluorescence could be measured, with the 
ability	 to	 discriminate	 even	 between	 Aβ	 dimers,	 trimers	 and	 tetramers.	 Only	 1-10	 nM	
protein	in	a	volume	of	2	μl	was	needed.	After	prolonged	incubation	of	a	sample	with	QDs,	
oligomer formation could be observed under the microscope in real-time. 
The	most	 important	advantage	of	using	this	technique	for	 imaging	Aβ	is	that	the	small,	
but very stable QDs enable visualization of a single molecule over longer time intervals 
in an intact cell system. Fixation or immobilization procedures, which are necessary in 
AFM and EM studies, are not required. Furthermore, the technique is relatively easy to 
perform. Only a fluorescence microscope is required and the QDs themselves, which are 
commercially available. A major disadvantage is that, although QDs are in the nanometer 
Figure 7: Two strategies to generate fluorescent labeled aggregates
In	strategy	A	labeled	monomeric	Aβ	is	incubated	during	the	oligomerization	and	fibrillization	process.	In	
strategy B the products after aggregation are subsequently fluorescently labeled. ([246] Copyright John 
Wiley and Sons. Reproduced with permission)
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size	range,	this	is	still	significantly	larger	than	an	Aβ	molecule.	This	most	likely	interferes	
with oligomerization processes and one could argue that the observed aggregation is not 
comparable to in vivo events. This problem was attempted to circumvent by incorporating 
only	a	few	QDs	with	Aβ40	into	emerging	fibrils	of	Aβ42. 
Fluorescence	microscopy	 can	be	used	either	 by	 labeling	Aβ	directly	with	 a	 fluorescent	
dye or by using quantum dots. The huge advantage of FM is the ability of imaging in a 
relatively intact sample, which is not the case for e.g. electron microscopy, and imaging 
in real-time. A draw-back for FM is, that labels (dye or QDs) have to be attached, which 
possibly influence aggregation and fibrillogenesis. Also the issue of auto-fluorescence 
might play a role. Proteins with tryptophan, tyrosine or phenylalanine can show some 
intrinsic fluorescence and thereby interfere with the analysis [273].
2.5 Techniques for quantification based on immunology
Immunodetection is based on the availability of specific antibodies. Currently, a large 
number	of	different	antibodies	is	available,	specific	for	an	Aβ-isoform,	a	conformational	
epitope	within	Aβ	or	even	an	isoform	in	a	specific	conformation	[274].	The	most-common	
technique	 for	 immunodetection	of	oligomeric	Aβ	 is	 the	enzyme-linked	 immunosorbent	
assay (ELISA). Novel variants on this classic design, such as the Bio-barcode assay (BCA) 
and immunofluorescent assays have been developed, which are more sensitive in 
detection with detection limits into the attomolar range. 
2.5.1 Sandwich ELISAs
ELISAs	[275]	are	commonly	used	for	detection	of	Aβ	monomers	and	usually	reach	a	detection	
limit	of	1-10	pM	in	about	100	μl	of	sample	[276].	Running	an	ELISA	takes	between	a	few	
hours and a day, depending on the number of incubation steps (also usually one overnight 
incubation). Given its relative simplicity, ELISA is also an attractive platform to measure 
oligomeric	Aβ	and	 the	availability	of	an	ELISA	 that	may	quantify	Aβ	oligomers,	but	not	
monomers,	would	be	of	great	interest	in	biomarker	research,	studies	of	the	Aβ	aggregation	
process	in	general,	or	studies	aimed	at	determining	the	neurotoxicity	of	Aβ	species.	Two	
strategies have been used to develop a specific quantification method for oligomers: (A) 
the use of the same capture and detection antibody (the latter labeled with e.g. biotin or 
horseradish peroxidase) or (B) the application of an oligomer-specific antibody in the ELISA 
(Box 2). 
 
An	 Aβ	 oligomer-specific	 ELISA	 according	 to	 strategy	 A	 has	 already	 been	 described	 in	
1999	[277].	Several	monoclonal	antibodies	directed	against	Aβ	have	been	applied	in	this	
technique. This type of ELISA has been used to study the time-dependent oligomerization 
of	Aβ	[277,	278],	which	resulted	in	a	temporal	increase	in	signal	suggesting	an	increased	
abundance of oligomers. Recently, it was described that, by using this approach, 
concentrations of high molecular weight oligomers were significantly elevated (p < 0.0001) 
in	 CSF	 of	 AD	 patients	 [194].	 Using	 Aβ	 fractionation	 by	 SEC	 it	was	 concluded	 that	 only	
HMW	oligomers	(mainly	10-20mers	of	synthetic	Aβ)	could	be	detected	by	this	assay.	The	
authors hypothesized that the epitopes for the detection antibody, located on residues 
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1-16, might have been hidden inside the 3D-structure of the relatively small oligomers, 
and were only accessible in the larger oligomers due to structural differences. 
Several	 different	 antibodies	 specifically	 directed	 against	 oligomeric	 Aβ	 have	 been	
developed	 and	 their	 specificity	 is	 usually	 shown	 in	 dot	 blots	 [279-281].	 Although	 using	
these	antibodies	 in	an	oligomer	specific	ELISA	(strategy	B)	seems	rather	straightforward,	
not	many	attempts	have	been	reported	yet.	Recently,	the	monoclonal	antibody	OMAB	was	
tested	 for	 its	 specificity	by	applying	 it	 as	 a	 capture	antibody	 in	 a	 sandwich	ELISA	 [282].	
Results	 showed	 that	 it	 is	 highly	 specific	 for	 oligomers,	 and	 does	 not	 detect	monomers	
or	 dimers,	 because	 it	 displays	 very	 fast	 dissociation	 kinetics	 for	 these	 molecules.	 In	
another	study	an	oligomer	specific	ELISA	was	designed	to	measure	Aβ	oligomers	in	brain	
homogenates	 [283].	 First,	 a	 well-studied	 antibody	 (designated	 as	 A11)	 was	 used,	 that	
detects	high	molecular	weight	Aβ	oligomers	(from	approximately	40	kDa	and	up),	but	not	
low	molecular	weight	Aβ	or,	on	the	other	hand,	fibrils	[281].	A11	is,	however,	not	specific	
for	Aβ,	but	also	recognizes	oligomer	preparations	of	other	proteins,	for	instance	multimers	
Box 2) Oligomer specific ELISAs: Two strategies to specifically measure oligomers in a sandwich ELISA 
have	 been	 described.	 In	 a	 monomer	 Aβ	 ELISA,	 the	 antigen	 is	 captured	 by	 a	 capture	 antibody	 and	
subsequently detected by another detecting antibody. In an oligomer ELISA according to strategy A the 
characteristic feature of monoclonal antibodies, i.e. the ability to specifically bind only one epitope in a 
molecule, is used. In this design, the same antibody is used for both capture and detection of the target 
protein. The detection antibody is labeled in order to discriminate it from the capture antibody. In a 
monomeric protein, only one copy of the target epitope is present, and when this epitope is occupied 
by the capture antibody, the detection antibody will not be able to bind.  In an oligomeric protein on the 
other hand, two or more copies of the specific epitope are available and, as a result, both the capture 
and detection antibody can bind and this will result in an ELISA signal. In contrast, in strategy B a capture 
antibody	directed	against	Aβ	is	used	in	combination	with	an	oligomer-specific	detection	antibody.
Total	Aβ	ELISA Strategy A: Same capture and   
labeled detection antibody
Strategy B: Oligomer 
specific antidbody
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of	α-synuclein,	polyglutamate,	prion	protein	and	several	heat	shock	proteins	[281,	284].	
However,	 this	 attempt	 was	 unsuccessful,	 and	 subsequently	 the	 authors	 succeeded	 in	
designing	an	oligomeric	Aβ	ELISA	using	two	other	oligomer-specific	antibodies,	7A1a	and	
1G5.	These	studies	showed	the	feasibility	of	detecting	specific	forms	of	Aβ	by	ELISA	with	
the	use	of	antibodies,	but	also	showed	that	not	every	oligomer	specific	antibody	might	be	
suitable	to	use	in	ELISA.	In	another	study,	oligomer-specific	antibodies	were	generated	by	
immunization	with	a	specific	oligomeric	Aβ	isoform,	designated	globulomers	[285].	These	
antibodies	recognized	oligomers,	but	not	monomers	or	fibrils.	Using	an	oligomer-specific	
polyclonal	antibody	for	capture	and	a	generic	Aβ	antibody	for	detection,	higher	signals	were	
obtained	in	AD	patient’s	and	transgenic	mice’s	soluble	brain	extracts	compared	to	controls.	
The	 same	 test	 failed	 to	 demonstrate	 detectable	 levels	 in	 CSF.	 Finally,	 a	 combination	 of	
both	strategy	A	and	B	has	also	been	described	[286].	In	this	study	a	monoclonal	antibody	
directed	against	protofibrillar	Aβ	was	used	both	as	capture	and	detection	antibody.	Results	
demonstrated	that	this	ELISA	detects	protofibrillar	Aβ	levels	 in	cell	culture	media	and	in	
homogenized mice brains. 
Thus,	ELISA	techniques	may	be	good	tools	for	specific	measurement	of	some	forms	of	Aβ	
oligomers. However, the functionality of the ELISA is highly dependent on the quality of 
the components used. With good quality antibodies, substrates with higher sensitivity, 
such as chemiluminescent or fluorescent, instead of chromogenic substrates such as 
TMB (3,3’,5,5’-Tetramethylbenzidine), can be used. However, both background levels and 
inter-assay variation may also increase. Background levels of non-specific binding to the 
Fc region can be eliminated by using only the Fab’ fragment of the detection antibody 
(conjugated with its detection label) [194]. Furthermore, the detection limit of the assay 
is highly dependent on the ability of the antibody to bind different types of oligomers, and 
application of these oligomer ELISAs may be hindered by the expected low concentrations 
of oligomers in e.g. body fluids. This is illustrated by a study in which oligomers were 
quantified in plasma samples. Plasma from 7 out of 10 control subjects and 17 out of 36 
AD	patients	 contained	 oligomeric	 Aβ	 levels	 below	 the	 detection	 limit	 [287].	 Detection	
limits of oligomer ELISA described are in the nM and pM ranges [286, 288]. In addition, 
oligomers are possibly ineffectively measured by ELISA methods, as not all epitopes may 
become occupied by antibodies or be available. Furthermore, the magnitude of this effect 
may depend on the size of the oligomers. This leads to an underestimation of their actual 
concentration [289], since the quaternary structure of oligomeric proteins may hinder its 
proper detection. 
Recently, it was described that false-positive results in human body fluids could be 
obtained with the type B oligomer ELISA, caused by heterophilic antibodies [290, 291]. 
These antibodies, present in human plasma, serum and CSF, are polyreactive and directed 
against antibodies from other species. An estimated 10-40% of patients are believed to 
have non-specific antibodies directed against murine antibodies (human-anti-mouse 
antibodies, HAMAs) and how these arise is still not completely clear [292]. Since the 
same capture and detection antibody are used in this assay, these can be cross-linked 
by heterophilic antibodies, leading to false-positive results in the absence of antigen 
as	demonstrated	 for	 the	previously	described	Aβ	protofibril	 specific	ELISA	 [286].	These	
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results point to the importance of ELISA specificity tests and lead to the conclusion that 
body	 fluids	 might	 need	 pre-treatment	 to	 remove	 heterophilic	 antibodies,	 before	 Aβ	
oligomers can be reliably measured. 
In	 short,	 an	 ELISA	 has	 potential	 as	 a	 robust	 and	 quantitative	 method	 of	 Aβ	 oligomer	
quantification, since it can be designed to detect solely oligomeric species with the 
exclusion of monomeric species. In this way, ELISA offers many advantages over other 
techniques, since it is simple, high-throughput, possibly very specific and quantitative. 
Disadvantages may include the need for additional techniques (e.g. SEC) to establish 
which oligomeric species are detected and which are not, and the necessity to exclude 
confounding factors such as the detection of heterophilic antibodies. Furthermore, the 
sensitivity	 of	 the	 ELISA	 technique	might	 not	 be	 sufficient	 to	measure	oligomeric	Aβ	 in	
human body fluids.
2.5.2 Bio-barcode assay
In 2003, a highly sensitive method for detection of molecules in body fluids was introduced: 
The BCA [293] (Box 3). This novel technique is based on sandwich methodology using 
magnetic microparticles (MMPs) and nanoparticles (NPs), and allows, due to an extra 
amplification step, measurement of protein targets at concentrations in the attomolar 
range. The BCA therefore offers a much lower detection limit than conventional ELISA 
techniques (see chapter 4.1).
Previously, the BCA has been used for detection of ADDLs in CSF, showing that it is possible 
to measure oligomers that were otherwise not detectable. In addition, AD patients 
and non-demented age-matched controls could be differentiated using this technique 
[294]. The ADDL concentration was 1.7 fM in the AD group and ~200 aM for the control 
group. Concentrations of more than 500 fM were too high to measure with the BCA. 
The assay could be completed in less than three hours. The main advantage of the BCA 
is the sensitivity provided for detecting proteins in body fluids. Only few ELISA-based 
techniques (e.g. immuno-PCR [295], single-molecule ELISA [296]) can compete with the 
BCA if compared in terms of limit of detection. However, sensitivity is also dependent on 
the specificity and binding efficiency of the antibodies used and on the size of the NPs and 
their loading capacity with oligonucleotides. Furthermore, the BCA offers the possibility 
for multiplexing. By using different antibodies against different targets with corresponding 
specific oligonucleotide tags, many analytes can be measured simultaneously in one 
sample. 
In its first design the BCA had a very limited dose-response curve. The assay was only 
applicable for antigens at very low concentrations and could only come into consideration 
after a conventional ELISA assay failed to detect the target. In addition, different 
concentrations of the antigen produced only small differences in detectable signal. The 
dose-response curve could be broadened to a range of about 4 logs by improving the 
light-scattering abilities of the gold NPs that were used for detection [295]. Yet the BCA 
is a complex method with several incubation and washing steps. Increase in speed and 
simplicity are achieved with bio-barcodes, containing a fluorophore label, that is attached 
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to polystyrene microparticles. These particles are larger than NPs and therefore can bind 
a much larger amount of bio-barcodes. After release, the bio-barcodes are not amplified 
before detection, but are detected directly by fluorescence analysis [297]. Although more 
bio-barcodes can be attached and measured directly, the sensitivity of this approach 
is slightly decreased and multiplexing possibilities are greatly reduced, limited by the 
amount of available fluorophores. In terms of specificity and quality of the used antibody 
as well as the risk in detecting HAMAs, the same considerations apply for the BCA as for 
the conventional ELISA (see chapter 4.1).
Recently a chip-based BCA has been developed, also called surface-immobilized bio-
barcode assay (SI-BCA) [298]. Here, MMPs are not needed anymore. Instead the capture 
antibody is attached to the inner surface of a microfluidic channel and the sandwich is 
formed on the modified surface. This SI-BCA is faster (only 80 min) than the MMP-based 
Box 3) Bio-Barcode Assay: The principle of the BCA is, like in many conventional ELISA methods, a sandwich 
design in which the target protein is sandwiched between a capture and a detection antibody (Fig. 10). 
The capture antibody is attached to magnetic microparticles (MMPs), while the detection antibody 
is coupled to nanoparticles (NPs) that, in addition, are loaded with doublestranded oligonucleotides. 
Here, one oligonucleotide strand is covalently attached to the NPs, whereas its complementary 
sequence (also called bio-barcode) is hybridized to the nanoparticle-bound oligonucleotide and later 
can be dehybridized again. The amplification signal is generated at this step due to the presence of 
multiple times more oligonucleotides than antibodies on these NPs. Both modified particles should 
be abundantly present to effectively capture and detect the target antigen and for effective isolation 
of the MMP-antigen-NP complexes by magnetic separation. Dehybridization of the doublestranded 
oligonucleotide sequences results in release of a large amount of bio-barcodes that can be analyzed by 
gel electrophoresis, fluorophore-labeling or scanometric detection, with the possibility of increasing the 
signal by a PCR-amplification step. In this design, many bio-barcodes are released per target molecule, 
resulting in a more sensitive assay than conventional ELISAs.
Source: [294] Copyright 2011 National Academy of Sciences, U.S.A. Reproduced  
with permission.
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BCA	and	also	requires	 less	reagent	volumes	(5	μl	per	wash	step),	but	at	the	same	time	
the SI-BCA is more sophisticated in its set-up and obtaining the required material can be 
difficult as it is not commercially available yet. 
In conclusion both, the BCA and the SI-BCA, have been proven to push the limit of detection 
of molecules into the attomolar range and therefore could be very useful techniques in 
detecting	low-abundant	Aβ	oligomers/ADDLs	in	body	fluids.	However,	to	our	knowledge	
only two groups have successfully set up a BCA [293, 299] and only one group did apply 
the	 assay	 to	measure	 Aβ	 [294].	 The	 need	 for	 expertise,	 specific	 equipment	 and	 time,	
that is necessary to invest in the development of such a complex assay, might hamper 
other groups. Future studies will have to show, whether BCA-based methods may become 
available for routine diagnostic measurements.
2.5.3 Immunofluorescence Assays
A	few	approaches	that	use	fluorescently	labeled	antibodies	to	detect	aggregates	of	Aβ	have	
been described. For instance in one study flow cytometry and fluorescence resonance 
energy	transfer	(FRET)	have	been	combined	to	demonstrate	the	presence	of	Aβ	oligomers	
in CSF [300]. Two antibodies that bind different epitopes, one labeled with Alexa Fluor 
488,	 the	other	with	Alexa	Fluor	594,	were	allowed	 to	bind	Aβ	molecules.	Next,	a	FRET	
signal is generated if both antibodies are located closer than 10 nm from each other. In 
this experiment monomers are not detected because these can only be bound by one 
antibody per antibody type, which will only generate a low intensity fluorescent signal. 
Binding of multiple antibodies to oligomers however, can cause a more intense signal 
that can be measured by flow cytometry. Using this technique, the authors succeeded 
in	quantitatively	measuring	Aβ	oligomers	in	CSF	from	control	patients	with	neurological	
diseases other than AD. The detection range of the technique was determined to be 
accurate from low nM down to low pM concentrations. Later, the same group used an 
adapted	version	of	this	assay	to	measure	Aβ	oligomers	in	plasma	samples,	for	which	the	
sensitivity	 and	 specificity	were	about	 the	 same	as	 in	 the	previous	 technique	 [301].	Aβ	
was first immunoprecipitated and immobilized to magnetic beads. Subsequently a rabbit 
Aβ	 oligomer-specific	 antibody	 and	 a	 fluorescently	 labeled	 anti-rabbit	 antibody	 were	
added and measurements in human plasma were conducted, using flow cytometry for 
detection. For this 2.5 ml of lithium heparin plasma was used per sample. Since flow 
cytometry is widely available and a relatively high throughput method, this technique can 
be widely applicable. Results of the study showed that oligomer levels were increased 
in AD patients compared to controls. Discrimination could be made with a specificity of 
81.2% and a sensitivity of 70.6%. 
In another study, a variant of a sandwich ELISA was used, in combination with 
2D-fluorescence	intensity	distribution	analysis	(2D-FIDA).	Here,	an	anti-Aβ	antibody	was	
coated	 on	 a	 glass	 surface	 and	 Aβ	 molecules	 were	 captured	 [302].	 Subsequently,	 two	
different fluorescently labeled detection antibodies, with different fluorescent labels 
but overlapping epitopes, were applied. In this way only oligomers and not monomers 
can be detected with both detection antibodies at the same time. Next, fluorescence 
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of both fluorescent labels is measured by a confocal laser scanner and Two-dimensional 
fluorescence intensity distribution analysis (2D-FIDA) was applied. Binding of both 
detection	 antibodies	 at	 the	 same	 time	 indicated	 the	 presence	 of	 Aβ	 oligomers.	 The	
benefit	 of	 the	 capturing	 step	 is	 that	 the	 technique	 becomes	more	 specific	 for	 Aβ	 and	
with additional washing the background signal can be reduced. This makes the method 
sensitive enough to detect and quantify single molecules, and concentrations in the nM 
range could be measured in 20 µl of sample. However, the use of the confocal microscope 
makes the technique very expensive and not high throughput. The first part of the 
procedure takes as long as a normal ELISA, however the measurement and analysis of 
2D-FIDA take much longer than a spectrometric readout.
2.6 Conclusion
The	 plaque-forming	 protein	 amyloid-β	 is	 a	 key	 player	 in	 the	 pathology	 of	 AD	 and	 its	
propensity to aggregate is an important aspect of the AD pathophysiology. It is generally 
assumed	 that	 oligomeric	 Aβ	 is	 the	 most	 toxic	 species	 in	 the	 amyloidogenic	 cascade.	
Therefore, there is a great need for techniques to identify, characterize, quantify and 
visualize	the	different	Aβ	species.	 In	this	review	we	have	 listed	and	described	all	major	
techniques to achieve these goals and pointed out their advantages and disadvantages 
(see table 1 for an overview). Here, we did not aim to list all the available techniques that 
were used in the past to study amyloidogenic proteins, but to give an overview of the most 
useful	and	most	often	applied	techniques	 in	analyzing	full	 length	Aβ40	and	Aβ42 in their 
different aggregation stages. Nonetheless, this paper can serve as a compass in directing 
the researcher to choose the methods best suited for his or her intentions. Since the 
various techniques each have their pros and cons, the use of a combination of different 
techniques	to	study	Aβ	oligomers	will	reveal	the	most	optimal	set	of	information.	Many	
different combinations have been used in the past. A number of different research aims 
can be defined that require different experimental approaches and we have listed here 
the most often used and most successfully applied combinations of techniques. 
1)  Investigation of aggregation pathways in vitro. For such studies a combination of 
techniques to determine size, kinetics and morphology are important. An elegant 
recent example of this was a combination of FCS (in which factors like concentration 
and time can be manipulated and arising oligomers can be sensitively measured) and 
transmission EM (which gave insight into the spherical morphology of certain HMW 
oligomers that were formed during aggregation) [141]. 
2)  Characterization of a particular type or range of oligomers, either brain derived or 
formed in vitro. A combination of the techniques PAGE, SEC-MALLS, analytical 
ultracentrifugation and AFM will provide a good overview of the composition of a 
synthetic,	 often	 heterogeneous	 Aβ-oligomer	 population,	 both	 in	 terms	 of	 size	 and	
morphology [189]. Also, SEC combined with Western blotting using an oligomer-
specific antibody, was successfully used to identify a highly toxic brain-derived oligomer 
species [144]. 
3)		Identification	 of	 a	 specific	 Aβ	 form	 requires	 its	 morphological	 and	 structural	
characterization. This can be done by using PAGE in combination with SV, providing 
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information about size and shape of the molecule, and CD, for structural information 
[303]. 
4)  Identification of potential therapeutic agents, e.g. aggregation inhibitors. For these 
studies ThT fluorescence experiments may be suitable, because of its relative quick 
estimation of effects on protein aggregation. A combination with AFM, or alternatively 
EM, may deliver validation of ThT results and provide morphological information [304]. 
5)  Analysis of oligomers in biological samples. Because of the supposed low levels 
of oligomers in brain tissue, plasma and CSF, high sensitivity is essential. ELISA 
methods (possibly in combination with an amplification method such as BCA), FCS or 
immunofluorescence assays seem most suitable for this. Information on oligomer size 
may then be derived from SEC or SDS-PAGE analysis [194].
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Table 1 : Schematic overview of techniques to analyze Aβ aggregates.
Techniques Advantages Disadvantages
Morphology
and structural 
conformation
Electron Microscopy -  High resolution (visualizes fibrils, but 
LMW molecules are more difficult)
- Prone to artefacts
- Only a small part of the sample is visualized
- No real-time imaging
Atomic Force 
Microscopy
-  High resolution (distinguishes also 
between ADDLs, protofibrils and 
fibrils)
- Real-time imaging possible
- Coiled structures are not always visualized properly
- Not all aggregates are absorbed to a mica surface
- limited availability of equipment
Fluorescence 
Microscopy
- Sensitive
- Small samples volumes sufficient
-  (limited) multiplexing possible 
when using differently coloured 
fluorophores
-  Aβ labelling with fluorophore might influence oligomerization 
process
- Autofluorescence might interfere with analysis
Circular Dichroism -  Real-time measurements in aqueous 
solutions
-  In heterogenous samples only the cross structural components 
are depicted
- limited availability of equipment
- high concentration needed
Determination
of molecular 
weight
Polyacrylamide gel 
electrophoresis
- Simple
- Inexpensive
-  Good resolution possible, dependent 
on conditions used
-  Disassembly of oligomers due to heat treatment, reducing and/or 
denaturing conditions
- Protein is lost after experiment
Size exclusion 
chromatography
- Non-denaturing conditions
-  Buffers with physiological 
composition can be used
-  Protein fractionation for further 
testing is possible
-  Procedure can cause disassembly of oligomers, dependent on 
conditions
- Low sample recovery
- Relatively low resolution
-  Elution characteristics of molecular weight standards are not 
always comparable to those of protein in the sample
Light scattering - Sensitive - Low resolution
-  Computational model required for indication molecular weight
Analytical 
Ultracentrifugation
-  Sensitive (differentiates even 
between monomers, dimers e.g.)
- Broad range of samples
-  pH, ionic strength or temperature are 
no problem
-  In measuring fibrils, there is no direct correlation between 
sedimentation coefficient and their size
- limited availability of equipment
- long running time
- high concentrations needed
Kinetic
charactistics 
Turbidity - Simple
- Equipment omnipresent
-  Only fibrils can be detected - Relatively insensitive, rather high 
concentrations necessary
Fluorescence 
spectroscopy
- Simple
- Fast
- Only protofibrils and fibrils can be detected
- Congo Red might influence aggregation
Quantification Sandwich ELISA’s - Sensitive
-  High specificity for target can be 
achieved
- High throughput
-  Antibodies that recognize Aβ oligomers might also recognice 
other amyloidogenic proteins
-  No information about the size of oligomers measured is acquired
-  Oligomers are ineffectively measured compared to monomers
Bio-barcode assay - Highly sensitive
- multiplexing possible
- quick
- complex
- not well established yet
Immunofluorescent 
assays
See fluorescence microscopy + 
use of antibodies adds to specificity
See fluorescence microscopy
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Abstract
In cerebrospinal fluid (CSF), concentrations of specific proteins tend to be quite low, which 
may account in particular for proteins that could serve as biomarkers for a neurological 
disease, such as Alzheimer’s disease (AD). Sensitive methods are needed to detect such 
low-abundant proteins in CSF. Previously, bead-based methods using gold nanoparticles 
(AuNPs) in the detection step of an immunological assay, have decreased the limit of 
detection of analytes. By applying oligonucleotides to the AuNPs, the limit of detection 
can be decreased even further as has been shown in the so-called Bio-barcode assay 
(BCA).	We	aimed	 to	develop	bead-based	prototype	assays	using	Aβ	oligomers	and	Aβ/
ApoE complexes as analytes.
We first designed an enhanced assay by using magnetic microparticles (MMPs) 
conjugated to the capture antibody and AuNPs conjugated to streptavidin with enzymatic 
tag.	This	combination	enhanced	the	signal	for	Aβ/ApoE	complexes	slightly	compared	to	
a conventional ELISA. We then developed a BCA by binding oligonucleotides (barcodes) 
that were conjugated to biotin with streptavidin-coated AuNPs instead of an enzyme tag. 
After elution of the barcodes, they were quantified as a surrogate for the analyte, in 
this	case	Aβ	oligomers,	by	quantitative	PCR.	We	succeeded	in	establishing	a	functional,	
concentration-dependent BCA, but the assay was not able to detect lower concentrations 
than a conventional ELISA, probably due to aspecific interactions of the AuNPs.
Development of a bead-based assay is a process that includes several steps, and each step 
might be affected by non-specific binding activities. Due to this complexity, the set-up of 
such an assay is very difficult. 
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3.1 Introduction
A popular method to quantify proteins as markers of a disease is the enzyme-linked 
immunosorbent assay (ELISA), a sandwich-type immunoassay that makes use of an 
enzyme-driven color reaction to determine the levels of its target. In Alzheimer’s disease 
(AD),	 three	 proteins	 (amyloid-β42,	 total	 tau	 and	 phosphorylated	 tau)	 are	 in	 use	 as	
diagnostic biological markers. These proteins are measured by ELISA in cerebrospinal 
fluid (CSF) with detection limits in the low nanomolar range and can discriminate AD 
from healthy controls with a sensitivity and specificity of 80-90% [98]. Many attempts 
to identify novel and better AD biomarkers were yet unsuccessful. This might be due 
to a lack in specificity in differential diagnosis, but also due to lack in sensitivity caused 
by very low concentrations of some analytes in CSF. Low abundant analytes in CSF 
could not only serve in differential diagnosis, but also hold the potential as preclinical 
biomarkers for AD as they are thought to identify early pathological changes in the 
brain. Therefore, development of new assays continuously focuses on achieving higher 
sensitivity. Minuscule particles and beads, to which antibodies are coupled, have offered 
great potential in improving the detection limit of an ELISA, as has the addition of nucleic 
acids as a surrogate target and detection with quantitative polymerase chain reaction 
(qPCR) [295]. ELISAs that use nucleic acids for detection by PCR (“immuno-PCR”) are able 
to detect molecules with maximum sensitivity in the zepto- to attomolar range (1,000 – 
100,000 molecules per sample) [305]. In bead-based assays, gold nanoparticles (AuNPs) 
are often applied as tool to increase the signal of an ELISA-based assay, whereby AuNPs 
are either used to increase the number of enzymes such as horse-radish peroxidase (HRP) 
and thus the signal strength, or to be detected by a sensitive scanometric method [306-
309]. A quite novel, high-sensitivity method, which makes use of AuNPs, but in addition 
also of nucleic acids, is the Bio-barcode assay (BCA) [293, 310, 311]. In the first set-up 
of the BCA a capture antibody was coated to magnetic micropaticles (MMPs) and for 
detection, AuNPs were coated simultaneously with the detection antibody and numerous, 
hybridized DNA tags (barcodes) [293]. Importantly, the barcodes were present at a high 
ratio to the protein target, which amplifies the signal. When barcodes were amplified by 
PCR, this ratio increased even further. Using PCR as detection system, the BCA achieved 
a sensitivity of 3 attomolar in detecting the protein prostate specific antigen, which was 
five magnitudes greater than conventional ELISAs [293]. 
We aimed to develop a highly sensitive prototype BCA, first by setting-up an enhanced 
assay using MMPs and AuNPs and then by modifying the AuNPs with barcodes which are 
detected	 by	 qPCR.	 As	 analytes	 we	 used	 Aβ/ApoE	 complexes	 and	 Aβ42 oligomers, both 
synthesized in our lab and for which we had previously developed ELISAs ([109] and 
chapter 4 of this thesis). Both analytes compose interesting targets as CSF biomarkers for 
AD,	and	in	particular	levels	of	Aβ/ApoE	complexes	have	not	been	reported	yet	in	CSF	due	
to difficulties in detection, which might be caused by too low concentrations.
64
Chapter 3
3.2 Materials and Methods
3.2.1 Antibodies & enzymes
In	the	Aβ/ApoE	complex	assay,	polyclonal	goat-anti-apoE	(Meridian,	Memphis,	TN,	USA)	
was	 used	 as	 capture	 antibody	 and	 monoclonal	 mouse-anti-Aβ	 clone	 Nab-228	 (Sigma-
Aldrich,	St.	Louis,	MO,	USA)	as	detection	antibody.	For	the	Aβ42 oligomer assay, monoclonal 
mouse-anti-Aβ	clone	VU-17	(kindly	provided	by	Dr.	Rob	Veerhuis,	VUMC,	Amsterdam,	The	
Netherlands) was used as capture antibody and biotinylated VU-17 as detection antibody. 
For detection purposes we used streptavidin and horse-radish peroxidase (HRP), both 
obtained from Sigma-Aldrich, streptavidin conjugated to a single HRP molecule (SA-HRP; 
Biosource, Bleiswijk, Netherlands), streptavidin conjugated to multiple HRP molecules 
(SA-polyHRP; Sigma-Aldrich) and rabbit-anti-mouse and rabbit-anti-goat, both conjugated 
to HRP and obtained from DAKO (Glostrup, Denmark). HRP and Nab-228 were biotinylated 
using the Biotin Label Kit - NH2 (Abnova, Taipei City, Taiwan), according to manufacturers’ 
instructions.
3.2.2 Preparation of antigens
Synthetic	 Aβ42 (21
st Century Biochemicals, Marlboro, MA, USA) was dissolved in 
hexafluoroisopropanol (HFIP; Sigma-Aldrich) and air-dried overnight at room temperature. 
The peptide film was dissolved in dimethyl sulfoxide (DMSO) to a concentration of 5 mM. 
To	 obtain	 Aβ/ApoE	 complexes	 (see	 also	 chapter	 4	 of	 this	 thesis),	 recombinant	 human	
ApoE3	protein	(Fitzgerald,	North	Acton,	MA,	USA)	and	synthetic	Aβ42	were	mixed	(500	
nM and 50 µM respectively) in PBS and incubated at 37°C for 24 h. The resulting analyte 
was	either	used	fresh	or	stored	at	-20°C	until	 further	use.	To	prepare	Aβ42 oligomers, 5 
mM	Aβ42	was	diluted	in	PBS	to	100	µM	and	was	incubated	for	24	h	at	4°C.	The	resulting	
oligomers were stored at -80°C until further use. To test patient material, human 
hippocampus samples (n=3) were obtained from Radboud University Medical Center, 
Nijmegen. Informed consent had been obtained from patients according to European 
guidelines. Samples had been obtained postmortem with a delay between 3-5 h. They had 
been snap-frozen and stored at -80°C. For use in the ELISA, samples were homogenized 
in carbonate buffer (100 mM Na2Co3, pH 11.5; with protease inhibitors) as described 
previously [312]. They were pooled and then diluted in sample diluent (INNOTEST hTau 
diagnostic ELISA kit, Innogenetics, Gent, Belgium).
3.2.3 Particles
Carboxylated magnetic microparticles (MMPs) with diameters of 1.4 µm were 
obtained from Microparticles GmbH (Berlin, Germany). To activate MMPs, 1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC; Sigma-Aldrich) and 
N-Hydroxysuccinimide (NHS; Thermo-Fisher Scientific, Waltham, MA, USA) were used. 
Gold nanoparticles (AuNPs) were obtained with diameters of 10 nm and 20 nm, either 
uncoated or streptavidin-coated (BBInternational, Cardiff, UK).
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3.2.4 Barcodes & primers
The biotinylated single-stranded DNA strand (bio-barcode; Biotin-5’-AAAAAAACAGG
GATGGAAGGACGGGATTTGTATTGATTGAGATTAAAGACCTCGGACGCTGCACTG-3’) and a 
forward (5’-CAGGGATGGAAGGACGGG-3’) and reverse (5’-CAGTGCAGCGTCCGAGGT-3’) 
primers were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov). Nucleic acid 
sequences were obtained from Biolegio (Nijmegen, The Netherlands).
3.2.5 Blocking agents
Odyssey blocking buffer was obtained from LI-COR Biosciences (Lincoln, NE, USA). 
Polyethylene glycol (PEG) molecules used were PEG6000 (Merck, Darmstadt, Germany) 
and PEG20,000 (Sigma-Aldrich). Cold water fish skin gelatin (cwfsg) and acetylated 
linear bovine serum albumin (BSA-c) were obtained from Aurion (Wageningen, The 
Netherlands). Other blocking agents were synthetic protein free buffer (Kem-En-Tec, 
Taastrup, Denmark) and skim milk powder (Campina, Heilbronn, Germany).
3.2.6 Preparation of antibody-coated MMPs
MMPs were washed by magnetic separation 3 times in 500 µl 0.1 M MES buffer pH 6.2 
and were diluted to 1 mg/ml. Subsequently, 50 µl of diluted MMPs was incubated with 50 
µl of 12 mg/ml EDC and 18 mg/ml NHS at room temperature for 1 h, rotating. MMPs were 
washed 3 times in 500 µl MES and then incubated with 100 µl anti-apoE using different 
concentrations of the antibody (0.17, 0.33, 0.66, 1.33, 4, 10, 20 µg/ml). Incubation was 
at room temperature for 2 h, during constant rotation. Thereafter, MMPs were washed 
3 times with 500 µl MES and were incubated at room temperature for 40 min, rotating, 
with 200 µl of EDC quenching solution (10 mM NH2OH·HCl). MMPs were then washed 5 
times with 500 µl PBST/BSA buffer (PBS, 0.05% Tween-20, 0.1% BSA). MMPs were stored 
in 50 µl PBST/BSA buffer over night at 4°C. To directly test the coupling success of the 
capture antibody, 100 µl of anti-goat antibody conjugated to HRP was added diluted 
1:5000 in PBS buffer, which was followed by a 5 times washing step with 500 µl PBST 
(PBS, 0.05% Tween-20). Thereafter, 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was 
added to obtain a color reaction, which was subsequently stopped with 1N H2SO4 and 
signals were measured at an optical density of 450 nm (OD450) using a Tecan plate reader 
(Männendorf, Switzerland). MMP assays were performed in a Nunc MaxiSorp flat-bottom 
96-well plate (eBioscience Inc; San Diego, CA, USA) which were washed in an automatic 
Hydroflex microplate washer (Tecan, Männedorf, Switzerland)  with a magnetic plate 
carrier (MBS carrier; Tecan) or in 1.5 ml polypropylene tubes using the MagneSphere 
tube holder (Promega, Madison, WI, USA).
3.2.7 Preparation of antibody-coated AuNPs
AuNPs were coated with streptavidin, SA-HRP, SA-polyHRP, Nab-228 and biotinylated Nab-
228. The optimal concentrations were determined visually in a Nunc 96-well plate using 
the coagulation test. In this test, 5 µl of different protein concentrations was incubated 
with 45 µl AuNPs for 1 min at room temperature with constant rotation. Then, 10% NaCl 
was added upon which AuNPs change color from red to blue when binding of the protein 
to the AuNP surface has not been saturated. Subsequently, AuNPs were coupled with 
the optimal concentration of the molecules in PBST at room temperature for 1 h during 
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constant rotation. To generate negative controls, first AuNPs were incubated with 1% BSA 
to occupy all possible binding sites, which was then followed by coupling of the different 
molecules to test aspecific binding. After coupling, AuNPs were blocked with 1% BSA in 
PBST for 1 h at RT, rotating. Thereafter, AuNPs were centrifuged for 20 min at 15,000 g and 
4°C and the supernatant was removed. After blocking, AuNPs were washed 3-5 times with 
500 µl PBST/BSA buffer by using the same centrifugation protocol. Coated AuNPs were 
resuspended in 45 µl PBST/BSA buffer and stored over night at 4°C. To directly detect the 
molecules on the AuNPs, biotinlyated HRP (1:3000) was used for streptavidin, rabbit-anti-
mouse HRP (1:40,000) for Nab-228, and SA-HRP (1:60,000) for biotinylated Nab-228, all 
in volumes of 100 µl with incubation for 1 h at room temperature, rotating, which was 
followed by 3-5 times washing. For AuNPs that had been coated with SA-polyHRP, no 
secondary detection molecule was necessary. Thereafter, 100 µl of TMB substrate was 
added and subsequently 50 µl of 1N H2SO4. Tubes were then centrifuged and supernatant 
was transferred into an ELISA plate. The plate was measured at OD450.
3.2.8 Design of assays
The enhanced assay (figure 1) was designed using antibody-coated MMPs for capturing the 
antigen and SA-polyHRP-coated AuNPs (10 nm) for detection of the antigen. As antigen, 
Aβ/ApoE	 complexes	were	 used.	 Anti-apoE	 coated	MMPs	were	 used	 in	 a	 volume	 of	 50	
µl and were first blocked in 250 µl 1% BSA in PBST for 1 h at 25°C, shaking at 1200 rpm, 
and thereafter washed twice with 500 µl PBST/BSA buffer. Then, MMPs were incubated 
with 100 µl of different concentrations of the antigen for 2 h at 25°C, followed by 3 times 
washing with 500 µl PBST/BSA buffer. After capturing of the antigen and the addition of 
the biotinylated Nab-228 antibody, 100 µl of SA-polyHRP-coated AuNPs that had been 
10 times diluted, were added and incubated as blocking buffer. Thereafter, washing 
was performed 5 times, and the signal was read at OD450, using TMB as substrate. The 
enhanced assay was compared to a standard ELISA set-up (figure 1) without the use of 
MMPs and AuNPs (see chapter 4 of this thesis).
The BCA (figure 1) was designed using streptavidin-coated AuNPs (20 nm) and biotinylated 
barcodes	as	surrogate	for	the	detection	of	Aβ42	oligomers.	Anti-Aβ	VU-17	antibody	was	
diluted to 1 µg/ml in 100 mM carbonate buffer pH 9.6 and 100 µl per well was coated on 
a Nunc 96-well plate overnight at 4°C, with shaking at 600 rpm. After coating, the plate 
was washed 1 time with  PBS. All subsequent washing steps were performed 3 times with 
300 µl TBST (20 mM Tris-HCl, 0.05% Tween-20, pH 7.5) using a plate washer. Next, the 
plate was blocked with 250 µl Odyssey blocking buffer (1:1 PBS and Odyssey blocking 
buffer)	per	well	for	2	h.	Aβ42 oligomers were diluted in TBST/BSA buffer (20 mM Tris-HCl, 
0.1% Tween-20, 150 mM NaCl, 0.1% BSA, pH 7.5) and were added in a volume of 100 µl 
per well. Incubation was 2 h, with shaking at 600 rpm. For detection, biotinylated VU-
17 antibody was diluted 1:2500 in TBST/BSA buffer and was added in a volume of 100 
µl per well for 1 h, with shaking at 600 rpm. In the standard ELISA set-up, SA-polyHRP 
(1:5000) was added in a volume of 100 µl per well and incubated for 1 h, with shaking at 
600 rpm. In the BCA set-up, streptavidin-coated AuNPs were added in a 100 µl volume 
and incubated for 1 h, with shaking at 600 rpm. Then, the plate was washed 4 times with 
TBST/BSA buffer. After washing, biotinylated barcodes that had been diluted in PBST/BSA 
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Figure 1: The different assay set-ups
1) Conventional set-up of a sandwich ELISA. 2) In the enhanced assay are carboxyl-functionalized MMPs 
coated with a capture antibody and AuNPs with streptavidin-polyHRP. After the analyte has been captured 
by the MMPs, a biotinylated detection antibody is added. The streptavidin-enzyme-coated AuNPs bind to 
the biotin tag of the detection antibody. Multiple enzymes on the AuNPs lead to a signal increase. 3) The 
BCA makes use of biotinylated barcodes that serve as surrogate for the analyte. First, AuNPs are coated 
with streptavidin. After the analyte is captured by a capture antibody that is in this case coated to a plate, 
an excess of barcodes are added. After washing, the barcodes are eluted by breaking the streptavidin-
biotin bond. Eluted barcodes can then be detected by quantitative PCR (qPCR).
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buffer were added in a volume of 100 µl and incubated for 1 h, shaking at 600 rpm to 
couple to the streptavidin on the AuNPs. Thereafter, excess barcodes were removed by 
9 times washing the plate with PBST. Thereafter, bound barcodes were eluted using 50 
µl per well de-ionized water or formamide elution buffer (98% formamide, 10 nM EDTA, 
0.02% Tween-20) at 70°C for 5 min. Eluted barcodes were transferred into new tubes and 
were 10 times, 100 times or 1000 times diluted in de-ionized water. The barcodes were 
added in a volume of 5 µl per reaction, mixed with 20 µl Maxima SYBR Green/ROX Master 
mix (Fermentas GmbH, St. Leon-Rot, Germany) and the primers (0.3 µM), and subjected 
to qPCR (2 min at 50°C, 10 min at 95°C, 40 cycles with 15 sec at 95°C followed by 30 sec at 
60°C and 30 sec at 72°C). The BCA was compared to a standard ELISA set-up without the 
use of AuNPs and barcodes as described previously [109]. 
3.2.9 Data analysis
Statistics were performed using Graph Pad Prism version 5 (La Jolla, CA, USA). Mann 
Whitney U test was applied to compare the MMP sandwich ELISA to the standard ELISA. 
P-values less than 0.05 were considered significant. To analyze qPCR results, CFX Manager 
from Bio-Rad (Hercules, CA, USA) was used. Samples were all measured in duplicates and 
the mean cycle threshold (Ct) was calculated with the standard deviation.
 
3.3 Results
3.3.1 Preparing and testing functionality of MMPs
The MMPs were first tested separately from AuNPs to determine the optimal coupling 
conditions. The anti-ApoE antibody was coupled to MMPs at different concentrations, 
and the signal reached a plateau at a concentration of 4 µg/ml (figure 2A). Next, MMPs 
coupled	with	4	µg/ml	anti-ApoE	were	used	in	the	sandwich	ELISA	set-up	to	capture	Aβ/
ApoE complexes. Initially, these experiments were performed in an ELISA plate, but 
obtained signals of the sandwich ELISA remained low using MMPs, while the assay using 
MMPs performed in polypropylene tubes generated much higher signals (data not shown). 
Therefore, all subsequent experiments were performed in tubes and the obtained signals 
were compared to the standard sandwich ELISA in 96-well plates. The mean result of 
several independent experiments that were performed under comparable conditions 
(n=7) revealed an overall increased signal of the MMP sandwich ELISA compared to the 
standard ELISA when signals were subtracted by the no-antigen-control (p = 0.017; figure 
2B). 
3.3.2 Preparing and testing functionality of AuNPs
AuNPs were also first tested separately. The optimal coupling concentrations to AuNPs 
tested by the coagulation test were determined for streptavidin (12 µg/ml for 10 and 20 
nm AuNPs), SA-HRP (25 µg/ml for 10 nm), SA-polyHRP (3.13 µg/ml for 10 nm, 6.25 µg/ml 
for 20 nm AuNPs), Nab-228 (16 µg/ml for 10 nm) and biotinylated Nab-228 (12.5 µg/ml for 
10 nm; data not shown since color shift from red to blue was determined visually). To test 
and compare their functionality, coupled AuNPs were subjected to optical densitometry 
using secondary antibodies or enzymes and including the corresponding negative control 
(figure 3A). For AuNPs coated with streptavidin, SA-polyHRP and Nab-228 high signals 
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Figure 2: Preparation of Magnetic microparticles
A) Standard curve of different concentrations of anti-ApoE coupled to MMPs. Anti-goat antibody 
conjugated to HRP was used for detection. B) Mean with standard deviation of several independent 
experiments	of	 the	MMP	sandwich	ELISA	 (n=7)	 and	 the	 standard	 sandwich	ELISA	 (n=3),	 using	Aβ/ApoE	
complexes (complex), buffer only (no antigen) or omission of the capture antibody when the complex was 
assayed (no capture).
Key: OD450 = optical density at 450 nm; ApoE = apolipoprotein; MMP = magnetic microparticles
Figure 3: Preparation of Gold nanoparticles
A) Signals of different molecules coupled to AuNPs (10 nm) (Positive signal) and negative control (BSA 
control). For BSA controls, AuNPs were coupled first with 1% BSA and thereafter with the different 
molecules as indicated. B) Signal generated by SA-polyHRP-coupled AuNPs with 10 and 20 nm diameters 
and negative controls (omission of antigen (no antigen) or capture antibody (no capture), or BSA control).
A
A
B
B
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were obtained, while the signals of the negative controls remained low. However, signals 
of the negative controls for coupling with SA-HRP and biotinylated Nab-228 were very 
high and these molecules were therefore excluded from further testing. AuNPs (10 nm) 
conjugated to SA-polyHRP were chosen for application in the enhanced assay set-up, 
since SA-polyHRP has already enzymatic activity and a secondary detection step would be 
required when using streptavidin or Nab-228. For the BCA, we wanted to use AuNPs with 
a larger diameter (20 nm), to enable binding of a high number of barcodes, as has also 
been done previously [299]. AuNPs with 10 and 20 nm were therefore compared using 
SA-polyHRP, and AuNPs with a 20 nm diameter generated a slightly higher signal (figure 
3B). Subsequently, 20 nm AuNPs were used in the BCA, which were coated first with SA-
polyHRP instead of streptavidin for direct testing.
3.3.3 Development and validation of the enhanced assay
Good signals with low background were obtained when anti-ApoE coated MMPs (MMPs 
only)	were	used	 instead	of	 the	anti-ApoE	antibody	coated	 to	an	ELISA	plate	 in	 the	Aβ/
ApoE ELISA (figure 2B). However, when 10 nm AuNPs conjugated to SA-polyHRP (MMPs 
& AuNPs) were added for detection instead of SA-HRP the background was very high. 
Therefore different blocking protocols were tested to reduce any aspecific binding. 
Blocking over night with 1% BSA generated the highest signal to background ratio when 
compared to the set-up with MMPs only (figure 4A). Next, the enhanced assay using 
Figure 4: Enhanced assay using MMPs & AuNPs
A) Signals of the sandwich ELISA’s using either MMPs only or MMPs and SA-polyHRP-coated AuNPs 
combined, using different blocking protocols. B) Signals in human hippocampus tissue, obtained by the 
standard	 sandwich	 ELISA	 to	 detect	 Aβ/ApoE	 complexes,	 sandwich	 ELISA	with	MMPs	 only	 and	 sandwich	
ELISA using MMPs and SA-polyHRP-coated AuNPs. Negative controls consisted of buffer only (no antigen) 
and omission of the capture antibody (no capture).
Key: OD450 = optical density at 450 nm; MMP = magnetic microparticles; BSA = bovine serum albumin; 
AuNPs = gold nanoparticles
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MMPs and AuNPs with overnight blocking was tested in human hippocampus samples, 
which generated high signals. However, only the standard ELISA had a low signal for the 
“no capture” control (figure 4B). Further testing of different blocking protocols such as 1 
h blocking with 10% BSA did not reduce the aspecific background signal (data not shown).
3.3.4 Development and validation of the BCA
Streptavidin-coated AuNPs (20 nm) in combination with biotinylated barcodes were used 
in	the	BCA	with	Aβ42 oligomers as antigen. In all experiments, several negative controls 
were tested to determine the signal specificity. First, the optimal concentration of the 
barcodes was determined. The sandwich ELISA was performed as described, but instead of 
an enzyme, streptavidin-coated AuNPs were added followed by different concentrations 
Figure 5: Bio-barcode assay (BCA) development
The BCA was developed by replacing the streptavidin-conjugated enzyme (SA-HRP) and the subsequent 
detection	 step	 with	 TMB	 substrate	 in	 the	 conventional	 Aβ	 oligomer	 ELISA	 with	 streptavidin-coated	
AuNPs followed by addition of biotinylated barcodes, which were eluted and measured by qPCR. Several 
conditions were assessed: A) Different barcode concentrations, B) different elution solvents and dilutions 
of the elution product, C) different dilutions of the AuNPs, D) different blocking protocols of the AuNPs, 
and E)	 different	 blocking	 reagents	 for	 the	 ELISA	 plate.	 Aβ42	 oligomers	 were	 used	 as	 antigen	 (positive	
signal), and negative controls were no antigen, omission of the capture antibody (no capture), BSA-coated 
AuNPs (BSA-AuNPs) or omission of the barcodes (no barcode). Data is expressed as mean Ct-values of two 
duplicates ± standard deviation.
Key: Ct = cycle threshold; BSA = bovine serum albumin; RT = room temperature, ON = overnight; BSA-c = 
acetylated BSA; cwfsg = cold water fish skin gelatin
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of barcodes. In this experiment, barcodes were eluted with formamide. With increasing 
numbers of barcodes, Ct-values decreased slightly, which means that when applied in 
higher concentrations, more barcodes were detected (figure 5A). However, since a 
barcode concentration of 207 µg/l did produce almost the same signal as a concentration 
of 20.7 µg/l, we chose to use the lower concentration for subsequent experiments. The 
negative control without barcodes (no barcode) however gave also a signal (Ct=25) and, 
similarly, the control in which BSA-coated AuNPs were used instead of streptavidin-
AuNPs also resulted in high background signals. Omission of antigen or capture antibody 
generated even higher background signals (~Ct=17). In all subsequent experiments, 
these negative controls were included with the aim to reduce these background signals. 
Since the no-barcode and BSA-AuNPs controls, and omission of antigen or capture 
antibody always generated similar signals, only the no-barcode and no-antigen controls 
are included in figures 5B and C. Next, two solvents (formamide or de-ionized water) 
were tested to elute the barcodes from the streptavidin-AuNPs, and several different 
dilutions of the eluted barcodes (figure 5B). Elution with de-ionized water provided 
lower Ct-values and thus higher signals than elution with formamide, and the difference 
between the positive signal and the no-antigen control was larger. A dilution of 100 times 
of barcodes eluted with de-ionized water was chosen since it provided higher signals 
than 1,000 or 10,000 times. The optimal AuNP dilution was then determined (figure 5C). 
The more diluted the streptavidin-coated AuNPs, the higher the Ct-values of the negative 
controls, while the positive signal at Ct=~15 remained at the same level which means that 
AuNPs were saturated. Therefore, a 16 times AuNP dilution was chosen. 
Figure 6: Bio-barcode assay validation
A)	 Mean	 signal	 intensities	 (with	 standard	 deviation)	 of	 different	 concentrations	 of	 Aβ42	 oligomers	
measured using the standard sandwich ELISA set-up. The arrow indicates the lowest detectable 
concentration at 78 ng/l just above the blank (no antigen). B) Mean Ct-values (with standard deviation) 
of	different	concentrations	of	Aβ42	oligomers	measured	using	 the	BCA.	The	arrow	 indicates	 the	 lowest	
detectable concentration at 39 ng/l just above the blank (no antigen).
Key:	OD450	=	optical	density	at	450	nm;	Aβ	=	amyloid-β;	Ct	=	cycle	threshold
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Several further attempts in optimizing the BCA were dedicated to decreasing the aspecific 
signals, thus increasing the Ct-value in particular of the no-antigen control (only negative 
control included in figure 5D and E). This was done by testing different blocking protocols 
for the AuNPs, which were considered the major cause of aspecific binding, and different 
plate blockings. AuNPs were blocked using several concentrations of different molecular 
weight PEGs, but these attempts did not reduce the background (data not shown). The 
best blocking protocol for AuNPs that reduced the background signals was an incubation 
with 1% BSA for 1 h followed by an overnight storage in BSA at 4°C (figure 5D). For plate 
blocking, different concentrations of BSA, an acetylated linear form of BSA (BSA-c), cold 
water fish skin gelatin (cwfsg), and other standard blocking buffers often used in ELISAs 
such as synthetic protein free buffer, Odyssey buffer and solved milk powder were applied. 
None of these blocking agents decreased the aspecific signals considerably (figure 5E). 
Finally,	 the	BCA	was	 compared	 to	 the	 standard	Aβ42 oligomer ELISA. For both assays a 
concentration	dependent	 standard	curve	was	generated	using	 synthetic	Aβ42 oligomers 
(figure 6A and B). In general, it seemed that the BCA detected slightly lower concentrations 
than	 the	 standard	 ELISA	 (arrows	 in	 figure	 6),	 and	 the	 concentration	 curve	 for	 Aβ42 
oligomers was slightly better with the BCA (p = 0.0015; r = -0.914) than with the standard 
ELISA (p = 0.0035; r = 0.918).
3.4 Discussion
The aim of this study was to develop a sensitive assay to be able to detect lower 
concentrations of analytes than standard ELISAs achieve. We set-up an enhanced assay 
using MMPs and AuNPs coated with SA-polyHRP, and we designed and developed a BCA 
using streptavidin-coated AuNPs and biotinylated barcodes as a surrogate for the analyte 
that	was	detected	by	qPCR.	As	analytes	for	these	assays	we	chose	synthesized	Aβ/ApoE	
complexes	 and	 Aβ42 oligomers, for which we had developed previously well-validated 
sandwich ELISAs ([109] and chapter 4 of this thesis). If the assays would be successful 
in detecting these analytes at lower concentrations than the standard ELISAs, the assays 
could	be	applied	for	a	wide	range	of	analytes	that	are	not	detected	yet	in	CSF.	Aβ/ApoE	
complexes are a typical example of these. 
3.4.1 Enhanced assay
In the enhanced assay set-up, which was basically a first step for the development of 
the BCA, we used MMPs as carriers of the capture antibody instead of coating them to 
an ELISA plate. MMPs might be more efficient in capturing an analyte in solution than a 
static capture antibody coated to the bottom of a plate. Furthermore, MMPs with the 
adjacent assay molecules can be washed by means of magnetic separation in a more 
efficient way than ELISA plates reducing washing and incubation times [306]. However, in 
our assay we noticed one important drawback when using MMPs. After several washing 
cycles using an automatic plate washer with a magnetic carrier situated under the ELISA 
plate, the number of MMPs decreased, even after several attempts to adjust the settings 
such as needle-height of the plate washer. Possibly, MMPs of a different manufacturer 
or another magnetic carrier with, for instance, magnets situated on the side of the wells 
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could have solved this problem. We continued however by washing MMPs by hand in 
polypropylene tubes using a magnet on the side of the tubes. This had also the advantage 
that the capture antibodies on the MMPs are dispersed in a larger volume, and a larger 
quantity of MMPs can be used per sample. However, a drawback was that washing MMPs 
by hand was very time-consuming and limited the number of samples in an experiment. 
Therefore, we chose not to include MMPs in the set-up of the BCA.
AuNPs coated by several SA-polyHRP molecules were used for detection in the enhanced 
assay. AuNPs have been used in the past to enhance the signal of immuno-based assays 
[306-309]. Standard ELISAs detect molecules with an LOD in the high picomolar to 
nanomolar range. Assays using AuNPs, usually between 10-20 nm in diameter, achieve 
LODs as low as 5-9 pg/ml, which is about 100 - 1000 times lower than conventional 
ELISAs achieve [307, 308]. These assays had designs comparable to our assay, but were 
developed to detect a different antigen and did not always use MMPs. We obtained a 
significant increase in signal intensity using AuNPs. However, application of the assay in 
human hippocampus tissue was hampered by aspecific interactions and high background 
signals. Especially , when omitting the capture antibody, this control resulted in high 
signals, which might be caused by aspecific binding of other proteins or components that 
are present in a tissue sample. Possibly, these aspecific interactions could be prevented 
by diluting the tissue sample in another solvent, depleting the sample of abundant 
proteins, or testing more blocking reagents for the MMPs such as PEGs that have been 
used previously to reduce nonspecific interactions with proteins and cells [313].  
3.4.2 BCA assay
We used streptavidin-coated AuNPs with a diameter of 20 nm in the development of 
the BCA, as has also been done previously [299]. Previously developed BCAs could 
detect	 concentrations	 of	 analytes	 (e.g.	 amyloid-β-derived	 diffusible	 ligands,	 prostate	
specific antigen, interleukin-2) in the attomolar range (as low as 30 aM) [293, 310]. 
The minimum concentration that was detected above the blank in our BCA was 39 pg/
ml, and this concentration was only slightly lower than with a standard ELISA (78 pg/
ml). However, our BCA is different from earlier developed BCAs, especially in the step 
were AuNPs and barcodes are added and detected. While we used streptavidin-coated 
AuNPs and biotinylated barcodes, others used AuNPs coated with oligonucleotides and 
hybridized the barcode sequences to these oligonucleotides. After dehybridization, the 
barcodes were subjected to PCR or to a scanometric detection method using yet another 
kind of AuNP [293]. Although, one group has successfully developed the BCA and several 
variants of it [293, 294, 310, 311, 314], reports in which the development of a BCA has 
been achieved by others are very scarce, and to our knowledge only one other group has 
reported such an assay, but does not use PCR as detection method of the barcodes [299]. 
The reason why we could not further decrease the limit of detection in our BCA might 
primarily be due to aspecific binding of the AuNPs, as the negative controls in which also 
AuNPs were added (omission of either antigen or capture antibody controls) kept generating 
rather high signals. Molecules attach to AuNPs by dative binding, ionic interaction or 
hydrophobic interactions [315]. The strength of these different chemical interactions can 
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vary which is also dependent on the molecule and the question remains, how stable the 
coated AuNPs really are. A good blocking or stabilizing agent is of considerable importance 
as is sufficient washing of AuNPs to remove all unbound molecules. Furthermore, the 
BSA-AuNP and omission of the barcode control also generated a signal. Possibly, samples 
were contaminated since buffers, particles and tubes etc that were used during the ELISA 
could not be obtained and used under sterile conditions. Also the elution product was not 
pure and likely consisted of biotinylated barcodes and streptavidin-coated AuNPs, since 
the elution also broke the bond between the biotinylated detection antibody. 
  
In further improving the BCA to detect lower antigen concentrations, many more 
conditions might be tested such as greater dilutions of streptavidin-AuNPs, more washing 
steps after addition of the AuNPs or the inclusion of MMPs, however, it might also be 
possible that the assay in its current set-up has to be changed entirely.
3.4.3 Conclusion and future of bead-based assay enhancement
We succeeded in establishing functional assays, but both the enhanced assay and the 
BCA were not able to considerably increase the detection of the chosen analytes above 
the performance obtained with conventional ELISA. To further improve both assay 
set-ups and their detection limit we provided several suggestions. However, it might 
be possible that the whole assay set-ups have to be changed, and that our choice of 
MMPs, AuNPs, barcodes and/or analytes interfere with each other and thus hamper 
assay improvement. Nowadays, a great variety of complex assays exist that use MMPs 
and AuNPs for enhancement, and due to this complexity, there is almost an uncountable 
number of possibilities to set-up bead-based assays. Recent reports can give more insight 
in which particles are most suited for assay development. For instance, MMPs with a 
porous surface in combination with AuNPs detected lower levels of a model protein than 
commercially available COOH-MMPs [316]. Unfortunately, AuNPs are often generated 
and characterized by individual laboratories, which makes repetition by others difficult. 
Although possibilities are immense for bead-based assay development, it remains a 
challenging task to develop such assays, in particular the BCA, in a regular diagnostic 
laboratory. The first BCA was developed by a group that is specialized in performing 
nano-optical methods, and who has sophisticated technology available for this purpose 
[293]. This group focused more recently on the development of a surface immobilized 
BCA with a microfluidic detection system based on the previously developed BCA, but 
with increased speed and simplicity [314]. Yet, the material required for such an assay is 
not widely available and the assay remains difficult to implement in routine laboratories. 
In conclusion, bead-based assays such as the BCA hold much potential to detect analytes 
of low abundance, but their design remains (too) complex to easily implement this 
technology into routine applications. 
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Abstract
In Alzheimer’s disease (AD), the most important genetic risk factor is the gene encoding 
for	 apolipoprotein	 E	 (ApoE),	with	 the	 ε4	 allele	 conferring	 an	 increased	 risk	 to	 develop	
AD.	ApoE	influences	aggregation	and	clearance	of	amyloid-β	(Aβ),	and	interacts	with	Aβ	
to form complexes. Complex formation is dependent on the ApoE isoform, since ApoE4 
forms	 less	 stable	 complexes	 than	 the	 ApoE2	 or	 ApoE3.	 A	 change	 in	 the	 levels	 of	 Aβ/
ApoE complexes may therefore be associated with AD. We aimed to develop a method 
to quantify these complexes, and to investigate their potential as biochemical marker for 
AD in serum.
We designed and characterized an enzyme-linked immunosorbent assay (ELISA) that 
specifically	 detects	 Aβ/ApoE	 complexes.	 We	 applied	 this	 ELISA	 to	 quantify	 levels	 of	
Aβ/ApoE	 complexes	 in	 serum	 samples	 of	 patients	 with	 AD,	 frontotemporal	 dementia,	
dementia with Lewy bodies or vascular dementia, and non-demented controls. 
The	 ELISA	 specifically	 detected	 synthetic	 Aβ/ApoE	 complexes,	 but	 not	 the	 individual	
proteins.	 Furthermore,	 Aβ/ApoE	 complexes	were	 successfully	 detected	 in	 serum	 of	 all	
patients, but levels of these complexes were similar in all dementia groups. 
In	conclusion,	this	study	does	not	provide	evidence	that	Aβ/ApoE	complexes	are	a	serum	
biomarker to differentiate the various dementia subtypes.
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4.1 Introduction
An estimated 36 million people suffered of dementia in 2010 worldwide, and these 
numbers are predicted to double every 20 years [2]. Although clinical diagnostic criteria 
for each of the major forms of dementia, such as Alzheimer’s disease (AD), frontotemporal 
dementia (FTD), dementia with Lewy bodies (DLB) and vascular dementia (VaD) have 
been defined [11, 13, 76], the assignment of an individual patient to a specific clinical 
dementia syndrome remains a challenge due to the lack of exact biomarkers. Biochemical 
markers	 such	 as	 the	 quantification	 of	 the	 proteins	 amyloid-β42	 (Aβ42),	 total	 tau	 and	
phosphorylated tau in the cerebrospinal fluid (CSF), or molecular ligands for positron 
emission tomography imaging such as Pittsburgh compound B [82] may support the 
diagnosis of AD. However, although these biomarkers may accurately discriminate AD 
patients from non-demented controls, the differentiation of AD from other dementia 
syndromes remains more challenging [317, 318].
AD is the most common type of dementia with the majority of cases developing late-
onset	AD.	According	to	the	amyloid	cascade	hypothesis,	Aβ	is	the	main	factor	that	causes	
development of the disease. The peptide is enzymatically cleaved from the amyloid 
precursor protein (APP) and exists in different isoforms with 38-43 amino acids, of which 
Aβ40	is	the	most	common	isoform	and	Aβ42 is most prone to form aggregates that are toxic 
for	neurons.	Aβ	aggregates	accumulate	in	the	brain	with	age,	which	might	be	caused	by	
a	decrease	in	Aβ	clearance	[319].	Except	for	age,	the	most	important	genetic	factor	that	
increases	the	risk	of	developing	AD,	is	the	ɛ4	allele	of	apolipoprotein	E	(ApoE)	[61].	This	
34 kDa protein occurs in three isoforms, i.e. ApoE2, -E3 and -E4. The primary function of 
ApoE is transport of lipoproteins and cholesterol in the circulation, but the protein also 
interacts	with	Aβ,	 influences	Aβ	clearance	from	the	brain,	e.g.	via	 interaction	with	low-
density lipoprotein receptor-related protein 1, which is the major receptor for transport 
of	Aβ	across	the	blood-brain	barrier	(BBB),	and	may	stimulate	Aβ	aggregation	and	thus	
its	 cerebral	 accumulation.	 Effects	of	ApoE	on	Aβ	are	 isoform-dependent,	 and	ApoE4	 is	
more	strongly	associated	with	senile	plaques,	toxic	Aβ	oligomers,	and	impaired	clearance	
of	Aβ	 than	ApoE2	and	ApoE3	 [73,	319-321].	 Several	 studies	 showed	 that	ApoE	and	Aβ	
bind to each other and form complexes, the strength of which is dependent on the ApoE 
isoform	[322-324].	In	general,	endogenous	ApoE4	forms	less	stable	bonds	with	Aβ	than	
ApoE3	[325].	A	 less	stable	 interaction	of	Aβ	with	the	ApoE4	 isoform,	thus	 less	complex	
formation,	might	subsequently	lead	to	an	increase	in	free	Aβ	levels	and	aggregation,	which	
might be a reason why ApoE4 poses a greater risk for disease development. Supporting 
this	 hypothesis,	 levels	 of	 Aβ/ApoE	 complexes	 are	 decreased	 in	 postmortem	CSF	 of	 AD	
patients	 carrying	 the	 ɛ4	 allele	 versus	 non-ɛ4	 carriers	 [53].	 In	 the	 same	 study	 it	 is	 also	
reported that complex levels are decreased in human synaptosomes of the parietal cortex 
and	 in	 postmortem	 CSF	 of	 AD	 patients	 compared	 to	 controls,	 and	 therefore	 Aβ/ApoE	
complexes	compose	an	interesting	biomarker	for	AD.	Since	Aβ	is	cleared	from	the	brain	
and	transported	towards	the	circulation	[326]	and	both	Aβ	and	ApoE	are	present	in	serum,	
we	 hypothesized	 that	 Aβ/ApoE	 complexes	 also	 appear	 in	 serum.	 If	 so,	 and	 if	 complex	
levels	are	different	in	AD	compared	to	other	dementias,	the	Aβ/ApoE	complex	could	serve	
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as	a	novel,	blood-based	biomarker	for	AD.	To	investigate	the	biomarker	potential	of	Aβ/
ApoE complexes, we designed an enzyme-linked immunosorbent assay (ELISA) for specific 
detection	of	those	complexes.	We	demonstrate	that	this	assay	detects	synthetic	Aβ/ApoE	
complexes in a concentration-dependent manner, but not the individual proteins. We 
applied	this	assay	to	measure	the	levels	of	Aβ/ApoE	complexes	in	serum	of	patients	with	
AD, FTD, DLB, VaD and non-demented controls.
4.2 Materials and Methods
4.2.1 Subjects
Serum from 20 AD, 26 FTD, 25 DLB, 22 VaD patients, and 17 non-demented controls 
(table 1) was obtained at the Radboud University Medical Center, Nijmegen. Patients with 
AD, FTD, DLB or VaD had been tested by clinical and neuropsychological examination, and 
routine laboratory investigation. Dementia was diagnosed by a multidisciplinary team 
using the following diagnostic criteria: NINCDS-ADRDA criteria for AD [75], NINDS-AIREN 
criteria for VaD [11], and published consensus criteria for DLB [13] and FTD [327]. Cognitive 
function had been assessed by mini-mental state exam (MMSE). Control subjects had been 
assessed for neurological disorders but were either diagnosed without a neurological 
disorder or with a systemic disease without neurological manifestations. Serum samples 
were obtained as part of the clinical diagnostic work-up of a patient. Patients were 
informed that their data, including serum, could be used for further scientific purposes 
and were given the option to object against this use, in which case their data were 
not used. Serum was collected by vena puncture, and was, after routine investigation, 
centrifuged, aliquoted and stored at -80°C within two hours after collection. Left-over 
samples were pooled and stored at -20°C before use for assay validation purposes.
4.2.2 Antibodies and peptides
For	detection	of	Aβ/ApoE	complexes	on	Western	blot	we	used	monoclonal	mouse-anti-
apoE clone E6D7 which reacts to the E2, E3 and E4 isoforms of ApoE (Meridian, Memphis, 
TN,	USA)	and	polyclonal	rabbit-anti-Aβ	40-4	(kindly	provided	by	Dr.	van	Nostrand;	Stony	
Brook, NY, USA). As secondary antibodies, we used Alexa 680-labelled goat-anti-mouse 
IgG (Life Technologies, Carlsbad, CA, USA), and IRDye800-labelled goat-anti-rabbit IgG 
(Rockland,	Limerick,	PA,	USA).	For	quantification	of	Aβ/ApoE	complexes		by	ELISA,	goat-
anti-ApoE (Meridian, Memphis, TN, USA) was used as capture antibody, and mouse 
monoclonal antibody clone Nab-228 (Sigma-Aldrich, St. Louis, MO, USA), which is directed 
against	 Aβ,	 but	 also	 recognizes	 APP	 and	 other	 APP-products,	 was	 used	 as	 detection	
antibody. Antibody Nab-228 was biotinylated using the Biotin Label Kit – NH2 (Abnova, 
Taipei City, Taiwan). Streptavidin conjugated to multiple horse-radish peroxidases (SA-
polyHRP; Pierce, Rockford, IL, USA) was used to detect biotinylated antibodies.
Synthetic	Aβ42 was purchased from 21
st Century Biochemicals (Marlboro, MA, USA), and 
was dissolved in hexafluoroisopropanol (HFIP) (Sigma-Aldrich) to bring it in a monomeric 
state and dried overnight by air. Peptide films were stored at -80°C. Prior to use, the peptide 
films were dissolved in dimethyl sulfoxide at a concentration of 5 mM. Recombinant 
human ApoE3 protein was obtained from Fitzgerald (North Acton, MA, USA).
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4.2.3 Preparation of Aβ/ApoE complex
Synthetic	 Aβ42 (50 µM) and recombinant ApoE3 (500 nM) were diluted and mixed in 
phosphate-buffered saline (PBS; Roche, Mannheim, Germany). The mixtures were 
incubated at 37°C for 24 hours, and stored at -20°C until further use.
4.2.4 Detection of Aβ/ApoE complexes by Western Blot
Aβ/ApoE	complexes,	or	samples	containing	only	Aβ	or	ApoE,	were	mixed	3:1	with	non-
reducing sample buffer and incubated at 37°C for 15 min. Samples were separated on 12% 
Tris-glycine gel for SDS-PAGE and proteins were transferred to a polyvinylidene fluoride 
(PVDF) membrane (Millipore, Billerica, MA, USA) which was subsequently blocked with 
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA), 1:1 diluted in PBS, for 
1 h at room temperature. The PVDF membrane was incubated with E6D7 anti-ApoE 
antibody (dilution 2500x, over-night at 4°C), washed with PBST (PBS, 0.05% Tween-20) 
and incubated with the Alexa 680-labelled goat-anti-mouse IgG (dilution 5000x, for 1 h 
at room temperature). Again, the membrane was washed and subsequently incubated 
with antibody 40-4 (dilution 2000x, for 1 h at room temperature). After washing, the 
membrane was incubated with a IRDye800-labelled goat-anti-rabbit IgG (dilution 10,000x, 
for 1 h at room temperature). All antibodies were diluted in blocking buffer. Protein bands 
were visualized using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Values are expressed as means ± standard deviations. 1Gender differences between groups were 
determined using Chi-square test. Mean age of groups was compared using ANOVA and Bonferroni’s 
post-hoc	test	for	multiple	comparison.	Disease	duration,	MMSE	score,	and	Aβ/ApoE	complex	levels	were	
compared between groups using Kruskal-Wallis test and Dunn’s post-hoc test for multiple comparison. 
2ApoE	ε4	carriers	carried	either	one	or	two	ε4	alleles.	3At the time of lumbar puncture. Disease duration 
data was not available for six AD, eleven FTD, fourteen DLB and fifteen VaD cases. The MMSE score had 
not been determined for six AD, eleven  FTD, sixteen DLB and eleven VaD cases. Key: AD = Alzheimer’s 
disease; FTD = Frontotemporal dementia; DLB = Dementia with Lewy bodies; VaD = Vascular Dementia; 
MMSE	=	Mini-mental	state	examination;	NA	=	not	applicable;	NS	=	not	significant;	Aβ	=	Amyloid	β;	ApoE	
= Apolipoprotein E
Table 1: Group characteristics
Control AD FTD DLB VaD p-value1
Number of patients 17 20 25 25 22
ApoE genotype  
(non-ɛ4 carrier/ɛ4 carrier)2
2/2 5/11 11/7 6/6 13/3
Gender (m/f ) 8/9 10/10 17/8 19/6 15/7 NS (p = 0.23)
Mean age (years)3 64.6 ± 10 71 ± 6.2 67.3 ± 8.3 72.9 ± 9 77.6 ± 6.3 p < 0.0001
Disease duration (months)3 NA 31.1 ± 33.4 17.5 ± 32.4 15.4 ± 18.3 24.7 ± 26.9 NS (p = 0.54)
MMSE score3 NA 18.8 ± 5.1 21.9 ± 5.7 18 ± 8.1 16.6 ± 4.2 NS (p = 0.07)
Aβ/ApoE serum levels  
(ng/ml of ApoE input for standards)
28.5 ± 40.4 19.6 ± 17.3 14.9 ± 9 16.0 ± 13.0 21.6 ± 9.6 NS (p = 0.24)
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4.2.5 Detection of Aβ/ApoE complexes by ELISA
An	 ELISA	 was	 developed	 to	 quantify	 Aβ/ApoE	 complexes	 in	 serum.	 Goat-anti-ApoE	
antibody was diluted to 0.33 µg/ml in PBS and coated on a Nunc MaxiSorp flat-bottom 96-
well plate (eBioscience Inc; San Diego, CA, USA) over-night at 4°C. Subsequently, and after 
each incubation step, the plate was washed 5 times with PBST using a Tecan Hydroflex 
plate washer (Männedorf, Switzerland). The plate was blocked with 200 µl Odyssey 
Blocking	 Buffer	 per	 well,	 for	 2	 h	 at	 room	 temperature.	 Next,	 the	 synthetic	 Aβ/ApoE	
complex (used as a standard) was serially diluted in sample diluent (obtained from the 
hTau Innotest, Fujirebio, Gent, Belgium) to concentrations that corresponded to ApoE3 
concentrations of 0.66 - 42.5 ng/ml. Serum samples were serially diluted in sample diluent 
for assay verification purposes, and 2x for final analysis. Five serum samples had very high 
concentrations and were diluted 4x, 8x and 16x for final analysis to obtain OD values 
within the linear range of the assay. As negative controls, a zero-standard (buffer), and 
antigen-solutions	containing	either	only	ApoE3	or	Aβ42 (concentrations corresponding to 
the highest standard concentration) were used. Samples were incubated for 2 h at room 
temperature on a shaking device (600 rpm). Then, the biotinylated detection antibody 
Nab-228 was added at a 250x dilution in PBST with 0.1% bovine serum albumin (BSA; 
Sigma-Aldrich) and incubated at room temperature for 1 h on a shaking device (600 rpm). 
Subsequently, the plate was incubated with 100 ng/ml SA-polyHRP for 30 min at room 
temperature while shaking (600 rpm). Finally, 3,3’,5,5’-Tetramethylbenzidine substrate 
(Sigma-Aldrich) was added for color generation. The reaction was stopped with 1N H2SO4 
and signals at OD450 nm were measured using a Tecan plate reader. 
4.2.6 Depletion of serum from Aβ/ApoE complexes
Protein A/G plus agarose beads (50 µl) (Thermo Scientific) were washed 3 times 
with 10 mM NaAc at pH 5.0 and each time centrifuged at 2500 rcf for 1 min. Then, 
beads were incubated with 5 µl goat-anti-ApoE (1 mg/ml) in NaAc for ~16 h at 
4°C while rotating. Next, beads were washed 3 times with PBS and resuspended in 100 µl 
serum. Serum was depleted for ~16 h at 4°C with constant rotating, after which samples 
were	centrifuged	and	supernatant	(depleted	serum)	was	analyzed	in	the	Aβ/ApoE	ELISA.
4.2.7 Data analysis
The	 limit	 of	 detection	 (LOD)	 of	 the	 Aβ/ApoE	 ELISA	 was	 calculated	 as	 the	mean	 of	 18	
replicates of the zero standard plus three times the standard deviation. Intra-assay 
variation was determined from 2 samples measured 3 times, and inter-assay variation 
from 3 samples, which were measured on 3 different occasions. All samples were 
measured	in	duplicates.	Levels	of	Aβ/ApoE	complexes	are	depicted	as	concentrations	of	
ApoE in the samples. Three serum samples were measured on each plate and were used 
to correct for inter-plate variability. Statistics were performed in Graph Pad Prism version 
5 (La Jolla, CA, USA), and groups were compared by Kruskal-Wallis test and Dunn’s post-
hoc test for multiple comparison. P-values less than 0.05 were considered significant. 
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4.3 Results
4.3.1 Aβ/ApoE complex formation
Successful	 formation	 of	 the	 Aβ/ApoE	 complex	 was	 confirmed	 by	 Western	 blotting.	
ApoE3 was detected as a single band at the predicted molecular weight (MW) 
of	 ~34	 kDa	 (figure	 1,	 lane	 1).	 Aβ42 was mainly visible as monomers (~4.5 kDa) 
(figure 1, lane 2). Upon co-incubation of both proteins, an additional band at ~42 kDa, the 
expected	size	of	an	Aβ/ApoE	complex,	appeared,	that	was	detected	by	both	the	anti-Aβ	
and anti-ApoE antibodies (figure 1, lane 3). 
4.3.2 Characterization of the ELISA to detect the Aβ/ApoE complexes
An	 ELISA	 was	 designed	 to	 specifically	 detect	 the	 synthetic	 Aβ/ApoE	 complexes.	 The	
ELISA	was	validated	 for	 its	 suitability	and	specificity	 to	also	detect	Aβ/ApoE	complexes	
in	serum.	To	generate	a	standard	curve,	we	used	synthetic	Aβ/ApoE	complex	at	different	
dilutions (figure 2A). The assay was linear (r = 0.99) at concentrations of the complex 
which corresponded to an ApoE3 concentration of 0.66-42 ng/ml. The LOD was calculated 
at concentrations of the complex which corresponded to an ApoE3 concentration of 3.5 
ng/ml. Mean intra-assay coefficient of variation (CV) was 4%, and mean inter-assay CV 
was 20%. Specificity of the signal was determined by testing several negative controls. 
The signal was reduced to control levels (i.e. when no antigen was added) if only ApoE or 
Aβ	were	added	 instead	of	 the	protein	 complex	or	 if	 the	capture	antibody	was	omitted	
(figure	2B),	showing	that	the	assay	specifically	measures	Aβ/ApoE	complexes.
Figure 1: Detection of Aβ/ApoE protein complex by 
Western Blot
Proteins	 (ApoE3	 	 and	 Aβ42) were separated on a 
12% SDS-PAGE gel, and the blot was stained with 
antibodies	 directed	 against	 ApoE	 (green)	 and	 Aβ	
(red). ApoE3 was loaded in lane 1 (open arrow), 
Aβ42	in	lane	2	and	Aβ/ApoE	complex	in	lane	3	(black	
arrow). 
Key:	ApoE3	=	apolipoprotein	E3,	Aβ42	=	amyloid-β42, 
MW = molecular weight
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Different serum dilutions were analyzed in the ELISA to determine the optimal dilution for 
quantification	of	Aβ/ApoE	complexes.	At	a	two	times	dilution,	levels	of	Aβ/ApoE	complexes	
were measured in the linear part of the standard curve (figure 2C). To further determine 
the	 specificity	 of	 the	 ELISA	 for	Aβ/ApoE	 in	 serum,	we	depleted	pooled	 serum	 samples	
(either	undiluted	or	diluted	twice	 in	sample	diluent)	 for	ApoE	and	Aβ/ApoE	complexes.	
After	depletion,	the	obtained	signal	for	the	Aβ/ApoE	complexes	was	significantly	reduced	
(figure	 2D).	 The	 overall	 efficiency	 to	 deplete	 the	 Aβ/ApoE	 complexes	 from	 serum	was	
between 50-80%.
Figure 2: Validation of the ELISA for detection of Aβ/ApoE complexes 
A)	Standard	curve	of	synthetic	Aβ/ApoE	complexes.	Samples	were	measured	 in	duplicate.	The	Aβ/ApoE	
complex concentrations are depicted as the corresponding ApoE input concentrations. B) Mean (with 
standard	 deviation)	 of	 the	 signal	 obtained	 in	 five	 independent	 experiments	 using	 Aβ/ApoE	 complexes	
(complex),	the	ApoE	protein	only	(ApoE),	the	Aβ42	peptide	only	(Aβ),		buffer	only	(no	antigen)	or	omission	
of the capture antibody when assaying the complex (no capture)  in ELISA (ANOVA; p < 0.0001). C) Mean 
(with	standard	deviation)	signal	of	Aβ/ApoE	complexes	in	undiluted	(100%),	two	times	(50%),	four	times	
(25%) and eight times (12.5%) diluted pooled sera. Samples were measured in triplicate. D) ELISA signal 
of	Aβ/ApoE	levels	in	pooled,	undiluted	or	two	times	diluted	serum,	which	were	either	undepleted	(closed	
dots)	or	depleted	(open	dots)	for	ApoE	and	Aβ/ApoE	complexes	with	anti-ApoE-coated	beads.	Key:	OD450	
= optical density at 450 nm.
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4.3.3 Quantification of Aβ/ApoE complexes in serum of demented 
and non-demented patients
Samples were matched for gender and disease duration. Age was significantly different 
between	groups	 (p	<	0.0001,	 table	1).	Mean	Aβ/ApoE	protein	 complex	 levels	 in	 serum	
from	non-demented	controls	were	26.7	±	40.3	ng/ml	(table	1,	figure	3A).	Mean	Aβ/ApoE	
levels in serum of AD, FTD, DLB, and VaD patients were not significantly different from 
each other and from non-demented controls (p = 0.24; table 1; figure 3A). Results did not 
change, when age was added as a covariate and an ANCOVA was performed. Two samples 
had very high values, one in the control group, one in the AD and one in the FTD group. 
Neither age, gender, or storage of the sample could be correlated to these abnormal 
high values, nor did we identify any other parameters in the blood such as protein 
or albumin levels that were abnormal in both samples. Results did not change when 
these outliers were removed from analysis. The ApoE genotype was available for 
65 subjects (patients and non-demented controls; figure 3B). No differences were 
detected	 in	 the	 concentrations	 of	 Aβ/ApoE	 complex	 levels	 between	 the	 different 
genotypes	 (ɛ4	 versus	 non-ɛ4)	 when	 all	 patients	 were	 combined	 (Mean	 ɛ4	 carriers	 = 
21.6	±	29.3	ng/ml;	Mean	non-ɛ4	carriers	=	18.5	±	12.1	ng/ml;	p	=	0.65;	data	not	shown).	
When	 comparing	 ɛ4	 versus	 non-ɛ4	 carriers	 in	 each	 patient	 group,	 only	 in	 the	 DLB 
group	differences	were	 detected	 (Mean	 ɛ4	 carriers	 =	 25.8	 ±	 21.4	 ng/ml;	Mean	non-ɛ4	
carriers = 7.4 ± 4.3 ng/ml; p = 0.004; figure 3B), but not in the other groups. When 
comparing	 only	 non-ɛ4	 carriers	 between	 the	 different	 dementia	 types,	 complex	 levels	
Figure 3: Quantification of Aβ/ApoE complexes in serum samples of dementia patients and non-demented 
controls
A)	 Scatterplot	 of	 Aβ/ApoE	 complex	 levels	 in	 controls,	 AD,	 FTD,	 DLB	 and	 VaD	 patients,	 depicted	 as	
corresponding ApoE input levels which has been used for in vitro preparation of the standard. Horizontal 
lines represent mean values. All samples were measured in the linear range of the standard curve. Five 
samples with OD values above the upper limit of detection were further diluted to achieve this. After 
application of the correction factor for inter-plate variability in six samples the concentration, which was 
originally within the linear part of the curve, fell below the limit of detection. B)	Scatterplot	of	Aβ/ApoE	
complex levels of the samples of which the ApoE genotype was available. Closed dots represent ApoE4 
carriers, open dots ApoE4 non-carriers.
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were decreased in DLB compared to AD (p = 0.004). No differences were found when 
comparing	ɛ4	carriers.
4.4 Discussion
In	 this	 study,	we	successfully	assembled	 synthetic	Aβ/ApoE	complexes	 in vitro, and we 
designed and validated an ELISA method that is able to specifically detect synthetic 
complexes.	Complex	 levels	were	quantifiable	 in	 serum	samples,	however,	 levels	of	Aβ/
ApoE complex did not differ between the investigated patient groups.
4.4.1 Aβ and ApoE interact with each other
Synthetic	Aβ	and	recombinant	ApoE	were	used	to	assemble	Aβ/ApoE	complexes	in vitro. 
Such complexes have been demonstrated on SDS-PAGE as a 40 kDa band [328, 329], which 
we	could	 confirm.	 There	are	multiple	 lines	of	 evidence	 that	 suggest	 that	ApoE	and	Aβ	
closely interact with each other in the brain. More than two decades ago, it was already 
demonstrated	that	ApoE	and	Aβ	co-localize	 in	senile	plaques	of	AD	patients	 [330],	and	
recently,	Aβ/ApoE	complexes	were	also	detected	and	quantified	in	human	synaptosomes	
and	postmortem	CSF	[325].	Aβ	either	binds	directly	to	ApoE,	or	is	linked	by	heparin,	which	
has	both	Aβ	and	ApoE	binding	sites	[331].	Direct	interaction	of	Aβ	and	ApoE	is	influenced	
by	the	lipidation	state	of	ApoE,	since	one	of	the	Aβ	binding	sites	within	ApoE	is	also	the	
site	 for	 lipid	 binding	 [74,	 332].	 Importantly,	 the	 strength	 of	 the	 interaction	with	 Aβ	 is	
determined by the ApoE isoform, since ApoE4 (for instance derived from plasma) forms 
less	stable	complexes	with	Aβ	than	ApoE3	[53,	322,	333,	334].	
4.4.2 ELISA specifically quantifies Aβ/ApoE complexes 
Only	recently,	the	first	ELISA	has	been	described	that	is	able	to	detect	Aβ/ApoE	complexes	
in mouse and human brain tissue, and in postmortem obtained CSF [53]. In the past, 
Western	blotting	was	mainly	used	to	study	Aβ/ApoE	complexes.	However,	for	quantification	
purposes, an ELISA is superior to Western Blot, since it is more sensitive, quantitative and 
allows	detection	of	the	Aβ/ApoE	complex	in	an	SDS-free	environment.	 In	this	study,	we	
showed	for	the	first	time	that	Aβ/ApoE	complexes	can	also	be	quantified	in	serum.	Our	
ELISA is comparable to the design of the previously described ELISA [53], but makes use 
of different capture and detection antibodies. For detection, we further used streptavidin 
conjugated to multiple HRP molecules, which increases the signal compared to a single 
HRP molecule that is either conjugated to streptavidin or to a secondary antibody (data 
not shown). The specific detection of the synthetic complex and the decrease in signal 
after depletion of ApoE (and thus the complex) in serum provided proof that the ELISA 
was	a	good	tool	for	quantification	of	Aβ/ApoE	complexes,	which	we	subsequently	applied	
to determine complex levels in the serum of different patient groups with dementia.
4.4.3 Aβ/ApoE complex levels in serum do not differentiate between 
dementia types
We	did	not	 identify	differences	 in	serum	complex	 levels	between	AD,	FTD,	DLB,	VaD	and	
non-demented	controls,	neither	did	we	detect	any	differences	in	Aβ/ApoE	complex	levels	
between	ɛ4	and	non-ɛ4	carriers,	with	the	exception	for	DLB	patients.	In	DLB	patients,	Aβ/
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ApoE	complex	levels	were	decreased	in	non-ɛ4	carriers	compared	to	ɛ4	carriers,	and	non-ɛ4	
carriers	 of	 DLB	 cases	 had	 decreased	 complex	 levels	 compared	 to	 non-ɛ4	 carriers	 of	 AD	
patients.	However,	 the	 size	of	 samples	of	 these	groups	with	an	available	ApoE	genotype	
was	rather	small	(6	ɛ4	carriers	and	6	non-ɛ4	carriers	of	DLB;	5	non-ɛ4	carriers	of	AD),	thus	
findings	might	have	been	biased	due	to	the	small	sample	size.	It	would	have	been	interesting	
to	investigate	homozygous	genotypes	of	ɛ3	versus	ɛ4	carriers	to	get	a	more	clear	picture	of	
a	genotype	effect,	but	most	of	the	samples	of	which	a	genotype	was	available,	contained	
mixed	genotypes.	In	DLB,	if	only	homozygous	ɛ3	(n	=	6)	versus	homozygous	ɛ4	carriers	(n	
=	2)	were	compared,	no	differences	of	Aβ/ApoE	complex	 levels	were	observed	 (data	not	
shown),	but	also	here	the	sample	size	is	too	limited	to	be	statistically	relevant.	
Previously,	 levels	of	Aβ/ApoE	complexes	were	 found	 to	be	decreased	 in	 the	brain	and	 in	
postmortem	CSF	of	AD	patients	compared	to	controls,	and	in	homozygous	ɛ4	carriers	versus	
homozygous	 ɛ3	 carriers	 of	 the	 AD	 patients	 [53].	 Our	 findings	 are	 not	 in	 line	with	 these	
results,	however,	Aβ/ApoE	complex	levels	that	are	found	in	serum	might	not	correspond	to	
brain and CSF levels. It has been reported that the complex itself is not likely to cross the 
BBB	 [335-337].	Therefore,	Aβ/ApoE	complexes	 that	are	measured	 in	 serum	are	probably	
formed	 in	 the	 circulation	 by	 interaction	 of	 soluble	 Aβ	 and	ApoE.	 Both	Aβ	 and	ApoE	 are	
produced in the brain, but also in the periphery. A major source of ApoE in the periphery 
is	the	liver	[338],	whereas	platelets	are	a	systemic	source	of	Aβ	[339].	Furthermore,	it	was	
recently	 shown	 that	 total	plasma	Aβ	measured	 in	 central	 veins	 is	 increased	by	Aβ	efflux	
from the brain only by ~7.5%, and this percentage might further decrease quickly by 
dilution	[340].	Therefore,	it	is	possible	that	Aβ/ApoE	complex	levels	in	serum	do	not	reflect	
pathological	events	 in	the	brain,	which	could	explain	the	similar	 levels	between	different	
patient	groups.	It	would	be	very	interesting	to	measure	Aβ/ApoE	complexes	in	antemortem	
obtained lumbar CSF. Unfortunately, using our ELISA, it was not possible to detect and 
quantify	complex	levels	in	CSF	samples,	which	might	be	due	to	too	low	concentrations	of	
the	complexes	or	their	complete	absence	in	lumbar	CSF.	The	latter	may	be	supported	by	a	
recent	report	showing	that	Aβ	and	ApoE	only	minimally	form	complexes	with	each	other	
in CSF [74]. Possibly, ApoE could simply be much higher in serum than CSF which enables 
detection	of	Aβ/ApoE	complexes.
We cannot rule out that our ELISA also detects ApoE/APP complexes, since binding between 
these proteins has been described once in literature [341] and Nab-228 may also recognize 
APP	(fragments),	although	Aβ	 is	a	stronger	binding	partner	for	ApoE	than	APP.	Use	of	an	
antibody	that	specifically	detects	Aβ	should	clarify	this	issue.	Further	validation	of	the	ELISA	
in	human	tissue	or	in	postmortem	CSF,	as	has	been	done	previously,	could	give	more	insight	
in	the	specificity	for	detection	of	endogenous	Aβ/ApoE	complexes.
4.4.4 Conclusion
In	 this	 study,	 we	 did	 not	 find	 proof	 that	 Aβ/ApoE	 complexes	 in	 serum	 can	 be	 used	 as	
biochemical	 marker	 to	 differentiate	 AD	 from	 other	 dementia	 types	 or	 non-dementia.	
With	our	ELISA	we	designed	a	tool	that	 is	able	to	quantify	synthetic	Aβ/ApoE	complexes.	
However,	further	validation	of	the	ELISA	to	detect	endogenous	Aβ/ApoE	complexes	might	
be warranted.
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Abstract
Neuronal Cell Adhesion Molecule (NrCAM) is a proposed new cerebrospinal fluid (CSF) 
biomarker in Alzheimer’s disease (AD). In this pilot study, we aimed to validate and extend 
previous results and measured NrCAM by ELISA in CSF of patients with AD, frontotemporal 
dementia, dementia with Lewy bodies and non-demented controls. NrCAM levels were 
comparable in all groups, but correlated positively with total tau and phosphorylated 
tau levels. Furthermore, NrCAM had no significant additional diagnostic value when 
combined	with	amyloid-β42, total tau and phosphorylated tau proteins. Therefore, NrCAM 
is not a suitable CSF biomarker to differentiate between dementia groups.
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5.1 Introduction
The diagnosis of Alzheimer’s disease (AD) is supported by abnormal cerebrospinal fluid 
(CSF)	levels	of	amyloid-β42	(Aβ42), total tau (t-tau) and hyperphosphorylated tau (p-tau). 
Together, these three biomarkers may differentiate AD patients from healthy controls 
with a sensitivity and specificity each above 80% [342]. However, in differentiating AD 
from other types of dementia, such as frontotemporal dementia (FTD) or dementia with 
Lewy bodies (DLB), these CSF biomarkers have their limitations. Several novel biomarkers 
have been suggested to improve the CSF biomarker-based diagnosis of AD. Neuronal Cell 
Adhesion Molecule (NrCAM) was identified as a candidate biomarker with decreased 
levels in AD patients compared to healthy controls [343]. NrCAM has also been described 
as a marker for disease severity in AD [344, 345]. In this pilot study, we aimed to confirm 
the usefulness of NrCAM as novel biomarker for differential diagnosis by measuring its 
levels in CSF by ELISA in non-demented controls, AD, FTD and DLB patients. 
5.2 Materials and Methods
5.2.1 Samples
CSF samples of 30 controls, 30 AD, 18 FTD and 17 DLB patients (Table 1) were obtained 
from the Radboud University Medical Center, Nijmegen, The Netherlands. Patients 
with AD, FTD or DLB had been tested by clinical and neuropsychological examination, 
and routine laboratory investigation. For AD, the clinical diagnosis was confirmed by 
NINCDS-ADRDA criteria [75]. Published consensus criteria were used for diagnosis of 
DLB [13] and FTD [327]. More recent diagnostic criteria for AD [76] were not applied, 
since the patients’ samples were collected prior to the introduction of these criteria. 
Cognitive function at the time of lumbar puncture was assessed by mini-mental state 
exam (MMSE). Control subjects had been assessed for neurological disorders but were 
either diagnosed without a neurological disorder or with a systemic disease without 
neurological manifestations. Routine CSF parameters (cell count, glucose, total protein, 
hemoglobin, bilirubin, oligoclonal IgG bands) were normal for these control subjects. CSF 
samples were obtained as part of the clinical diagnostic work-up of a patient. Patients 
were informed that their data, including CSF, could be used for further scientific purposes 
and were given the option to object against this use, in which case their data was not 
included. The CSF was collected by lumbar puncture in polypropylene tubes, and was, 
after routine investigation, centrifuged, aliquoted and stored at -80°C within two hours 
after collection.
5.2.2 Enzyme-linked immunosorbent assays (ELISA’s)
The NrCAM ELISA (DuoSet, R&D systems, Minneapolis, MN, USA) was performed 
according to the manufacturer’s instructions, using a Nunc MaxiSorp flat-bottom 96-well 
plate	(eBioscience	Inc.,	San	Diego,	CA,	USA).	Aβ42, t-tau and p-tau levels were determined 
using Innotest ELISA (Fujirebio, Ghent, Belgium). All samples were measured in duplicate.
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5.2.3 Data analysis
The	limit	of	detection	(LOD)	of	the	ELISA	was	calculated	as	the	mean	of	24	replicates	of	
the	 zero	 standard	 plus	 three	times	 the	 standard	 deviation.	 The	 coefficients	 of	 variation	
(%CV)	were	determined	from	10	replicates	for	 intra-assay	variation,	and	from	3	samples	
with	different	NrCAM	levels,	measured	on	5	different	occasions,	for	inter-assay	variation.	
Mean	 recovery	 was	 assessed	 on	 3	 samples	 spiked	 with	 3	 different	 concentrations	 of	
NrCAM	 standard	 (500,	 1000	 and	 2000	 pg/ml).	 Statistics	 were	 performed	 in	 Graph	 Pad	
Prism version 5 (La Jolla, CA, USA) and SPSS version 20 (Armonk, NY, USA); for ROC 
comparisons we used MedCalc version 14.8.1 (Mariakerke, Belgium). NrCAM levels in 
patient	groups	were	compared	to	each	other	by	Kruskal-Wallis	test	and	Dunn’s	post-hoc	
test	 for	 multiple	 comparison.	 Correlations	 between	 parameters	 were	 calculated	 using	
Pearson	r	or	Spearman	r.	The	diagnostic	value	of	combinations	of	biomarkers	(Aβ42, t-tau 
and p-tau without or with NrCAM) to discriminate AD from controls was evaluated using 
linear	regression	and	receiver	operating	characteristics	(ROC)	analysis.	P-values	less	than	
0.05	were	considered	significant.	
5.3 Results
5.3.1 ELISA validation
The LOD of the NrCAM ELISA was 7 pg/ml. Intra-assay CV was 10.2% and the mean 
inter-assay CV was 24.8%. Mean recovery was 74.2%. The assay was linear until a 
concentration of 2000 pg/ml. Measurement of NrCAM at different CSF dilutions 
(4-64x) showed that consistent results could be obtained within the linear part of the 
standard curve at a 64x dilution (data not shown).
5.3.2 CSF NrCAM levels
Mean CSF NrCAM levels in control and patient groups were slightly different from each 
other (p = 0.02; Table 1; figure 1A). Post-hoc analysis revealed decreased mean NrCAM 
levels in the DLB versus control group, although with large overlap. Four samples had 
very high NrCAM levels, one in the AD group and three in the FTD group. These abnormal 
NrCAM levels were neither related to abnormal handling or storage time of the samples 
nor to age at time of lumbar puncture or MMSE scores. Removal of these data did 
not affect the results. NrCAM levels did not correlate with MMSE scores in any of the 
dementia groups, but NrCAM levels negatively correlated with disease duration in the 
combined AD, FTD and DLB patient groups (r = -0.41 ; p = 0.003; figure 1B). Also, NrCAM 
levels were correlated with t-tau (AD: r = 0.68; p < 0.0001; FTD: r = 0.60; p = 0.008; DLB: 
r = 0.72; p = 0.001) and p-tau (AD: r = 0.77; p < 0.0001; FTD: r = 0.49; p = 0.03; DLB: r = 
0.68;	p	=	0.002),	but	not	with	Aβ42.	The	established	CSF	biomarkers	(Aβ42, t-tau and p-tau) 
were in accordance with a typical AD profile in 22 of 30 cases (i.e. at least two of the three 
biomarkers were abnormal). Linear regression analysis followed by ROC analysis revealed 
that	NrCAM	did	not	significantly	increase	the	AUC	of	the	combined	Aβ42, t-tau and p-tau 
analysis	to	discriminate	AD	from	controls	(AUC	=	0.978	for	Aβ42, t-tau, p-tau with NrCAM 
versus	AUC	=	0.959	for	Aβ42, t-tau and p-tau without NrCAM; p = 0.16).
95
5
CSF NrCAM is not different in dementia disorders
Values are expressed as means ± standard deviations. 1Gender differences between groups were 
determined	using	Chi-square	test.	Mean	age	of	groups	and	amyloid-β42 were compared using ANOVA and 
Bonferroni’s Multiple Comparison. Disease duration, MMSE score, total protein, total tau, phosphorylated 
tau and NrCAM levels were compared between groups using Kruskal-Wallis test and Dunn’s post-hoc test 
for multiple comparison. 2At the time of lumbar puncture. 3Disease duration data was not available for five 
AD, five FTD and five DLB cases. 4The MMSE score had not been determined for four AD, five FTD and nine 
DLB cases. Key: AD = Alzheimer’s disease; FTD = Frontotemporal dementia; DLB = Dementia with Lewy 
bodies; MMSE = Mini-mental state exam; NA = not applicable; ND = not determined; NS = not significant; 
NrCAM = Neuronal cell adhesion molecule
Table 1: Group characteristics
Control AD FTD DLB p-value1
Number of patients 30 30 18 17
Gender (Male/Female) 20/10 10/20 13/5 17/0 p < 0.001
Mean age (years)2 66.2 ± 9.3 72.2 ± 8.8 66.1 ± 7.7 72.2 ± 9.2 p=0.01
Disease duration (months)2,3 NA 11.9 ± 21.1 12.2 ± 17.8 29 ± 28.7 NS (p=0.15)
MMSE score2,4 ND 20.5 ± 3.2 19.6 ± 6.9 21.8 ± 8.5 NS (p=0.23)
Total protein (µg/ml) 480 ± 162 542 ± 174 578 ± 132 559 ± 219 NS (p=0.55)
Amyloid-β42 (pg/ml) 886 ± 332 466 ± 111 763 ± 232 534 ± 205 p < 0.0001
Total tau (pg/ml) 287 ± 107 732 ± 495 438 ± 326 261 ± 141 p < 0.0001
Phosphorylated tau (pg/ml) 48 ± 18 110 ± 44 74 ± 31 51 ± 19 p < 0.0001
NrCAM (ng/ml) 36 ± 20 34 ± 22 57 ±77 21 ± 9 p=0.02
Figure 1: CSF NrCAM levels in dementia patients and healthy controls 
A) Scatterplot of CSF NrCAM levels in healthy controls and AD, FTD and DLB patients. Horizontal lines 
represent mean values. B) Correlation of NrCAM levels in the combined AD, FTD and DLB patient groups 
with disease duration. Disease duration data was not available for all patients (table 1).
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5.4 Discussion
In	 a	 previous	 study,	 CSF	 NrCAM	 levels,	 measured	 using	 a	 multiplexing	 platform,	 were	
decreased in AD compared to controls (p < 0.001) and could, together with some other 
selected	analytes,	improve	the	diagnostic	accuracy	of	Aβ42 and t-tau from 89% to 96% [343]. 
In	 another	 study,	 CSF	 NrCAM	 levels	were	 lower	 in	 AD	 patients	with	 CDR	 1	 compared	 to	
controls [344]. Our results contradict these results, since we found similar NrCAM levels in 
controls	and	AD	patients,	and	addition	of	NrCAM	to	the	current	AD	CSF	biomarkers	did	not	
significantly	improve	the	diagnostic	accuracy	for	AD.	We	found	a	small	difference	between	
control	 and	 DLB	 groups,	 but	 due	 to	 the	 large	 overlap	 in	 values,	 this	 is	 not	 of	 diagnostic	
importance.
An	explanation	for	the	conflicting	results	with	the	multiplex	analysis	might	 lie	 in	technical	
differences.	 NrCAM	 undergoes	 extensive	 splicing	 resulting	 in	 different	 isoforms	 [346],	
and	can	also	be	cleaved	by	metalloproteinases	 [347].	Our	ELISA	uses	a	different	antibody	
combination	 than	 the	multiplex	 panel,	 and	might	 detect	 other	NrCAM	 species.	However,	
the	same	ELISA	was	used	to	detect	differences	in	AD	patients	with	CDR	1	compared	to	CDR	
0	 [344].	 In	our	 study,	CDR	 scores	were	only	 available	 for	 a	 subset	of	AD	patients	 (mostly	
CDR 1) who had NrCAM levels comparable to controls. We cannot exclude, however, that 
differences	in	the	composition	of	the	study	groups	might	be	the	reason	why	we	could	not	
replicate	previous	findings.
Rather	than	differentiating	different	dementia	types,	CSF	NrCAM	levels	may	be	correlated	
to disease stage of AD. It was reported that NrCAM levels decreased at an annual rate of 
approximately	 10%	 in	 AD	 patients,	 which	 was	 not	 observed	 in	MCI	 or	 controls	 however	
[345].	Although	we	detected	no	 correlation	of	NrCAM	 levels	with	MMSE,	we	 identified	a	
correlation	with	disease	duration,	which	is	in	line	with	this	previous	study.	Therefore,	more	
extensive analysis of CSF NrCAM levels as a measure of disease severity is warranted, e.g. 
using	patients	with	MCI	due	to	AD,	but	this	was	beyond	the	scope	of	our	pilot	study.
In	 our	 study,	 NrCAM	 levels	 positively	 correlated	 with	 t-tau	 and	 p-tau.	 Such	 correlations	
between NrCAM and tau have also previously been reported [343, 345]. NrCAM helps in 
regulation	of	cell	to	cell	adhesion,	axonal	growth	and	guidance	[348]	at	neuronal	synapses	
[349].	Tau	phosphorylation	destabilizes	 the	microtubules,	which	distorts	synaptic	 function	
[350].	 The	 location	 and	 proximity	 of	 NrCAM	 and	 tau	might	 explain	 why	 their	 CSF	 levels	
correlate	with	each	other.	Another	possible	functional	link	of	tau	and	NrCAM	might	be	their	
regulation	by	a	protein	named	“fused	in	sarcoma”	(FUS).	The	splicing	of	both	NrCAM	and	tau	
is	regulated	by	FUS,	and	mutations	in	FUS	disturb	these	splicings	[351-354].
 
In	conclusion,	although	our	pilot	study	is	limited	by	its	retrospective	design	and	the	inclusion	
of	a	relatively	small	number	of	clinically	diagnosed	patients,	 it	provided	evidence	that	CSF	
NrCAM	levels	in	AD	patients	are	not	different	from	controls,	and	that	its	biomarker	potential	
is	limited	for	differential	diagnosis	of	dementia	groups.	However,	evaluation	of	NrCAM	levels	
in	dementia	patient	groups	at	various	stages	of	disease,	characterized	using	CDR,	MMSE,	CSF	
biomarkers,	and	preferably	with	a	neuropathologically-confirmed	diagnosis,	is	warranted.
97
5
CSF NrCAM is not different in dementia disorders
98
99
Part III
MicroRNA biomarkers for AD
100
Chapter 6
MicroRNAs in Alzheimer’s 
disease: differential expression 
in hippocampus and cell-free 
cerebrospinal fluid
Mareike Müller1, H. Bea Kuiperij1, Jurgen A. Claassen2, Benno Küsters3,4,  
Marcel M. Verbeek1
1  Department of Neurology, Department of Laboratory Medicine, Donders Institute for Brain, Cognition and 
Behaviour, Radboud Alzheimer Centre, Radboud University Medical Centre, Nijmegen, The Netherlands
2  Department of Geriatric Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud 
Alzheimer Centre, Radboud University Medical Centre, Nijmegen, The Netherlands 
3  Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands
4  Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands
 
Published in Neurobiology of Aging, 2013, 35(1): 152-158
102
Chapter 6
Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that function in complex networks to 
regulate protein expression. In the brain, they are involved in development and synaptic 
plasticity. In this study, we aimed to identify miRNAs with a differential expression in 
either hippocampus or cerebrospinal fluid (CSF) from Alzheimer’s disease (AD) patients 
and age-matched non-demented controls by quantitative PCR. In hippocampus, we also 
differentiated between AD patients with an intermediate stage, featured by Braak III/
IV, and a late stage, characterized by Braak VI. Eight selected miRNAs were analyzed in 
hippocampus, and the expression of miR-16, miR-34c, miR-107, miR-128a and miR-146a 
were differentially regulated. In CSF, out of eight selected miRNAs only miR-16 and miR-
146a could be reliably detected. In addition, we identified an effect of blood contamination 
on the CSF levels of miR-16, miR-24 and miR-146a. For group comparisons, we therefore 
selected CSF samples absent with or containing only low numbers of blood cells. Levels of 
miR-146a were significantly decreased in CSF of AD patients. In conclusion, the abnormal 
expression of several miRNAs in hippocampus of intermediate and late stage AD patients 
suggests their involvement in AD pathogenesis, and low levels of miR-146a in CSF are 
associated with AD. 
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6.1 Introduction
Alzheimer’s disease (AD) is the most common type of dementia with more than 13% of 
the elderly above the age of 65 suffering from its devastating symptoms. While incidence 
of the disease keeps increasing, no cures have been developed yet. Effective treatment is 
not only hampered by the lack of curing medicine, but also by lack of knowledge on the 
disease mechanisms and the difficulties of accurately diagnosing AD in its earliest stages 
before clinical symptoms occur. Current cerebrospinal fluid (CSF) biomarkers, including 
amyloid-β	 (Aβ)42,	 total	 tau	 and	phosphorylated	 tau,	 can	 support	 the	 clinical	 diagnosis	
of AD with a sensitivity and specificity of 85-90%, if AD patients are compared to non-
demented control subjects [99, 355]. However, in differentiating AD from other types of 
dementia, the current biomarkers have their limitations. 
In the past years, microRNAs (miRNAs) have gained increasing attention in studies on 
neurodegenerative diseases. An estimated number of 70% of these small, approximately 
20 nucleotides long, non-protein-coding RNAs are expressed in the brain and many 
are brain-specific or brain-enriched. MiRNAs act by binding to the 3’untranslated 
region of messenger RNAs (mRNAs), and inhibit translation, causing downregulation of 
specific targets. A single miRNA can bind multiple mRNAs and can therefore fine-tune 
the expression and function of numerous proteins. Vice versa, several miRNAs can be 
involved in the regulation of one single protein. The first study that described abnormal 
expression of miRNAs in AD, was published in 2007 [116]. Three miRNAs, miR-9, miR-
125b and miR-128, were upregulated in the hippocampus of AD patients compared to 
age-matched controls.
Furthermore,	some	miRNAs	may	inhibit	expression	of	Aβ	precursor	protein	(APP)	in	mice	
(e.g. miR-16 [356]) or beta-site APP cleaving enzyme 1 (BACE1) (e.g. miR-107 [117]) in 
humans.	Both	proteins	 are	 involved	 in	 the	production	of	Aβ,	which	accumulates	 in	AD	
brains.	Higher	Aβ	production	could	be	explained	by	decreases	in	miRNAs	that	regulate	APP	
or BACE1. Other miRNA expression studies demonstrated that the expression of several 
miRNAs was up- or downregulated in hippocampus and the cortex of AD patients [117, 
118]. Therefore, miRNAs may be added to the list of targets with potential to be used in 
treatment or diagnosis. Two studies focused on miRNA quantification in body fluids of AD 
patients [122, 357], and in one of them CSF was analyzed in parallel with hippocampus, 
medial frontal gyrus and cerebellum tissue. Several differentially expressed miRNAs in AD 
were identified in these studies, but these results have not been confirmed yet.
The present investigation was designed to assess differential expression of miRNAs in 
brain tissue and translate these observations into potential new CSF biomarkers for AD. 
We show that some miRNAs are indeed differentially regulated in the hippocampus of 
AD patients compared to non-demented controls, the degree of which is dependent 
on the Braak stage. In CSF, we demonstrate that miRNA expression levels may strongly 
depend on the number of blood-derived cells in the sample, which we took into account 
for comparative measurements. Of eight miRNA targets, only two are detected in CSF, and 
concentrations of miR-146a are lower in AD compared to controls. 
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6.2 Materials and Methods
6.2.1 Subjects
Tissue samples from hippocampus, containing all four cornu ammonis (CA) regions and the 
dentate	gyrus,	were	obtained	postmortem	 from	patients	 that	were	all	 scored	 for	CERAD	
and Braak (table 1). Postmortem delay was between three and six hours and similar in the 
AD and control groups. Groups were age- and gender-matched. AD samples with Braak 
stages VI (n=10) and control samples (n=6) were obtained from the Radboud University 
Medical	 Centre.	 Additional	 control	 hippocampus	 samples	 (n=5)	 and	 samples	with	 Braak	
stages III (n=5) and IV (n=5) were obtained from the Netherlands Brain Bank, Amsterdam. 
CSF	 of	 controls	 (n=22)	 and	 AD	 patients	 (n=20)	 were	 obtained	 from	 Radboud	 University	
Medical	 Centre,	 Nijmegen.	 AD	 patients	 had	 been	 diagnosed	 by	 clinical	 NINCDS-ADRDA	
Alzheimer’s criteria [75] and mini-mental state exam (MMSE) (table 2). Controls were 
identified	 as	 non-demented.	 They	 had	 been	 assessed	 for	 another	 neurological	 disorder	
but	 were	 diagnosed	 with	 either	 a	 systemic	 disease	 without	 neurological	 manifestations	
or, for example, tension-type headache or burn out. CSF sample groups were matched for 
age and gender (table 2), and were selected on the absence of cells or presence of only 
low	 numbers	 of	 leukocytes	 (1-2	 cells/μl)	 and	 erythrocytes	 (below	 200	 cells/μl)	 
(table 2). CSF samples were obtained by lumbar puncture, collected in polypropylene 
tubes,	and,	after	routine	investigation,	centrifuged,	aliquoted	and	stored	at	-80°C.	Routine	
investigation	also	included	manual	counting	of	cells	using	a	counting	chamber.	
6.2.2 Preparation of cell-spiked CSF samples
To	 evaluate	 the	 effects	 of	 blood	 contamination	 on	 miRNA	 levels	 in	 CSF,	 we	 used	
two blood samples, obtained by vena puncture from two healthy volunteers, and 
CSF	 samples	 that	 did	 not	 contain	 blood	 cells	 as	 determined	 by	 manual	 counting. 
A	 concentration	 gradient	 of	 whole	 blood	 was	 spiked	 into	 0.5	 ml	 aliquots	 of	 the 
CSF	samples,	corresponding	to	final	erythrocyte	counts	of	10	to	20,000	cells/µl	CSF.	Numbers	
of	cells	were	confirmed	using	flow	cytometry.	CSF	samples	were	left	for	three	hours	at	room	
temperature, then one series (series 1) was stored at -80°C, while the other series (series 
2)	was	first	centrifuged	for	10	minutes	at	3000	rpm	and	10°C	to	remove	cells,	and	only	the	
supernatant was retained at -80°C. In this way, the various ways of processing CSF in clinical 
practice	were	simulated.
6.2.3 RNA Isolation of tissue samples
Twenty	milligrams	of	hippocampus	tissue	were	used	by	cutting	sections	(each	7	μm	thick)	
using a cryostat. Total RNA was isolated from hippocampus tissue and CSF samples by 
using the miRVanaTM miRNA Isolation kit (Life Technologies, Carlsbad, CA, USA). In brief, 
hippocampus sections were lysed with lysis buffer supplied by the kit, and homogenated. 
Lysed samples were then subjected to a phenol-chloroform extraction step, followed by 
the addition of 100% ethanol. Next, samples were loaded onto a glass-fiber filter and 
subjected to several washing steps. Finally, total RNA was eluted from the filter cartridge 
with	 100	 μl	 sterile	 water,	 that	 had	 been	 heated	 to	 95°C.	 The	 RNA	 concentration	 of	
hippocampus extracts was determined using a Nanodrop ND 2000 instrument (Thermo 
Scientific, Rockford, IL, USA).
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Values are expressed as means ± standard deviations. 1P-value for differences in gender using Chi-square 
test, and for differences in age, postmortem delay and RNA concentration/tissue weight using ANOVA 
and Bonferroni’s Multiple Comparison test for normally distributed data or Kruskal-Wallis test and Dunn’s 
Multiple Comparison test for non-Gaussian distribution. 2All AD cases (Braak VI) were sporadic. Two early 
AD cases (Braak III/IV) had a family history in dementia, but for other early AD cases this was not known. 
Key: AD = Alzheimer’s disease; CERAD = Consortium to establish a Registry for Alzheimer’s disease; NS = 
not significant; NA = not applicable 
Values are expressed as means ± standard deviations. 1P-value for differences in age and total protein 
using student’s t-test or Mann-Whitney U test. 2At the time of lumbar puncture. 3For five AD samples, 
the MMSE score was not determined, diagnosis of AD was here based only on clinical NINCDS-ADRDA 
Alzheimer’s criteria. Key: CSF = cerebrospinal fluid; AD = Alzheimer’s disease; MMSE = mini mental state 
examination; NS = not significant; NA = not applicable; ND = not determined
Table 1: Hippocampus tissue sample data
Table 2: CSF sample data
Control Early AD AD p-value1
Number of patients2 11 10 10
Gender (Male/Female) 4/7 5/5 3/7 NS (p=0.643)
Mean age (years) 82.5 ± 7.01 81.9 ± 6.1 77.8 ± 10.6 NS (p=0.38)
Postmortem delay (hours) 4.5 ± 1.1 4.4 ± 0.7 3.7 ± 0.8 NS (p=0.144)
CERAD score (0/A/B/C) 0 or A B or C B or C NA
Braak stage (0-VI) ≤ II III or IV VI NA
RNA concentration (ng)/
tissue weight (mg) 419 ± 162 433 ± 253 240 ± 78 *p=0.011
Control AD p-value1
Number of patients 20 20
Gender (Male/Female) 10/10 10/10 NS
Mean age (years)2 63.7 ± 9.8 69.7 ± 9.6 NS (p=0.058)
MMSE score ND 20.2 ± 3.43 NA
Total protein (mg/l) 486 ± 99 568 ± 148 p=0.126
Numbers of cells/μl erythrocytes: 13.4 ± 29
leukocytes: 1.1 ± 0.8
erythrocytes: 15.9 ± 47
leukocytes: 0.6 ± 0.9
p=0.676
p=0.773
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6.2.4 RNA Isolation of CSF samples
More steps had to be performed to detect miRNAs in CSF than in hippocampus tissue. An 
overview of the different procedures is described in a workflow (figure 1). CSF samples 
(0.5	ml)	 were	 spiked	with	 1	 μg	MS2	 carrier	 RNA	 to	 increase	 the	 yield.	 The	 liquid	was	
removed by freeze-drying on an Alpha 1-2 LDplus freeze dryer (Christ, Osterode am Harz, 
Germany)	 and	 samples	were	 resuspended	with	 200	 μl	 sterile	water.	 RNA	was	 isolated	
using the miRCURYTM RNA Isolation kit for biofluids (Exiqon, Vedbaek, Denmark). Briefly, 
samples were lysed and proteins were partly removed by precipitation. Isopropanol was 
added and RNA was purified by washing the samples several times on a spin column. RNA 
was	eluted	from	the	column	in	50	μl	RNase-free	water.	
Total RNA concentration of CSF samples was not measurable using the Nanodrop. 
Therefore, equivalent CSF volumes were used as input for the RNA isolation.
Figure 1: Workflows for miRNA detection of different origins
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6.2.5 Primers for reverse transcription (RT) and quantitative PCR 
(qPCR) 
Individual RT and qPCR primers for miRNAs (hsa-let-7f, hsa-miR-9-3p, hsa-miR-16, hsa-
miR-34a, hsa-miR-34c, hsa-miR-107, hsa-miR-128a, hsa-miR-146a, hsa-miR-24), and for 
small nuclear RNAs (snRNAs) (RNU44, RNU6b and U6 snRNA) were obtained from Life 
Technologies. Primer sequences for miRNA targets and snRNAs can be found at http://
www.mirbase.org and http://appliedbiosystems.com.
6.2.6 RT and pre-amplification
The RT reaction was performed using the TaqMan® MicroRNA RT Kit (Life Technologies) and 
individual miRNA RT primers in a specific stem-loop conformation. 10 ng of hippocampal 
total RNA, in a 5 µl volume, was used in the RT reaction according to the manufacturer’s 
protocol (16°C for 30 min, 42°C for 30 min, 85°C for 5 min, followed by a 5 minute incubation 
on ice). RT-products of hippocampus tissue were diluted 3.75x in sterile water. RNA of CSF 
samples	was	subjected	first	to	a	freeze-drying	step	and	samples	were	resuspended	in	20	μl	
sterile	water,	of	which	5	μl	was	used	for	the	RT	reaction	as	described	above.	RT-products	
of CSF samples were directly subjected to a pre-amplification step using TaqMan® PreAmp 
Master Mix (Life Technologies) and individual TaqMan® MicroRNA primers for qPCR. The 
procedure was carried out according to the manufacturer’s protocol for multiplexed pre-
amplification. The pre-amplification product was then diluted 8x in 0.1x TE buffer.
6.2.7 qPCR
In	the	qPCR	reaction,	5	μl	of	diluted	RT-products	of	hippocampus	and	pre-amplification	
products of CSF were used according to manufacturer’s procedure, with TaqMan® 
Universal Master Mix II (Life Technologies) and individual TaqMan® MicroRNA primers 
for qPCR. Samples were measured in duplicates. Amplification was performed using a 
qPCR Thermal Cycler (Applied Biosystems, Nieuwerkerk ad IJssel, The Netherlands) with 
a denaturation step at 95°C for 10 min, followed by 40 (hippocampus material) or 50 (CSF 
material) cycles of 95°C for 15 s and 60°C for 60 s. 
6.2.8 Data and statistical Analysis
The hippocampus samples with Braak stage III/IV were measured on a later time point than 
the AD and control samples. To compare the groups with each other, two control samples 
were freshly processed and measured on both occasions to account for differences in 
batches for each miRNA. After correction, data were normalized by a uniformly expressed 
small RNA (reference RNA). Relative expression levels (REL) were calculated using the 
formula REL=2-∆Ct,	 where	 ∆Ct	 =	 Ct[miRNA]	 -	 Ct[reference	 RNA].	 Statistical	 differences	
were determined with Graph Pad Prism version 5 (La Jolla, CA, USA). Hippocampus 
samples of the three groups (control, Braak III/IV and Braak VI) were compared by ANOVA 
and Bonferroni multiple comparison test when data was normally distributed. With non-
parametrically distributed data, we used Kruskal-Wallis and Dunn’s multiple comparison. 
To compare the CSF AD group to the CSF control group, student’s t-test was used. For 
correlation analysis, numbers of erythrocytes were transformed with log10. All data for 
correlation analysis were normally distributed and Pearson r was calculated. P-values less 
than 0.05 were considered significant. Receiver operator characteristics (ROCs) analysis 
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was used to determine the diagnostic value of CSF miRNA levels. Area under the curve 
(AUC) was calculated with 95% confidence interval, and Youden index (sensitivity + 
specificity – 1.0) and likelihood ratio (sensitivity/(1-specificity)) were determined.
6.3 Results
6.3.1 MiRNA expression in hippocampus
Mean total RNA amount per mg tissue was slightly, but significantly lower in the AD Braak 
VI group compared to the control and AD Braak III/IV group (p=0.01; table1). However, 
the input of total RNA for reverse transcription was the same for each sample. RNU6b and 
RNU44, in other studies selected as internal control RNAs [358, 359], were differentially 
expressed between groups and could therefore not be used for normalization (data not 
shown). Alternatively, let-7f, which displayed similar levels in control, Braak III/IV and 
Braak VI samples (p=0.48) and also across samples of one group (figure 2A), was used 
for normalization. No correlation was detected between total RNA concentration per mg 
tissue and mean Ct-values for let-7f (r=0.11, p=0.56; data not shown). 
Of the tested targets, five miRNAs displayed differential expression levels in AD with 
Braak stage III/IV or Braak stage VI compared to control samples, and two showed equal 
levels between groups (figure 2B). Most prominent differences were detected for miR-
16 (p<0.0001) and miR-146a (p<0.0001). Both miRNAs were decreased in the Braak VI 
group, whereas samples with Braak stage III/IV had increased miRNA levels. In Braak VI 
samples, also miR-107 (p=0.0004) and miR-128a (p=0.002) were decreased compared to 
the two other groups. In contrast, miR-34c was elevated in samples with Braak stage III/
IV compared to the two other groups. Finally, next to the internal control let-7f, levels of 
miR-9 and miR-34a were unchanged between groups.
6.3.2 Effects of CSF blood cells on CSF miRNA levels
CSF samples often contain blood-derived cells. We therefore investigated, whether blood 
cells present in CSF, obtained after lumbar puncture, could affect miRNA levels. Hereto, 
we generated two series of CSF samples spiked with blood. The number of erythrocytes 
and leukocytes was quantified with a cell-counter. In series 1 (no centrifugation prior 
to freezing), which was used as positive control, we measured miR-24, and in series 2 
(centrifugation and removal of cells prior to freezing), which represents the standard 
procedure in a laboratory for use of CSF samples in research, we measured miR-24, miR-
16 and miR-146a. Ct-values for miR-24 in series 1 were, as expected, strongly negatively 
correlated with the number of cells spiked in the CSF samples (r=-0.95, p<0.0001; figure 
3A), indicating higher miR-24 levels with increasing cell numbers. However, also in series 
Figure 2: Expression of miRNA targets in hippocampus tissue of AD patients and controls
A) Scatterplots of mean Ct-values of let-7f B), and expression levels of miR-9, miR-16, miR-34a, miR-
34c, miR-107, miR-128a and miR-146a in hippocampus tissue of controls, early stage (Braak III/IV) and 
late stage (Braak VI) AD patients. Relative expression levels (REL) were calculated after normalization by 
let-7f. The black horizontal lines represent median Ct or REL values ± interquartile range. P-values were 
determined by ANOVA and Bonferroni or Kruskal-Wallis and Dunn. *p<0.05, **p<0.01 and ***p<0.001
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2, Ct-values of miR-24 were significantly negatively correlated with the number of cells 
(r=-0.88, p=0.002; figure 3B). Likewise, the obtained Ct-values for miR-16 in series 2 
were negatively correlated with the number of cells that were spiked into CSF (r=-0.86, 
p=0.003; figure 3B). An effect of cells was not evident for miR-146a (r=-0.53, p=0.14; 
figure 3B). When, however, removing the data points for CSF with the highest number of 
cells	(>	2000	erythrocytes/μl;	figure	3B	open	dots),	levels	of	miR-146a	were	significantly	
correlated to erythrocyte cell numbers (r=-0.89, p=0.008). Based on these results, we 
concluded that presence of blood cells in CSF, even if they are removed by centrifugation 
before analysis, can lead to a bias in expression levels of miR-24, miR-16 and miR-146a. 
6.3.3 MiRNA levels in CSF
We measured all miRNA targets that were analyzed in hippocampus, in (nearly) cell-free 
CSF samples, but their detection was more challenging than in tissue samples. Let-7f, 
Figure 3: Effect of CSF spiking with blood cells on miRNA expression 
A) Correlation of expression of miR-24 to the number of spiked blood cells into an initially cell-free 
CSF sample, that were not centrifuged before analysis. B) Correlation of expression of miR-24, miR-16 
and miR-146a to the number of blood cells that were spiked in a cell-free CSF sample and removed by 
centrifugation before analysis. 
A B
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miR-9, miR-107 and miR-128a could not be detected in most of the CSF samples even 
after a pre-amplification step. Levels of miR-34a and miR-34c were close to the limit of 
detection, resulting in too high variability in duplicate measurements for reliable analysis 
(data not shown). From our selected targets, only miR-16 and miR-146a were reliably 
detectable in almost all samples. However, even those two miRNAs were not detectable 
in some samples. MiR-16 was not measurable in two and miR-146a was not detected in 
five of the forty samples, all were AD cases. As internal control, miR-24 had been selected 
from the literature [360, 361], and could be measured in all samples, but Ct-values were 
significantly lower in AD than in control samples (p=0.0009; data not shown). The snRNA 
U6, which had also been used before as internal control in CSF [362], was equally present 
in AD and controls (p=0.06; figure 4A), and was used for normalization purposes. After 
normalization, expression levels of miR-16 were not different in the AD group compared 
to controls (p=0.056; figure 4B). Levels of miR-146a were significantly decreased in AD 
Figure 4: Expression of miRNA targets in CSF of AD patients and controls
A) Scatterplots of mean Ct-values of U6 snRNA, B) and expression levels of miR-16 and miR-146a in CSF 
of AD patients and controls. Levels were normalized using U6 snRNA. The black horizontal lines represent 
median Ct or REL values ± interquartile range. P-values were determined by t-test. ***p<0.001
A
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compared to controls (p=0.0005; figure 4B). If those AD cases, in which miR-146a and 
miR-16 could not be quantified, also would be included in the analysis with Ct-values set 
at the limit of detection (Ct=40), levels of miR-16 would also be significantly decreased 
in the AD group (p=0.016) and levels of miR-146a would even be more significantly 
decreased in AD compared to controls (p<0.0001). 
To study whether miR-146a levels in CSF depend on the AD stage, as we observed in 
hippocampus, we correlated miR-146a levels to the MMSE score of each patient. 
However, no correlation could be identified (r=-0.07, p=0.83; data not shown). Finally, 
we determined the value of miR-146a as CSF biomarker with ROC analysis. MiR-146a 
differentiated AD from controls with a sensitivity of 60% and a specificity of 90% (cut-off 
< 0.24, AUC = 0.79, likelihood ratio = 6, Youden index = 0.5). Sensitivity increased to 65% 
and specificity to 95% (cut-off < 0.17, AUC = 0.84, likelihood ratio = 13, Youden index = 
0.6), if the five AD cases in which analysis failed to quantify miR-146a, were included in 
the ROC analysis with a Ct-value of 40.
6.4 Discussion
With this investigation we aimed to identify the relation between the expression levels of 
several miRNAs and the stage of AD pathology by quantification of selected miRNA targets 
in hippocampus tissue. We identified a differential expression pattern in hippocampus of 
AD patients with different Braak stages for miR-16, miR-34c, miR-107, miR-128a and miR-
146a. In addition, we aimed to identify miRNAs as potential CSF biomarkers. Two miRNAs, 
miR-16 and miR-146a, could be detected in CSF, of which the latter was decreased in AD. 
Importantly, we observed a strong correlation between the expression of miR-16, miR-24 
and miR-146a, and the number of blood cells in CSF, which may influence the application 
of miRNAs as biomarkers in CSF.
6.4.1 Reference RNAs for normalization of miRNAs
For normalization procedures, we initially selected two snRNAs, RNU44 and RNU6b, 
as reference RNAs in hippocampus tissue and one miRNA, miR-24, as reference in CSF. 
SnRNAs have been commonly used in other studies for normalization of miRNA levels, 
because of their similar size to miRNAs and their abundant and uniform expression in 
most tissues [358, 359, 363]. We, however, found differences in expression of RNU44 
and RNU6b in hippocampus tissue of controls compared to AD Braak III/IV or AD Braak VI 
samples. RNU44 and RNU6b were therefore considered not suitable for normalization, and 
we chose to use one of our target miRNAs (let-7f) that fulfilled the criteria for an internal 
reference: equal expression in all groups with a small variation across samples in each 
group. An even bigger challenge was to identify an internal control in CSF. Only a handful 
of studies have been performed so far on miRNA levels in CSF and almost every study used 
another internal control [357, 360, 362]. In addition, many miRNAs and snRNAs cannot be 
detected in CSF. We initially selected miR-24 as reference RNA, based on previous studies 
[360, 361], but levels were significantly different, and miR-24 was therefore abandoned. 
Concentrations of snRNA U6 were similar in AD and controls and therefore, snRNA U6 
was used as internal reference. Normalization remains a controversial issue for analyzing 
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miRNA expression. If possible, more than one internal control should be used that will 
generate similar results, for instance several snRNAs or the median of several miRNAs 
[364], but currently there are no widely accepted “housekeeping” miRNAs identified yet.
6.4.2 Detection of miRNAs in hippocampus
In hippocampus, five miRNAs (miR-16, miR-34c, miR-107, miR-128a, miR-146a) were 
differentially expressed. Notably, these miRNAs were all upregulated in early AD cases with 
Braak III/IV compared to late AD cases with Braak VI, and, except miR-34c, downregulated 
in Braak VI compared to controls. Possibly, generalized cell loss and atrophy in the 
hippocampus in Braak VI may be responsible for this reduced expression rather than 
specific downregulation of miRNAs. Comparing our results with expression levels that 
were reported in other studies of AD and with target-miRNA interaction studies offers more 
insight. MiR-16 and miR-146a were both upregulated in Braak III/IV and downregulated 
in Braak VI compared to controls. This could indicate that these miRNAs play a role in 
early pathological processes of AD. MiR-146a may stimulate inflammation in AD brains 
by downregulating complement factor H, interleukin-1 receptor and tetraspanin-12 
[119, 365-367]. Inflammation in the brain is a relatively early event in AD that promotes 
degeneration of neurons. MiR-16 has been identified as suppressor of APP expression, 
and decreased expression of miR-16 has been described in transgenic mice compared to 
controls [356], which is in line with our observation of a downregulation in Braak VI AD 
cases, but not in Braak III/IV cases. In addition, we observed a downregulation of miR-107 
in hippocampus tissue of Braak VI compared to controls, but also compared to AD Braak 
III/IV, which confirms the previous decreased miR-107 expression in AD cortex compared 
to controls [117, 368-370]. MiR-107 targets BACE1, which is involved in APP processing, 
and cofilin, a protein that plays a role in cytoskeletal disruption in AD [117, 370]. Thus, 
downregulation of miR-107 and subsequent upregulation of its targets may promote AD 
pathogenesis. MiR-128a was also reduced in Braak VI, which is in accordance with one 
study [371], but also in contrast to another study [116]. MiR-34c was the only miRNA 
that was exclusively upregulated in Braak stage III/IV, which is in line with other human 
and transgenic mouse studies [372]. Since miR-34c downregulates SIRT1 levels, a protein 
related to cognitive function and plasticity [373], the observed increased expression 
may relate to reduced cognition. We did not detect any significant differences for miR-9 
and miR-34a, whereas in some other studies differences have been reported [357, 374]. 
However, previous reports are also not always consistent with each other, for instance 
hippocampal miR-9 has been reported to be increased [116] and decreased [357] as well. 
These discrepancies have no clear explanation, but miRNA levels could be affected by 
its stability, which can be influenced by postmortem delay, storage and processing of a 
sample. Furthermore, the relatively small number of samples in each group in this and 
similar studies may skew miRNA expression results due to genetic makeup of the selected 
sample population, for instance a European sample cohort might display different miRNA 
expression levels than American sample cohorts. For follow-up studies, careful selection 
and handling of samples and use of larger sample groups with a heterogenic background 
are suggested.
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6.4.3 Detection of miRNAs in CSF
Blood cell effects on miRNA levels
We noticed that the presence of blood cells in CSF can affect miRNA expression. Blood 
cells and plasma components can enter CSF either after infiltration into the brain during 
infectious or inflammatory conditions, after subarachnoid hemorrhages or, a more likely 
cause in AD, by traumatic puncture. Subsequently, miRNAs that are expressed by blood 
cells or are present in plasma may lead to falsely elevated “CSF” levels when CSF cell count 
or protein levels are elevated, leading to incorrect interpretations. We demonstrated 
that, even after cell removal by centrifugation, increased levels of miR-24, miR-16 and 
miR-146a were observed after addition of small amounts of blood. Even minute amounts 
of	blood,	determined	by	less	than	100	erythrocytes/μl,	can	influence	miRNA	expression	
levels. Therefore, to avoid any bias in results, we suggest that the number of blood cells in 
CSF samples should be determined and taken into account when measuring miRNA levels. 
The effects of high CSF total protein levels, in the absence of elevated cell numbers, has 
not been evaluated by us and deserves further study. 
MiRNA levels in CSF of AD and controls
Seven of our selected miRNA targets and the snRNAs RNU44 and RNU6b were either 
undetectable or unreliably measurable in CSF. The difficulty of the quantification of some 
miRNAs in extracellular sources, might be due to a fast turnover of those miRNAs. Indeed, 
specific miRNAs can display fast decay, for instance during the cell-cycle [375] or during 
light-dark adaptation in the retina [376]. In particular in neurons, miRNAs seem to be 
subjected to tight up- and downregulation [376, 377]. In contrast, some miRNAs also 
have been reported to be extremely stable [378, 379], and extracellular detection makes 
them therefore suitable as biomarkers [380]. High concentrations of some miRNAs have 
been found in blood [381], serum [382], urine [383] and in CSF [357, 360, 362, 384]. Those 
extracellular miRNAs might be able to resist degradation, because they are secreted in 
exosomes or are protected by argonaute proteins [379, 385], which interact with miRNAs 
to form the RNA-induced silencing complex. One of the miRNAs we successfully quantified 
in CSF, miR-16, is indeed present in blood in a complex with Argonaute-2 (Ago2) [379]. 
The miRNA-Ago2 complex was indicated as very stable and long-lasting. However, miR-
16 levels in CSF were not different between AD samples and controls. MiR-146a was in 
all, except five AD cases, detectable, and also seems to have an extracellular destination. 
It is secreted in vitro	 by	 Aβ-stressed	 cells	 and	 induces	 inflammation	 in	 cultured	 brain	
cells [386]. In the same study, increased levels of this miRNA were observed in CSF and 
neocortical extracellular fluid of AD patients compared to controls. This is in contrast to 
our own results in CSF, where we observed a strong decrease of miR-146a in AD, but would 
fit in with our analysis of the hippocampus tissue in which we observed an increased 
expression of miR-146a in Braak III/IV. Possibly, differences in CSF cell count may have 
affected the results in this previous study, but information on CSF cell count was not 
provided [386]. In ROC analysis, miR-146a revealed high specificity for differentiating AD 
from control cases, but at moderate sensitivity which may limit its potential application 
as a biomarker for AD. 
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6.4.4 Conclusion
We detected five miRNAs that were differentially regulated in hippocampus, indicating a 
role of these miRNAs in AD pathophysiology. In CSF, we noticed that levels of miR-16, miR-
24 and miR-146a were strongly influenced by the addition of, even minute amounts, of 
blood. MiR-16 and miR-146a were reliably measured in a cohort of selected CSF samples 
that were carefully controlled for number of blood cells. MiR-146a levels were decreased 
in CSF of AD patients, and could differentiate AD from controls at high specificity but with 
moderate sensitivity.
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Abstract
The identification of reliable biomarkers for Alzheimer’s disease (AD) remains challenging. 
Recently, abnormal levels of microRNAs (miRNAs) miR-27a, miR-29a, miR-29b and miR-
125b in cerebrospinal fluid (CSF) of AD patients were reported.  We aimed to confirm the 
biomarker potential of these miRNAs for AD diagnosis. Additionally, we examined the 
influence of blood contamination on CSF miRNA levels as potential confounding factor. 
We studied expression levels of the four miRNAs by quantitative PCR in CSF samples of AD 
patients and non-demented controls, and in blood-spiked CSF. Levels of miR-29a, but not 
of the other three miRNAs, were increased by a factor of 2.2 in CSF of AD patients. Spiking 
of small amounts of blood into CSF revealed that miR-27a and miR-29a, but not miR-125b 
levels were strongly influenced by the number of blood cells in the sample. In conclusion, 
miR-29a may be a candidate biomarker for AD, but only when used in cell-free CSF. 
119
7
MiR-29a as biomarker for Alzheimer’s disease in cell-free CSF
7.1 Introduction
Alzheimer’s disease (AD) is the most common form of dementia worldwide. Diagnosis of 
AD is currently supported by measurement of total tau (t-tau), phosphorylated tau (p-tau) 
and	amyloid-β42	 (Aβ42) in cerebrospinal fluid (CSF). However, diagnostic accuracy of this 
panel of biomarkers has its limitations [387]. MicroRNAs (miRNAs) have been introduced 
as promising novel biomarkers. They are small, non-coding RNAs that can bind to specific 
mRNAs and regulate their expression by translational repression or degradation. Several 
miRNAs have been reported to regulate AD-associated proteins in the brain [117-119]. 
Furthermore, miRNAs appear to be very stable in body fluids [388-390] and even low 
concentrations are detectable by the widely used method of quantitative PCR (qPCR). 
Therefore, miRNAs are attractive targets in the search of novel biomarkers.
Altered expression of several miRNAs in CSF of AD patients has been previously reported. 
In two recent publications it was reported that the levels of miR-27a and miR-125b are 
lower in CSF of AD patients than in controls [121, 124], whereas miR-29a and miR-29b 
levels are higher [121]. We aimed to confirm the potential of these miRNAs as biomarkers 
for AD. We previously showed that miRNA levels in CSF can be influenced by blood 
contamination [391]. Therefore, we also investigated whether traumatic lumbar puncture 
may influence CSF levels of these miRNAs. If so, this might influence outcomes of miRNA 
expression studies and the reliability of using these miRNAs as CSF biomarkers for AD.
7.2 Methods
7.2.1 Samples
CSF of 18 AD patients and 20 healthy individuals was obtained at the Radboud University 
Medical Center, Nijmegen. The samples had been collected by lumbar puncture in 
polypropylene tubes, centrifuged, aliquoted and stored at -80°C. AD patients had been 
diagnosed as probable AD according to the criteria of the National Institute of Neurological 
and Communicative Disorders and Stroke, and Alzheimer’s Disease and Related Disorders 
Association (NINCDS/ADRDA), based on clinical evaluation, magnetic resonance imaging 
and neuropsychological testing [75]. More recent diagnostic criteria [76] were not applied, 
since the patients’ samples were collected prior to the introduction of these criteria. 
However, most AD cases (14/18) had a typical CSF biomarker profile with abnormal levels 
of	t-tau,	p-tau	and	Aβ42. In three cases two of these biomarkers were abnormal and in one 
case one biomarker was abnormal. None of the AD patients had a CSF biomarker profile 
compatible with controls. Control subjects had been assessed for neurological disorders 
but were either diagnosed without a neurological disorder or with a systemic disease 
without neurological manifestations. CSF samples were obtained as part of the clinical 
diagnostic work-up of a patient. Patients were informed that their data, including CSF, 
could be used for further scientific purposes and were given the option to  object against 
this	use,	in	which	case	their	data	was	not	used.	Only	CSF	samples	with	<4	leukocytes/μl	
and	<200	erythrocytes/μl	were	selected.	Controls	and	AD	patients	were	from	Western-
European (Caucasian) origin, and were age- and sex-matched. An overview of patient and 
sample characteristics is given in table 1.
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7.2.2 Preparation of blood-spiked CSF 
Fresh whole blood from a healthy individual was spiked into 500 µl aliquots of cell-free 
CSF to final concentrations of 10 to 20,000 erythrocytes/µl CSF. Cell count was confirmed 
using flow cytometry. Samples were incubated at room temperature for 3 hours, followed 
by centrifugation to remove cells to imitate CSF processing in clinical circumstances. 
Likewise, the effect of incubation time was examined by applying incubation periods of 0 
to 180 minutes between spiking of 20,000 cells/µl and centrifugation.
7.2.3 RNA isolation and quantitative PCR
RNA isolation, reverse transcription, pre-amplification and qPCR were performed as 
previously described by us [391]. Primer sequences of hsa-miR-27a-3p, hsa-miR-29a, hsa-
miR-29b-2-5p and hsa-miR-125b-5p can be found at http://appliedbiosystems.com.
7.2.4 Data analysis
To normalize expression levels of miRNAs, the geometric mean (GM) of three reference 
RNAs was used. Those had similar cycle threshold (Ct) values in the CSF of AD and control 
groups. The following formulas were used to calculate relative expression levels (RELs) 
and GM: REL=2-ΔCt,	 with	 ΔCt=CtmiRNA–GM, and GM=∛CtmiR-16∙ CtmiR-24  ∙ CtU6. Data were 
analyzed using GraphPad Prism version 5 (La Jolla, CA, USA). Normally distributed RELs 
were compared using a two-tailed t-test, and the Mann Whitney U test was used for 
non-parametric data. Correlations were determined using Pearson r. Statistical outliers 
were identified using the Dixons Q test and the Grubbs test for outliers. P-values were 
considered significant when p<0.05. Receiver operator characteristics (ROCs) analysis 
was used to determine the diagnostic value of miR-29a and miR-125b. Area under the 
All data are expressed as mean ± standard deviation. 1The minimum-maximum range of 
the number of erythrocytes, leukocytes and total protein is indicated in parentheses. 
2Gender distribution of AD and control groups were compared using the chi-square 
test, all other parameters using a 2-tailed t-test. Key: AD=Alzheimer’s disease; NS=not 
significant; MMSE=Mini Mental State Exam, ND=not determined, NA=not applicable
Table 1: Group characteristics
AD Control p-value2
Number of patients 18 20
Gender (male/female) 8/10 8/12 NS (p=0.78)
Mean age (years) 70.4 ± 9.1 63.2 ± 12.3 NS (p=0.05)
MMSE 19.7 ± 3.2 ND NA
Number of erythrocytes/µl1 17.7 ± 49.0
(0 – 165)
3.0 ± 5.8
(0 – 21)
NS (p=0.19)
Number of leukocytes/µl1 0.6 ± 0.9
(0 – 3)
0.4 ± 0.6
(0 – 2)
NS (p=0.39)
Total protein (mg/L)1 566 ± 156 
(374 – 976)
578 ± 212
(284 – 971)
NS (p=0.85)
121
7
MiR-29a as biomarker for Alzheimer’s disease in cell-free CSF
curve (AUC) was calculated with 95% confidence intervals. The optimal cut-off value was 
determined using the Youden index (sensitivity + specificity – 1.0) and likelihood ratio 
(sensitivity/(1-specificity)). 
7.3 Results
7.3.1 MiRNA levels in CSF 
We measured miR-27a, miR-29a, miR-29b and miR-125b levels in (nearly) cell-free CSF 
samples of AD patients and controls. Numbers of leukocytes and erythrocytes and total 
protein levels did not differ between groups (table 1). MiR-29b could only be detected in 
five AD and five control samples and was therefore excluded from further analysis. The 
other three miRNAs were detectable in all samples. Mean miR-27a levels were similar in 
AD and control samples (figure 1A), but mean miR-29a levels were increased by a factor 
of 2.2 in the AD group compared to controls (p=0.0001, figure 1B) and differentiated 
AD from controls with a sensitivity of 89% and a specificity of 70% (cut-off > 3.61; area 
under the curve (AUC)=0.87, likelihood ratio=2.96, Youden index=0.59). Mean miR-125b 
levels were slightly increased in AD (p=0.025, figure 1C) and differentiated between AD 
and controls with a sensitivity of 78% and a specificity of 60% (cut-off > 3.64; AUC=0.71, 
likelihood ratio=1.94, Youden index=0.38). However, this difference mainly depended on 
one statistical outlier in the AD group. Without this outlier, the difference in expression 
was no longer significant (p=0.058).
7.3.2 Effect of blood contamination on CSF miRNA levels
We studied the effect of blood contamination, which often occurs during lumbar puncture 
of CSF, on miRNA levels. We simulated this effect by spiking whole blood into cell-free CSF. 
Mean Ct-values of miR-27a and miR-29a were negatively correlated with the numbers of 
erythrocytes (miR-27a: r=–0.89, p=0.001, figure 2A; miR-29a: r=–0.88, p=0.002, figure 
2B), indicating a strong dependence of these miRNA levels on the number of blood cells 
present in the CSF sample. No correlation was evident for miR-125b (figure 2C). We 
also investigated how fast the effect of blood contamination on miRNA levels occurred. 
A comparison of the Ct-values for miR-27a and miR-29a in cell-free and blood-spiked 
Figure 1: MiRNA levels in cell-free CSF of AD patients and controls 
A) Relative expression levels (REL) of miR-27a, B) miR-29a C) and miR-125b in CSF of AD patients and 
control subjects. Data are presented as scatter plots with mean REL value ± standard deviation indicated.
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CSF samples showed that mean Ct-values for these miRNAs in CSF decreased, and thus 
miRNA levels increased, immediately after blood-spiking (figure 2D and 2E). A plateau 
was reached after 30 minutes. As expected, miR-125b levels were not affected by blood 
contamination at any time duration of incubation (figure 2F).
7.4 Discussion 
In AD, many miRNAs (e.g. miR-9, miR-146, miR-107, miR-124) have been described that 
are differentially expressed in the brain and regulate proteins involved in AD pathogenesis 
(see for an overview [392] and [393]). A subset of miRNAs can also be detected in CSF. 
Therefore, these miRNAs have been suggested as potential diagnostic tools for AD, 
provided that their levels can be quantified in volumes that are suitable for diagnostic 
purposes (< 1 ml) [121, 124, 391]. In an earlier study, we investigated several miRNAs 
of interest in hippocampus and CSF, but only few miRNAs (miR-16 and miR-146a) were 
detectable in CSF, and furthermore, we discovered that the levels of miR-146a are 
influenced by blood contamination [391]. With this study, we aimed to investigate other 
recently proposed miRNA biomarkers in CSF, and tested whether miR-27a, miR-29a, 
miR-29b and miR-125b (previously reported with different levels in CSF of AD patients 
compared to controls [121, 124]) may indeed serve as biomarkers for AD.
Figure 2: Effect of spiking cell-free CSF with whole blood 
A) Cell-free CSF was spiked with different volumes of whole blood. After centrifugation, miR-27a, B) miR-
29a and C) miR-125b levels were analyzed. Also, the effect of incubation period with blood cells on CSF 
miRNA levels was measured. D) Spiked blood cells were removed from CSF after various periods of time 
and expression levels of miR-27a, E) miR-29a and F) miR-125b were measured. Data are represented by 
cycle threshold (Ct) values. Key: *p < 0.05; ***p < 0.001; o = cell-free CSF; ● = blood-spiked CSF
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We found similar levels of miR-27a in CSF samples of AD patients and controls, which 
contradicts the previously reported decrease of miR-27a levels in AD CSF [124]. A possible 
explanation for this discrepancy is the effect of blood contamination on miR-27a CSF 
levels as we demonstrated in this study. However, since no information on cell count 
was provided in the earlier study, our assumption remains speculative. MiR-29a levels in 
CSF of AD patients were significantly increased compared to controls and discriminated 
AD from controls with good sensitivity and moderate specificity. The increased miR-
29a levels in AD confirm previous findings [121] and are also in line with a report on its 
increased levels in the medial frontal gyrus of AD patients [357]. In contrast, another 
study reported decreased miR-29a levels in the cortex of AD patients [394]. Interestingly, 
BACE1,	an	enzyme	involved	in	proteolytic	production	of	the	Aβ	protein	from	its	precursor	
protein, is regulated by miR-29a [118]. A potential drawback for the biomarker potential 
of CSF miR-29a levels may be that its levels are strongly correlated to the number of blood 
cells if present in the CSF, as we show in this study. Our finding of slightly increased miR-
125b levels in CSF of AD patients compared to controls is in contrast to a previous study 
in which a decrease was reported [121]. The increase we found was mainly dependent 
on one AD sample, and should therefore be interpreted with caution. Our findings are, 
however, consistent with the reported levels of miR-125b in brain tissue, i.e. an increase 
in hippocampus, medial frontal gyrus and temporal cortex of AD patients [357, 395]. If 
additional studies can confirm the increased levels of miR-125b in CSF of AD patients, its 
potential as a diagnostic marker would be strengthened by the fact that miR-125b levels 
are not influenced by blood contamination. 
MiRNAs are found in plasma  and in serum [121, 396], and in several cell types present 
in blood (e.g. blood mononuclear cells , erythrocytes  or leukocytes [122, 397, 398]). It is 
therefore possible that these are the sources of blood-derived miRNAs that are released 
in the CSF upon traumatic lumbar puncture, hence influencing miRNA levels. The effect 
of blood contamination on miR-27a and miR-29a levels in CSF occurred very fast. Their 
levels are altered within 10 minutes after blood spiking, which means that contamination 
cannot be prevented by fast processing of samples. Thus, these miRNAs cannot serve as 
biomarkers in CSF collected after a traumatic lumbar puncture.
This study demonstrated that reproducing previously reported CSF miRNA expression 
data can be challenging and that blood contamination may be a major factor that 
influences miRNA levels. Hereby, blood-derived miRNAs may alter the levels in CSF, 
but possibly also other factors such as miRNA degrading enzymes present in the blood 
may play a role in influencing miRNA CSF levels.  For our study, we also cannot exclude 
that the mean difference in age, although not statistically significant, between the AD 
and the control group may have  biased our results. This, however, requires further 
study. Other factors that may account for contradictory miRNA expression data are 
normalization methods [399] and cohort size. Also, degeneration of the brain in AD 
might be an important factor that could lead to decreased levels of some miRNAs, rather 
than specific downregulation. However, this does not account for the miRNAs that were 
investigated in this study, which were either upregulated or were present at equal levels 
in AD patients compared to controls. Further, there is increasing evidence that etiology 
124
Chapter 7
plays an important part in genetic variation, including variations in miRNA-encoding DNA, 
and that expression profiles are population-specific and therefore could lead to different 
results across different populations [400, 401]. Despite these considerations, miR-29a 
may be a promising biomarker for AD. However, significantly larger studies in patients 
with different genetic backgrounds will be necessary to further validate miR-29a as an 
AD biomarker. This study investigated four miRNAs, but there may be more miRNAs that 
could serve as biological markers in CSF, either stand-alone or as part of a miRNA panel. 
In addition, miRNAs may be useful biomarkers for AD severity and should be tested 
in different stages, for instance in patients with mild cognitive impairment due to AD 
compared to AD patients with different CDR scores.
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Abstract
MicroRNAs (miRNAs) regulate translational inhibition of proteins, but are also detected in 
body fluids, including cerebrospinal fluid (CSF), where they may serve as disease-specific 
biomarkers. Previously, we showed differential expression of miR-146a, miR-29a and miR-
125b in the CSF of Alzheimer’s disease (AD) patients versus controls. In this study, we 
aim to confirm these findings by using larger, independent sample cohorts of AD patients 
and controls from three different centers. Furthermore, we aim to identify confounding 
factors that possibly arise using such a multicenter approach. The study was extended by 
including patients diagnosed with mild cognitive impairment due to AD, frontotemporal 
dementia and dementia with Lewy bodies. Previous results of decreased miR-146a levels 
in AD patients compared to controls were confirmed in one center. When samples from 
all three centers were combined, several confounding factors were identified. After 
controlling for these factors, we did not identify differences in miRNA levels between the 
different groups. However, we provide suggestions to circumvent various pitfalls when 
measuring miRNAs in CSF to improve future studies.
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8.1 Introduction
Circulating microRNAs (miRNAs) are increasingly recognized as potential disease 
biomarkers [402]. Mature miRNAs are non-coding, single-stranded RNA molecules, 
between 19 to 22 nucleotides long that function in the regulation of translation. By 
downregulating the expression of a great variety of proteins, they are involved in many 
physiological processes such as development, differentiation, cell proliferation and 
apoptosis. Although miRNAs act intracellularly on the protein synthesis machinery, they 
are also secreted by cells for intercellular exchange and are protected from degradation 
by the inclusion in extracellular vesicles such as exosomes [403, 404], or by the association 
with specific proteins such as the argonaute (Ago) proteins [379]. Extracellular miRNAs 
can be detected in various body fluids including plasma, urine, saliva and cerebrospinal 
fluid (CSF) [405]. This possibility, together with their complex involvement in different 
processes makes miRNAs an interesting tool for the diagnosis, early detection and 
prognosis of diseases. Indeed, several studies have shown the usefulness of circulating 
miRNAs as diagnostic or prognostic markers for various types of cancer [360, 406-408]. 
Neurodegenerative diseases constitute a new area in which miRNAs are explored as 
potential CSF biomarkers. Especially in Alzheimer’s disease (AD) as the leading cause of 
dementia, miRNA function and differential expression are widely studied [393]. Several 
pathological processes that occur in AD such as neuronal loss, angiogenic changes, 
release	of	inflammatory	factors	by	immune	cells,	formation	of	amyloid-β	(Aβ)	aggregates	
and neurofibrillary tau tangles are mediated by miRNAs. For instance, miR-146a regulates 
complement factor H, an important repressor of the inflammatory response in the brain, 
and	 is	 differentially	 expressed	 in	AD	 [119].	 The	production	of	Aβ	 is	 also	modulated	by	
several	miRNAs,	which	 target	 Aβ	 precursor	 protein	 (APP)	 (e.g.	miRNAs	 let-7,	miR-101,	
miR-15a and miR-106b) or beta-site APP cleaving enzyme (BACE1) (e.g. miR-15a, miR27a, 
miR-29a/b-1, miR-9, miR-19b, miR-107) [117, 118, 124]. Several of these miRNAs show 
differential expression in AD and therefore hold potential as candidate biomarkers in CSF. 
Previously, we have shown that miR-146a levels are decreased, and miR-29a and miR-125b 
levels are both increased in the CSF of AD patients compared to dementia-free controls, 
whereas levels of miR-27a remained unchanged [391, 409]. However, previous studies 
on miRNA levels in CSF of AD patients and controls, have shown contrasting results [121, 
124, 410]. Blood contamination is an important confounding factor when performing 
miRNA measurements in CSF, as we showed previously for miR-146a, miR-29a and miR-
27a [391, 409]. Another factor to consider is that many miRNA studies are performed in 
small sample groups with subjects of the same genetic and ethnic background [400]. 
Thus far, only few studies investigated the potential of miRNAs as early biomarkers for 
AD, or for differential diagnosis of various forms of dementia. Earlier findings, including 
our own, indicated that the expression of miRNAs in hippocampus, medial frontal gyrus, 
cerebellum and postmortem CSF can vary extensively between different Braak stages of 
AD [357, 391]. For instance, miR-146a expression is increased in the hippocampus of AD 
patients with Braak stage III and IV, but is decreased in AD patients with Braak stage VI 
[391], which indicates that miRNAs may be associated with early stages of AD. Studies 
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in which the expression of miRNAs in AD versus frontotemporal dementia (FTD) and 
dementia with Lewy bodies (DLB) is analyzed are very limited, but some do indicate that 
miRNAs can play specific roles in dementias other than AD [411-413].
With this multicenter study we therefore aimed to overcome a few of the above 
mentioned drawbacks by carefully controlling for the number of blood cells in CSF and 
by using large sample groups of different origin to confirm our previous findings in AD 
patients and cognitively normal controls. Furthermore, we extended our efforts by 
investigating miRNAs as early CSF biomarkers in well-characterized patients with mild 
cognitive impairment due to AD (MCI-AD) compared to controls, and in FTD and DLB 
patients, to investigate their potential to distinguish between AD and non-AD dementia. 
Finally, this study enabled us to investigate important confounding factors that arise when 
performing a multicenter study and may affect the outcomes of miRNA measurements.
8.2 Material and methods
8.2.1 Samples
CSF samples (table 1) of 60 AD, 39 MCI-AD, 37 FTD, 37 DLB cases and 40 controls 
were obtained from three different European centers: Radboud University Medical 
Center, Nijmegen, The Netherlands (AD=20, DLB=12, controls=19); Clinica Neurologica, 
Perugia, Italy (AD=20, DLB=5, FTD=12, MCI-AD=39, controls=21); BIODEM, University 
of Antwerp, Belgium (AD=20, DLB=20, FTD=25). Patients were assessed by thorough 
clinical and neuropsychological examination, including the Mini-mental state exam 
(MMSE). Additional information was obtained by routine laboratory investigation of CSF 
Aβ42,	 total	 tau	 and	phosphorylated	 tau	 levels.	 The	diagnosis	 of	 AD	patients	 had	been	
established using NINCDS-ADRDA criteria before 2011 [75] and NIA-AA criteria after 2011 
[76]. Published consensus criteria were used for the diagnosis of DLB [414] and FTD [327] 
cases. The MCI-AD group was diagnosed according to Albert criteria [25] and MCI patients 
had been followed for a maximum of four years to monitor the progression from MCI 
to AD [415]. The control group consisted of patients that had been subjected to lumbar 
puncture for various diagnostic reasons, but did not have any cognitive decline or any 
neurodegenerative disease. All patients were informed that their data could be used for 
further scientific purposes and were given the option to object against this use, in which 
case their data was not included. CSF had been collected by lumbar puncture in sterile 
polypropylene tubes. We aimed to include only CSF that contained no or only low numbers 
of cells (< 200 erythrocytes/µl; < 4 leukocytes/µl). These cell number cut points are based 
on our previous observations [391]. Some samples contained a slightly higher number of 
leukocytes (table 1), but since the number of erythrocytes in these samples was very low 
these samples were included into analysis. One CSF sample (AD) with a very high number 
of erythrocytes (19,200 erythrocytes/µl) was excluded from analysis. Sample groups were 
matched for the number of leukocytes (table 1). All samples from Nijmegen and Perugia 
were centrifuged for 10 min at 3,000 x g, after which the supernatant was transferred to 
clean polypropylene tubes. According to a formerly used pre-analytical protocol, samples 
from Antwerp were either centrifuged (AD=10, DLB=2, FTD=1) for 10 min at 4,000 x g 
followed by transfer of supernatant to clean polypropylene tubes, or were immediately 
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frozen and stored without centrifugation in case of non-blood contaminated samples 
(AD=10, DLB=18, FTD=25) [416]. All samples were stored at -80°C until analysis.
8.2.2 RNA isolation and qPCR
RNA isolation, reverse transcription (RT), pre-amplification and qPCR were performed as 
previously described by us [391]. For RNA isolation, we randomly divided CSF samples 
from each patient category over groups of 20 samples, that were used for RNA isolation 
on several days. RT and pre-amplification were each performed in three separate runs on 
the same day. For qPCR the samples from each patient category were evenly distributed 
over five runs per miRNA target. Three additional AD CSF samples that had been analyzed 
previously, were included in each run to correct for inter-plate differences. Since the 
coefficient of variation (%CV) for the five qPCR plates was very low (%CV < 0.5 for the 
target miRNAs; %CV < 2.1 for the reference miRNAs) all data were pooled. The following 
miRNAs and snRNA were analyzed: hsa-miR-27a-3p, hsa-miR-29a, hsa-miR-125b-5p, hsa-
miR-146a-5p, hsa-miR-16-5p, hsa-miR-24-3p, and U6 snRNA. Primer sequences of these 
RNAs can be found at http://appliedbiosystems.com. 
Values are expressed as means ± standard deviations. 1MCI cases were categorized into amnestic (n=33) 
and non-amnestic (n=6) cases, of which 27 amnestic cases were multiple domain and 6 single domain. No 
differences in miRNA levels were identified when amnestic and non-amnestic MCI cases were compared, 
nor when amnestic cases with multiple domain where compared to amnestic cases with single domain. 
2Gender differences between groups were determined using Chi-square test. Mean age of groups were 
compared using ANOVA and Bonferroni’s post-hoc test for multiple comparison. Sample storage time, 
MMSE score, and number of leukocytes were compared between groups using Kruskal-Wallis test and 
Dunn’s post-hoc test for multiple comparison. 3The DLB group consisted of significantly more males than 
females, mean age at time of lumbar puncture was significantly lower in the control and FTD groups 
compared to AD, MCI-AD and DLB groups, and sample storage time was significantly lower in control and 
MCI-AD compared to AD, FTD and DLB. 4At the time of lumbar puncture. 5The MMSE score had not been 
determined for nineteen control, two AD, five FTD and eight DLB cases. 6The minimum-maximum range 
of the number of leukocytes is indicated in parentheses. Key: AD = Alzheimer’s disease; MCI-AD = Mild 
cognitive impairment due to AD; FTD = Frontotemporal dementia; DLB = Dementia with Lewy bodies; 
MMSE = Mini-mental state examination; NS = not significant
Table 1: Group characteristics 
Control AD MCI-AD1 FTD DLB p-value2
Number of patients 40 57 37 37 35
Gender (m/f )3 21/19 26/31 15/22 21/16 26/9 p = 0.038
Mean age (years)3,4 61.4 ± 11.1 72.9 ± 7.6 73.1 ± 4.9 66.1 ± 10.1 74.1 ± 7.5 p < 0.0001
Sample storage time (years)3 2.5 ± 1.0 5.6 ± 3.7 1.8 ± 0.9 6.6 ± 4.7 8.4 ± 4.8 p < 0.0001
MMSE score4,5 27.2 ± 2.2 20.0 ± 4.7 24.8 ± 1.9 20.1 ± 7.0 20.0 ± 6.0 p < 0.0001
Number of leukocytes/µl4,6 0.9 ± 0.9
(0 – 3)
1.4 ± 2.0
(0 – 12)
0.6 ± 0.7
(0 – 2)
0.5 ± 0.8
(0 – 3)
0.8 ± 1
(0 – 4)
NS
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8.2.3 Data analysis
MiRNA levels were normalized by the geometric mean (GM) of two reference RNAs, miR-
16 and miR-24, and the relative expression levels (RELs) were calculated using following 
formulas: REL=2-ΔCt,	 ΔCt=CtmiRNA–GM, and GM=
2√CtmiR-16 · CtmiR-24. If analyses included 
samples from only one center, data were normalized by the GM of U6, miR-16 and miR-
24: GM=3√CtU6·CtmiR-16 · CtmiR-24. Data were analyzed using GraphPad PRISM, version 5 (San 
Diego, CA, USA) and SPSS version 20 (Chicago, NY, USA). RELs of miRNAs were compared 
using Mann Whitney U test and Kruskal-Wallis test with Dunn’s post-hoc test for multiple 
comparison as non-parametric tests or Student’s t test and ANOVA with Bonferroni’s post 
hoc test as parametric tests. To perform a statistical test with covariates, most data was 
log-transformed and ANCOVA with Bonferroni’s post-hoc test for multiple comparison 
was applied. Correlations were determined using Pearson r for normally distributed data 
or the Spearman test when data were not normally distributed. P-values less than 0.05 
were considered significant.
8.3 Results
8.3.1 Selecting reference RNAs
For normalization, snRNA U6 and miRNAs miR-16 and miR-24 had been selected based on 
our previous study [409]. While U6 was detected in all samples, miR-16 was not detected 
in 2 samples and miR-24 was not detected in four samples (AD: n=2, MCI-AD: n=2, DLB: 
n=2). These samples were therefore excluded from further analysis. In our previous 
study, we observed equal expression levels of these reference miRNAs in control and AD 
CSF samples. However, in this study differences due to sample origin and centrifugation 
status were observed in the reference RNAs. Notably, when comparing only AD samples, 
Ct-values of miR-16 and miR-24 were increased in the Perugia samples compared to 
Nijmegen and/or Antwerp, while Ct-values of U6 were similar in the AD samples from 
all centers (figure 1A). The Ct-values of all three reference RNAs were decreased (i.e. 
higher expression) in non-centrifuged samples compared to centrifuged samples (figure 
1B). We therefore tested the comparability of the reference RNAs between the groups 
in the three centers separately, including in the Antwerp samples only non-centrifuged 
samples. MiRNAs miR-16 and miR-24 were present at similar levels in all groups within 
one center, except for a small increase of miR-24 Ct-values in DLB patients compared to 
AD patients in the Nijmegen center (p = 0.026; supplemental figure 1). Ct-values of U6 
snRNA were similar between groups in Perugia and Antwerp, but were also increased in 
the Nijmegen DLB group compared to AD (p = 0.009; supplemental figure 1). We then 
tested the correlation of the reference RNAs with each other. Mean Ct-values of miR-16 
and miR-24 correlated strongly in all samples (r = 0.76; p < 0.0001) whereas a weaker 
correlation was observed for miR-24 and U6 (r = 0.43; p < 0.0001) or miR-16 and U6 
(r = 0.28; p < 0.0001; figure 1C). Because U6 clearly showed the weakest correlation with 
the other reference RNAs, and showed a stronger difference in DLB samples compared to 
AD samples in one center, compared to the other reference RNAs, we decided to exclude 
U6 as a reference RNA and normalized miRNA levels to the geometric mean of miR-16 
and miR-24.
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8.3.2 Confounding factors
Differences between the groups were observed in gender, age and sample storage (table 
1, supplemental figure 2A-C).The target miRNAs miR-29a and miR-125b were detected 
in all samples, whereas miR-146a was not detected in one sample of the AD group and 
miR-27a was not detected in two samples, one of the AD and one of the MCI-AD group. 
As for the reference RNAs miR-16 and miR-24, profound differences were detected in 
Ct-values of the targets caused by sample origin and centrifugation status. All four target 
miRNAs had lower levels (increased Ct-values) in samples from the Perugia center, similar 
as the reference RNAs miR-16 and miR-24. This was most evident when AD samples 
from the different centers were compared (figure 2A). After normalization, levels of 
miR-27a and miR-29a were similar in the AD patients of all centers, whereas differences 
between AD groups in levels of miR-125b (p = 0.02) and miR-146a (p < 0.0001) remained. 
Furthermore, levels of miR-29a and miR-146a were higher (decreased Ct-values) in 
non-centrifuged samples compared to centrifuged samples. This was most evident in 
comparing centrifuged and non-centrifuged samples from AD patients (figure 2B). After 
normalization, these differences due to the centrifugation protocol were only resolved 
Figure 1: Reference RNAs
A) Boxplots of mean Ct-values of miR-16, miR-24 and U6 in AD samples from the three different centers; 
and B) in the AD samples from Antwerp that had been centrifuged or not centrifuged. C) Correlation of 
reference RNAs with each other.  p<0.05*, p<0.01**, p<0.001***
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for miR-146a, but differences between centrifuged and non-centrifuged samples were 
still evident for miR-29a (p = 0.003) and now also for miR-27a (p = 0.004) and miR-125b 
(p = 0.003). Of note, storage time correlated significantly with Ct-values of all four miRNA 
targets and the reference RNAs, but after normalization, only miR-27a (r = 0.16; p = 0.02) 
and miR-125b (r = 0.25; p = 0.0003) weakly correlated with storage time.
For these reasons, gender, age and sample storage, center of origin and centrifugation 
status of the samples were included as confounding factors in the ANCOVA to compare 
miRNA expression between the groups.
8.3.3 miRNAs in early and late stage AD
To confirm earlier findings we first compared AD patients (n=20) to controls (n=19) of 
only the Nijmegen center. In this independent cohort, we could confirm the decrease in 
expression levels of miR-146a in AD (p = 0.02; Mann-Whitney test), and the similar levels 
of miR-27a. However, in contrast to our earlier findings where we detected increased 
levels of miR-29a and miR-125b in AD, we did not find changes in the current cohort. 
Next, expression levels of miRNAs were compared between dementia-free controls and 
AD patients of all three centers. Levels of all four miRNAs were similar in the AD and 
dementia-free control group (figure 3). Levels of miR-125b displayed a trend towards 
a decreased expression in AD patients (p = 0.06; Mann-Whitney test), but when results 
were controlled for confounding factors this trend disappeared (p = 0.1; ANCOVA). 
To	identify	potential	early	AD	biomarkers,	we	further	investigated	the	four	target	miRNAs	
for	 differences	 in	 MCI-AD	 versus	 controls.	 Expression	 levels	 of	 miR-27a,	 miR-29a	 and	
miR-125b	 were	 similar	 (figure	 3).	 The	 levels	 of	 miR-146a	 were	 increased	 in	 MCI-AD	
patients	compared	to	dementia-free	controls	(p	=	0.03;	Mann-Whitney	test;	figure	3),	but	
when	 confounding	 factors	 were	 included	 in	 the	 analysis	 no	 differences	 were	 observed 
(p	=	0.3;	ANCOVA).	To	exclude	origin	and	centrifugation	protocol	as	confounding	factors,	
we	also	compared	MCI-AD	patients	(n	=	37)	to	controls	(n	=	21)	of	only	the	Perugia	center.	
No	differences	 in	 the	 four	 target	miRNAs	were	 identified.	 Finally,	we	compared	MCI-AD	
patients	to	AD	patients	of	all	centers	to	identify	differences	between	early	and	advanced	
stages of AD. Levels of miR-27a, miR-125b and miR-146a (p = 0.047; p = 0.001 and 
p	=	0.01	respectively;	Mann	Whitney	test)	were	 increased	 in	MCI-AD	patients.	However,	
after	correction	for	the	confounding	factors,	these	differences	were	lost	(p	=	0.18,	p	=	0.3,	
p	=	0.29	respectively,	ANCOVA).
8.3.4 miRNAs in AD and non-AD dementia
We	investigated	the	 four	miRNAs	 for	differential	expression	between	 late	stage	AD,	FTD	
and	DLB	(figure	4).	CSF	miRNA	levels	of	miR-27a,	miR-29a	and	miR-125b	were	comparable	
in these groups. Levels of miR-146a were similar in AD and DLB groups, but were increased 
in	 FTD	 patients	 compared	 to	 AD	 patients	 (p	 =	 0.04;	 Kruskal-Wallis	 test).	 However,	 this	
difference	 disappeared	 when	 the	 covariates	 were	 included	 in	 the	 group	 comparisons	 
(p = 0.9; ANCOVA).
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Supplemental Figure 2: Confounding factor of group characteristics
A) Diagram of number of males and females in each group. B) Boxplots of age and C) storage time in years. 
p<0.01**, p<0.001***
Supplemental Figure 1: Reference RNAs per center
Boxplots of mean Ct-values of miR-16, miR-24 and U6 comparing the different groups in each center 
(Antwerp: only non-centrifuged samples were included). p<0.05*, p<0.01**
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Figure 2: Confounding factors
A) Boxplots of mean Ct-values of miR-27a, miR-29a, miR-125b and miR-146a in the AD samples from the 
three centers; Nijmegen, Perugia and B) in the AD samples from Antwerp that had been centrifuged or not 
centrifuged. p<0.05*, p<0.01**, p<0.001***
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Furthermore,	 when	 specifically	 looking	 at	 the	 	 FTD	 and	 DLB	 groups,	 no	 significant	
differences	 were	 identified	 for	 FTD	 patients	 compared	 to	 dementia-free	 controls	 (data	
not	shown).	When	comparing	DLB	patients	to	dementia-free	controls	we	found	decreased	
miR-125b levels in the DLB group (p = 0.03; Mann-Whitney test), which changed into a 
trend	towards	decreased	levels	after	inclusion	of	the	covariates	(p	=	0.056;	ANCOVA;	data	
not	 shown).	 Levels	 of	miR-27a,	miR-29a	 and	miR-146a	were	 not	 different	 between	 the	
control and DLB group. 
Also all groups (controls, MCI-AD, AD, FTD and DLB) were compared to each other. 
Differences	were	detected	in	levels	of	miR-125b	(p	=	0.003;	Kruskal-Wallis	test).	However,	
again	after	correction	for	confounding	factors,	no	differences	were	detected	between	the	
groups (p = 0.14; ANCOVA).
8.4 Discussion
Previous pilot studies performed by us indicated differential expression of miR-29a, 
miR-125b and miR-146a in the CSF of AD patients compared to dementia-free controls, 
whereas similar expression of miR-27a was found [391, 409]. With this multicenter study 
we aimed to confirm these previous findings in a larger, independent sample cohort, and 
aimed to identify possible confounding factors that inevitably arise when using such a 
retrospective, multicenter design. We furthermore extended the investigation of miR-
27a, miR-29a, miR-125b and miR-146a towards samples from patients with MCI-AD, FTD 
and DLB. 
8.4.1 Expression of miRNAs in AD versus controls
In this study, we were able to confirm our previous results of miR-27a and miR-146a in an 
independent cohort of the Nijmegen center. However, when comparing AD patients and 
controls from three different centers, we could only confirm findings for miR-27a which 
was again comparable between AD patients and controls. In contrast, the levels of miR-
146a, miR-29a and miR-125b were not different between AD patients and controls. The 
levels of miR-125b even showed a tendency towards a decrease in AD, which, although 
not in line with our own previous findings, corresponds to the results of another study 
in which miR-125b was shown to be decreased in the CSF of AD patients compared to 
controls [121]. However, this trend was only evident when the covariates had not been 
included in the analysis. Others have reported increased levels of miR-29a and miR-146a, 
and decreased levels of miR-27a in the CSF of AD patients versus controls [121, 124, 410], 
which is also partly different from our current and previous results.
8.4.2 Expression of miRNAs in MCI-AD versus controls
We did not identify differences in levels of miR-27a, miR-29a miR-125b and miR-146a 
between MCI-AD patients and controls. Also, when comparing MCI-AD patients to the 
controls in only one center, thus excluding origin and centrifugation protocol as confounding 
factors, no differences were detected. Expression of miRNAs has been investigated in MCI 
patients only in a small number of studies [417-419], and even in fewer studies that make 
use of CSF [420, 421]. MiR-125b has been investigated before in amnestic MCI patients 
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compared to AD patients and controls, but this study was performed in plasma [418]. 
Notably, in this study several promising miRNAs were identified and the ratios of miRNA-
pairs (in particular the miR-132 and miR-134 families paired with miR-491-5p and miR-
370 respectively) demonstrated high sensitivities (79-89%) and specificities (83-100%) in 
differentiating MCI from age-matched controls. Similar percentages were obtained when 
these ratios were tested in a larger follow-up study with MCI and control subjects [417]. 
It might be interesting to also study these miRNA-pairs longitudinally in MCI patients, to 
study their possible predictive value for developing AD. 
8.4.3 Expression of miRNAs in AD versus non-AD dementia
As with MCI, the literature on miRNAs in FTD and DLB is scarce, and the present study 
is to our knowledge the only study in which miRNA expression in FTD and DLB has been 
investigated in CSF. Using this particular panel of miRNAs we did not identify significant 
differences among the groups. In other studies, miRNAs that regulate levels of proteins 
Figure 3: CSF miRNA levels of AD, MCI-AD and controls
Boxplots of relative expression levels (REL) of miR-27a, miR-29a, miR-125b and miR-146a in CSF of non-
demented controls, MCI patients and AD patients. REL values are log-transformed and depicted as median 
± interquartile range and outliers (circles). MCI and AD patients were compared separately to controls by 
Mann-Whitney test; p<0.05*.
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that are involved in FTD pathology, have been identified. For instance, miR-29b regulates 
progranulin which is a glycoprotein encoded by the GRN gene and mutations of this gene 
are present in a subset of familial FTD cases [422]. In an FTD mouse model, a decrease 
of miR-124 levels was associated with deregulation of AMPA receptor expression, which 
possibly is involved in the onset of behavioral deficits in FTD  [423]. Furthermore, in 
a recent pilot study, deep sequencing of small RNAs in the cerebral neocortex of AD, 
DLB, FTD, hippocampal sclerosis and controls identified miR-132-3p and miR-100 as 
differentially expressed miRNAs [411]. It would be interesting to test these miRNAs in CSF 
as possible biomarkers for FTD or DLB.
8.4.4 Variations across studies and possible confounding factors
Our results in AD patients and controls show once more how challenging it is to reproduce 
the findings of previous miRNA studies, especially when studying miRNA levels in body 
fluids such as CSF. Also in cancer studies, conflicting results have been reported about the 
Figure 4: CSF miRNA levels of AD, FTD and DLB
Boxplots of relative expression levels (REL) of miR-27a, miR-29a, miR-125b and miR-146a in CSF of AD, 
FTD and DLB patients. REL values are log-transformed and depicted as median ± interquartile range and 
outliers (circles). Analysis by Kruskal-Wallis test; p<0.05*
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levels of circulating miRNAs relating to the same type of tumor (reviewed in [402]). Such 
variations between studies might lie in technical differences such as different methods for 
RNA isolation or quantification, but even when the same techniques are used within the 
same laboratory, inter-study differences cannot be ruled out, as we showed. Previously, 
we also showed that blood contamination of CSF samples has a major effect on levels 
of miR-146a, miR-27a and miR-29a [391, 409]. Based on these previous observations, 
one of the major criteria in selecting CSF samples for this study had been the number of 
blood cells in CSF, which had to be kept as low as possible to exclude any influence (here 
maximal number was 50 erythrocytes/µl and 13 leukocytes/µl). Many other CSF miRNA 
studies however do not provide information on blood cell count and whether groups 
are matched according to the number of cells. Results of miRNA levels might therefore 
be biased by samples that were possibly contaminated with blood. Other pre-analytical 
confounders such as differences in RNA quality of the sample and CSF processing may play 
important roles. The quality of RNA is usually determined by quantifying ribosomal RNA 
(rRNA) integrity using, for instance, a bioanalyzer [424]. However, in our experience RNA 
concentration in CSF is too low to quantify rRNA. Furthermore, it would be questionable 
whether rRNA integrity can be interchangeably used for miRNA integrity, since miRNA 
stability can be different from rRNA stability as has been observed in tissue samples [425]. 
We therefore used CSF volume as input measure, as has also been done previously in 
other miRNA studies using CSF [124, 360, 426]. CSF pre-analytical protocols such as time 
of processing and temperature, centrifugation protocol and storage might also influence 
the outcome of miRNA studies. As we observed in this multicenter study, centrifugation 
of CSF and subsequent removal of the spin-down-product can lead to differences in 
miRNA levels when compared with non-centrifuged samples. The increased miRNA levels 
detected in non-centrifuged versus centrifuged samples might result from unremoved 
cells that release their miRNA content when subjected to RNA extraction procedures. 
Furthermore, by only comparing AD samples, we identified differences between the three 
centers, which might be ascribed to differences in storage time or other unidentified pre-
analytical factors (supplemental table 1).
Most of these factors might be controlled for by normalization using endogenous 
reference RNAs. However, an important concern with miRNA studies remains the lack 
of an established endogenous miRNA control. Also commonly used endogenous miRNA 
controls such as snRNAs may be differentially expressed in various conditions [391]. 
Recently, it has been suggested to use more than one endogenous RNA as reference 
and calculate the mean or geometric mean for normalization purposes [364], a strategy 
which we also applied in our current and previous study [409]. In our previous study 
we chose three endogenous controls (U6, miR-16 and miR-24) that had similar levels in 
the investigated groups (AD and dementia-free controls). In the current study, miR-16 
and miR-24 were comparable in almost all groups when analyzed per center, and also 
U6 was nearly similar. However, miR-16 and miR-24 correlated better with each other 
than with U6, and further showed the same patterns in differences due to origin as was 
observed for the target miRNAs. We therefore chose to exclude U6 as a reference, and 
calculated the geometric mean of miR-16 and miR-24 for normalization. However, even 
after normalization, miRNA levels were influenced by confounding factors such as storage 
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time or centrifugation protocol. Therefore, all identified confounders were included in 
the statistical analyses. 
All these factors might explain why miRNA studies are often not in agreement with each 
other, and might also be the reason why we could not repeat previous results. However, 
when only comparing AD patients and controls of Nijmegen, which excludes most of the 
pre-analytical factors, we could only repeat previous findings of differential expression of 
miR-146a, but not of miR-29a and miR-125b. Possibly, differences observed in miR-29a 
and miR-125b levels were too small to be reliably identified, particularly when testing 
small study populations. Nonetheless, we did observe a downregulation of miR-146a in 
AD patients compared to controls in two independent study cohorts, measured under 
comparable conditions. This miRNA therefore deserves further attention.
8.4.5 Conclusion and future directions
In this study, we have measured several miRNAs with biomarker potential in a large cohort 
of patients, enrolled in three European centers. The use of large cohorts is a desirable 
feature to be considered for future miRNA studies in CSF samples. The use of samples 
from different centers to enlarge groups and diversity within groups introduced several 
confounding factors and possibly such a great bias that previously obtained results could 
not be replicated. Considering all the confounding factors found in this study, there are 
several recommendations for the quantification of miRNAs in CSF to be applied in future 
studies. We suggest that samples should be well-controlled for the number of blood cells 
which would be preferably as low as possible, for instance < 50 erythrocytes/µl and < 4 
leukocytes/µl, to exclude any effects of blood contamination. Furthermore, pre-analytical 
protocols should be standardized, as is also suggested when measuring other CSF 
biomarkers [416, 427]. In particular, samples should be controlled for storage time and 
1  Samples from Antwerp, which underwent one freeze-thaw cycle were 6 AD, 5 DLB and 5 FTD samples. 
When samples of one group which had underwent one freeze-thaw cycle were compared to samples 
within the same group (only samples from Antwerp) that had not been freeze-thawed, no differences 
were found for all four target miRNAs (Mann-Whitney test).
Supplemental Table 1: Pre-analytical data
Antwerp Nijmegen Perugia
Tube type for storage Nalgene Sarstedt Sarstedt
Tube volume 1.5 ml 2.0 ml 0.5 ml
Delay before freezing 1 h Variable ; 2-4 hrs 1 h
Freeze-thaw cycles None or 1x1 None None
Freezing temperature -80°C -80°C -80°C
Needle used during LP (outer diameter) 20 gauge 21 gauge 21 gauge
Time of day of LP 8-12 a.m. Variable, 9 a.m. -17 p.m. 8-11 a.m.
Intervertebral space of LP L3/L4 or L4/L5 L3/L4 or L4/L5 L4/L5
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centrifugation status. For normalization purposes, we suggest to use the geometric mean 
of several miRNAs or other small RNAs that are present at similar levels between groups. 
This may exclude any bias which could arise by including only one RNA as reference.
We identified once again decreased levels of miR-146a in AD samples versus controls in 
the Nijmegen center. This strengthens the possible biomarker value for miR-146a. In the 
future, this miRNA should be investigated in larger studies under well-controlled pre-
analytical conditions. However, miRNAs regulate many processes and a single miRNA 
usually has several protein targets, and might be differentially regulated in several 
diseases. An individual miRNA might therefore not be specific enough as biomarker for a 
disease, and also the size of effect of one miRNA to differentiate two groups might be too 
small. Therefore, we suggest to focus future research on a panel of several differentially 
expressed miRNAs, as other studies for different cancers already did, to increase specificity 
and power [123, 360]. Particularly, in differentiating different stages of AD versus 
controls, or AD from non-AD dementia types, a panel of miRNAs, possibly in combination 
with protein biomarkers, might be the most suitable approach. Finally, many circulating 
miRNAs are enclosed into exosomes, which might be specifically secreted by neuronal 
cells and be present in CSF, but it is not certain if these are lost during precipitation or 
centrifugation steps of the RNA extraction. Methods of extracting and measuring such 
exosomal miRNAs in CSF are just beginning to emerge [428], and this might be a new 
approach to test miRNAs as biomarkers.
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9.1 Summary
With the studies described in this thesis, we aimed to identify novel biomarkers using 
two different strategies: 1) Development of a method that is able to measure low 
concentrations of promising proteins that cannot be detected yet with regular methods, 
2) Studying several proteins and microRNAs (miRNAs) as potential biochemical markers 
for discrimination between AD and other dementias.
In Part I,	I	focused	on	different	technical	aspects	to	study	amyloid-β	(Aβ).	Aggregates	of	
Aβ	are	perhaps	the	most	important	pathological	hallmark	of	AD	and	the	different	sizes	of	
the protein can be studied by a great variety of methods. In chapter 2 the major methods 
and techniques are reviewed, which are not only useful for identification of the different 
Aβ	 species,	 but	 which	 have	 also	 profoundly	 contributed	 to	 our	 understanding	 of	 the	
neurotoxic	Aβ	oligomers.	Furthermore,	advantages	and	disadvantages	are	listed	for	each	
method, and examples are given of successful combinations of some of the techniques. 
We paid special attention to a novel and very sensitive variant of a conventional ELISA, the 
Bio-barcode assay (BCA), which has previously been shown to detect low concentrations 
of analytes. In chapter 3, we describe our efforts to set-up such a BCA, using particles 
and oligonucleotides to enhance the signal, and the problems that arise. We succeeded 
in developing a functional assay that detects the chosen analyte in a concentration-
dependent manner. However, upon comparison with a standard ELISA, the assay did 
not detect substantially lower concentrations than the conventional ELISA, which was 
most likely hindered by non-specific interactions between gold particles and the other 
compounds.
Proteins as potential AD biomarkers were investigated in part II. In two studies we 
described how we selected, based on previous literature, two biomarker candidates, which 
we measured by ELISA. Both candidates were tested for their suitability in differential 
diagnosis between AD, controls and the most important other dementia types, namely 
frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and vascular dementia 
(VaD). In chapter 4,	 not	 a	 single	 protein,	 but	 a	 protein	 complex	 of	 Aβ	 and	 ApoE	 was	
chosen as target. Both proteins play important roles in the development of AD and have 
been described to interact with each other [53]. We developed and validated an ELISA for 
specific	detection	of	Aβ/ApoE	complexes,	and	measured	them	in	serum	of	AD,	FTD,	DLB,	
VaD and non-demented control patients, but did not detect any differences. We therefore 
concluded	that	we	cannot	proof	that	Aβ/ApoE	complexes	are	a	serum	biomarker	for	AD.	
In chapter 5, we validated an already developed ELISA to investigate the levels of the 
protein neuronal cell adhesion molecule (NrCAM) in CSF. Previously, this protein had been 
identified as potential CSF biomarker for AD [343] and we aimed to validate and extend 
these findings in AD compared to controls and patients with FTD and DLB. While we could 
not provide evidence that NrCAM is a suitable marker for AD in CSF, we showed that 
NrCAM CSF levels correlate with disease duration and suggested further evaluation of 
NrCAM in AD staging.
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Part III is dedicated to the search of miRNAs as possible AD biomarkers. Only few studies 
have been published previously about miRNAs as CSF biomarkers [357, 360, 390], and 
chapter 6 is one of the first studies in which miRNAs are investigated in CSF of AD patients. 
In this study, we selected a panel of eight miRNAs and measured them in hippocampus 
samples of controls and patients with early and late AD stages. We identified differences 
in miR-16, miR-34c, miR-107, miR-128a and miR-146a. When we measured these miRNAs 
in CSF, we observed that blood contamination is a major confounding factor for miRNA 
analysis. We quantified miR-16 and miR-146a in CSF, which was controlled for the number 
of blood cells, and showed that miR-146a was decreased in AD patients compared to 
controls. Recent findings in the literature suggested that there are more miRNAs that 
could serve as possible biomarker in AD [121, 124]. Therefore, chapter 7 was our second 
study in which we investigated a panel of four miRNAs (miR-29a, miR-29b, miR-27a and 
miR-125b) in CSF of AD patients and controls, again testing and controlling for effects of 
blood contamination before quantification. We could, however, only confirm the previous 
findings of miR-29a which was increased in AD patients, showing that repeating earlier 
findings can be challenging. Chapter 6 and chapter 7 were set-up as pilot studies, and 
since results are not always in line with previous reports, we designed a third study on 
a larger scale. Chapter 8 is a multicenter study in which we aimed to validate our own 
findings described in chapter 6 and 7 by using twice as many control and three times as 
many AD CSF samples compared to our previous studies. Furthermore, we extended our 
previous findings towards identification of a miRNA biomarker for differential diagnosis 
by including FTD and DLB samples, and for identification of miRNAs as an early biomarker 
for AD by including CSF of MCI due to AD (MCI-AD) patients. However, we noticed that 
several problems arise when performing a study with a multicenter design. By controlling 
as much as possible for these confounding factors, we found that we could not repeat our 
earlier findings in AD patients versus controls, with the exception of miR-146a. This miRNA 
was, as previously, decreased in AD compared to controls in samples of only the Nijmegen 
center, but not when results from all three centers were combined. We further did not 
find differences of miRNA levels between controls and MCI-AD patients or between AD, 
FTD and DLB patients. The question remains, whether reproducing earlier findings was 
hampered by unnoticed or uncontrollable confounding factors of such a multicenter 
design, or whether earlier findings had been biased by too small sample groups. Based on 
our experience with miRNA measurements in CSF, we concluded chapter 8 with several 
suggestions on how to proceed in testing miRNAs as potential CSF biomarker for AD and 
related dementia subtypes.
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9.2 General Discussion
9.2.1 Introduction 
AD is one of the most prevalent neurodegenerative diseases, affecting approximately 
10.6 million people in the USA and Europe [2], with no treatment yet available. One major 
issue concerning AD is the correct identification of the disease. The diagnosis of AD can 
only be made with certainty postmortem, after neuropathological examination [429]. 
Based on this standard, clinical examination identifies AD with a sensitivity of 70-87% and 
specificity of 44-71% [430]. However, this percentage accounts for AD patients that have 
already progressed into a severe state of the disease with impaired memory and daily 
functioning. Biochemical changes in AD however may occur as early as 20 years before 
the presentation of any symptoms [431], and therefore the measurement of biochemical 
markers could be of great benefit in early identification of the disease, for instance for 
the enrolment of AD patients in clinical trials. Biochemical markers can be analyzed in 
CSF,	and	the	proteins	Aβ42, total tau (t-tau) and phosphorylated tau (p-tau) have emerged 
as the current leading diagnostic entities. When combined, these three biomarkers are 
useful for differential diagnosis of AD from controls with an accuracy of >80%, and in 
predicting disease progression from MCI to AD and even from healthy controls to AD, 
although with a more limited accuracy [98, 432]. However, the current CSF biomarkers 
do not differentiate well between AD and other dementias such as VaD, FTD and DLB. 
Therefore, we are in need of better biomarkers to improve differential diagnosis of AD 
and the early identification of the disease. Since many analytes might be present at low 
levels in CSF, we are also in need of more sensitive detection methods to measure and 
quantify biomarkers.
9.2.2 Sensitive biomarker detection methods
The most frequently applied assays to detect protein biomarkers in body fluids are ELISAs, in 
particular sandwich ELISAs that make use of a capture and detection antibody. ELISAs have 
the advantage of being practical and easy to implement, and have a relatively good sensitivity 
in detecting many analytes [433]. To detect also low-abundant analytes, tools such as the 
polymer horseradish peroxidase (HRP), whereby multiple HRP enzymes are attached to a 
secondary antibody, streptavidin or beads in the detection step, can slightly enhance the 
signal of a conventional ELISA. To further push the limit of detection, oligonucleotides can 
be introduced into the ELISA as substitutes for the antigen and can be detected by spotting 
and scanometric detection or by quantitative PCR (qPCR), as we also described in chapter 
3. Another sensitive ELISA-based method using DNA to enhance the ELISA signal is 
called rolling-circle amplification (RCA), whereby an oligonucleotide is conjugated to the 
detection antibody and is amplified by hybridization of a complement DNA circle and the 
presence of DNA polymerase [434]. Although RCA increases the sensitivity of an ELISA 
over several logs, a drawback of this method is the relatively poor dose response curve 
[295]. Other sensitive techniques based on ELISA, which are commercially available, have 
been developed recently, such as the single molecule array (SiMoATM) from Quanterix, the 
single molecule counting (SMCTM) from Singulex and, as already mentioned in chapter 3, 
Immuno-PCR (Imperacer®) from Chimera Biotec [435]. The Singulex platform for instance 
has	also	been	applied	to	detect	a	wide	size	range	of	Aβ	oligomers	in	CSF	with	a	limit	of	
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detection at approximately 0.15 pg/ml [436]. These assays are promising tools to also 
detect other low-abundant molecules in CSF.
In the future, also non-ELISA based methods may become increasingly important to improve 
the qualitative and quantitative measurements of ligands in biofluids. For instance, using 
quantitative mass spectrometry (MS), such as the targeted multiple reaction monitoring 
(MRM), which enables the measurements of analytes in biofluids with good sensitivity 
down into the picomolar range, and over several orders of magnitude [437]. Apart from 
sensitivity, another important issue for detection methods is their ability to measure 
several analytes at the same time, which is called multiplexing. MRM is also a method 
that is well-suited for multiplexing (see also subchapter 9.2.3). 
9.2.3 Identification of novel biomarker candidates for AD
To identify novel CSF biomarkers, two main strategies are applied: The deductive method, 
in which specific biomarkers are selected based on the knowledge that we have about the 
disease; and the inductive method, an unspecific approach in which numerous analytes 
are tested at the same time using techniques such as proteomics, immunoassay-based 
multipanels or (micro)arrays [438]. The deductive approach relies on understanding the 
underlying causes of AD development and progression. Candidate biomarkers are selected 
based on their involvement in the neuropathological processes of the disease by either 
directly interacting with other important disease players or by being differently regulated 
during	 disease	 development.	 We	 followed	 this	 approach	 when	 investigating	 Aβ/ApoE	
complexes (chapter 4), NrCAM (chapter 5) and several miRNAs that had been associated 
with AD (chapter 6, 7 and 8). Quantifying a protein complex in AD as biomarker, and 
determining the suitability of miRNAs as CSF biomarkers were quite novel ideas and the 
literature on these subjects is very limited. Here, it will be discussed whether a protein 
complex	such	as	Aβ/ApoE	complex	is	useful	as	novel	biochemical	marker	for	AD.	Likewise,	
I will discuss the potential of miRNAs as CSF biomarkers.
Has a protein complex potential as biomarker for AD?
The	 currently	 used	 CSF	 biomarkers	 that	 support	 AD	 diagnosis	 (Aβ42, t-tau and p-tau) 
are proteins that play important roles in AD pathology. Abnormal CSF levels correlate 
with abnormal accumulation of these proteins in the brain, which compose the two 
most	 important	 hallmarks	 of	 AD,	 Aβ	 plaques	 and	 neurofibrillary	 tangles.	 ApoE	 is	 the	
most important genetic risk factor for AD development. The normal function of ApoE is 
transport of lipids such as cholesterol [439], but it has also been observed to interact and 
to	form	complexes	with	Aβ	[53].	This	lead	us	to	the	idea	to	study	Aβ/ApoE	complexes	as	
possible biomarker for AD, as is described in chapter 4.
 
We	did	not	find	differences	in	serum	levels	of	Aβ/ApoE	complexes	between	controls,	AD,	
FTD, DLB and VaD patients. Although using serum to measure biomarkers has several 
advantages, such as easy accessibility and a collection method that is well tolerated 
by patients, the blood brain barrier (BBB) interface prevents direct contact with the 
brain, where pathological events in neurodegenerative diseases occur. While levels of 
Aβ42	are	similar	 in	blood	of	AD	patients	compared	to	controls	[440,	441],	Aβ42 levels in 
150
Chapter 9
CSF of AD patients have been extensively demonstrated to be decreased. The same type 
of	discrepancy	may	account	for	the	Aβ/ApoE	complex,	since	it	was	reported	previously	
that concentrations of the complex are decreased in postmortem ventricular CSF of 
AD patients compared to controls [53]. It should be noted however that postmortem 
ventricular CSF may differ in its protein composition from antemortem obtained lumbar 
CSF [442], since it may contain higher levels of proteins due to disruptions of the BBB 
and	released	proteins	due	to	cell	lysis.	Therefore,	analysis	of	lumbar	CSF	for	the	Aβ/ApoE	
complex levels may hold promise, but the protein levels are expected to be lower than 
in	ventricular	CSF.	Indeed,	with	our	ELISA,	it	was	not	possible	to	detect	and	quantify	Aβ/
ApoE complexes in lumbar CSF, and to our knowledge this has also not been reported 
elsewhere. Complex levels in antemortem lumbar CSF may be too low for quantification 
using regular ELISA or the complexes may be completely absent. These assumptions may 
be	supported	by	a	recent	report	showing	that	Aβ	and	ApoE	only	minimally	form	complexes	
with each other in CSF [74]. Furthermore, in the same report it was shown that in vitro 
only	about	5%	of	cell-derived	Aβ	assembled	into	complexes	with	reconstituted,	lipidated	
ApoE when physiological concentrations, comparable with those in CSF, were used. Thus, 
more sensitive techniques using more sophisticated detection systems may be needed 
to	quantify	levels	of	these	low-abundant	Aβ/ApoE	complexes	in	CSF.
 
Aβ	interacts	and	forms	complexes	also	with	a	variety	of	other	proteins,	for	instance	with	
albumin	[443],	the	transglutaminase	Factor	XIIIa	[444],	transthyretin	[445],	αB-crystallin	
[103], Dickkopf-related protein 3 [446] and tau [52]. The knowledge about the role of 
these complexes may help in gaining more insight in the development of AD, but the 
complexes are also interesting study objects for biomarker research. As such they might 
be	more	specific	than	Aβ	itself	in	differentiating	AD	from	other	dementia	types.	Sandwich	
ELISA’s that quantify the levels of such complexes in body fluids using two antibodies 
that are directed against the separate proteins are very useful to detect complexes 
in	body	 fluids,	as	we	also	 showed	 for	Aβ/ApoE	complexes	 in	 serum.	For	 instance,	Aβ/
tau complexes were measured in CSF and were decreased in AD and MCI-AD patients 
compared	to	other	types	of	dementia	[52].	Complexes	of	Aβ	and	the	blood	clotting	Factor	
XIIIa may be a unique CSF biomarker for patients with cerebral amyloid angiopathy, yet 
another dementia type of which symptoms show overlap with AD [444]. And in serum, 
decreased	levels	of	albumin-Aβ	complexes	were	associated	with	an	increased	prevalence	
of	AD,	and	might	be	useful	to	monitor	AD	progression	[443].		Aβ-protein	complexes	are	
therefore a novel class of potential CSF or serum biomarkers for AD and other dementias 
that	are	worth	further	investigation.	Since	Aβ/ApoE	complexes	were	decreased	in	brain	
and postmortem CSF of AD patients versus controls, which correlated with an increase 
of	Aβ	oligomers,	these	complexes	still	compose	an	interesting	target	as	CSF	biomarker,	
under the condition that detection methods improve in CSF.
Are miRNAs useful as CSF biomarkers for AD?
Less than a decade now, miRNAs are studied in AD. In the first studies, differential miRNA 
expression was reported in human hippocampus and cortex of AD patients compared 
to controls by using techniques such as microarray and qPCR [116-118, 357, 394, 447]. 
Some of these differentially expressed miRNAs could also be linked to AD-associated 
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proteins such as APP or BACE1 [118, 448]. Since then, many more miRNAs have been 
studied in the brain of AD patients. 
The first study in which miRNAs were investigated in CSF of AD patients compared to 
controls, was published in 2008 [357]. More than 300 miRNAs had been investigated by 
qPCR and many differentially expressed miRNAs were identified. However, in this study 
postmortem CSF had been used and later, it was shown that miRNA expression in CSF 
substantially differs between samples that had been obtained antemortem or postmortem 
[124]. Many more miRNAs can be detected in postmortem CSF than in antemortem 
samples, and it was reasoned that this difference might be caused by different locations 
of CSF sampling (lumbar puncture for antemortem CSF versus sampling in the cisterna 
magna for postmortem CSF), or by increased cell death and thus release of miRNAs 
and/or by leakage through the blood brain barrier in postmortem-obtained CSF [124]. 
Thereafter, a handful of reports were published about CSF miRNA expression from AD 
patients [121, 124, 449], but results of these studies differ extensively. In chapter 6 and 
8, we discussed several factors that might cause this variation such as the influence of 
blood contamination and pre-analytical factors such as storage time and centrifugation 
protocol. Importantly, CSF studies, including our first two pilot studies, commonly rely on 
small cohorts of maximally 20 samples (some even only on 10 samples) per group, which 
might cause selection bias. Before miRNAs can be used as biomarkers for the diagnosis 
of AD, much more work needs to be done in validating them in larger cohorts, identifying 
all accountable confounding factors, and generalizing the methods such as normalization. 
As such, we made first efforts in that direction with our multicenter study in chapter 8.
9.2.4 Future directions in identifying novel AD biomarkers
Large-scale screening methods for biomarker discovery
Although a great variety of analytes have been tested as potential CSF biomarkers for 
AD, none has been reported to outperform the AD CSF markers that are currently in use. 
Therefore, we still are in need for better AD biomarkers, and the deductive approach alone 
has not been proven sufficient enough to identify such biomarkers. Next to the deductive 
method, in which specific biomarkers are selected based on the knowledge that we have 
about the disease; there is also the inductive method, an unspecific approach in which 
numerous analytes are tested simultaneously using techniques such as multipanels, 
arrays and proteomics [438]. 
To identify proteins and peptides, especially proteomics has been given increasing 
attention for novel biomarker discovery. Explorative proteomics in biological samples 
such as CSF is performed by applying either two-dimensional (2-DE) polyacrylamide gel 
electrophoresis or liquid chromatography (LC), which are both combined with MS for 
detection. In the past, several studies have been performed using these techniques and 
many differentially expressed proteins were identified in samples of AD patients versus 
controls. Using 2-DE/MS in CSF, for instance apolipoprotein A-1, ApoE, prostaglandin H2 
D isomerase and transthyretin were decreased in AD patients compared to controls [450-
453]. However, the overlap between these studies is rather low, and only few proteins 
that are differentially regulated with the same direction of change are identified in more 
than one proteomic study [454]. Reasons are the complex and laborious sample work-up 
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and thus a small number of samples is usually used. This then results in selection bias 
of the samples. Also, often samples are pooled, but one or two outliers in these pools 
may easily cause false-positive or false-negative results. Furthermore, low-abundant 
proteins may be overlooked, whereas especially in CSF, low-abundant proteins might 
reflect pathological changes and might be most interesting as biomarkers. Proteomics 
has much potential in identifying novel biomarkers for AD, but the inclusion of a larger 
number of samples is necessary in future studies [455]. For instance tandem mass tag 
(TMT), a proteomic variation that labels peptides with a set of structurally identical tags 
and enables currently up to 10-plexing, could in the future enable the testing of several 
hundreds of subjects in one study [454]. In any case, biomarkers that have been identified 
by proteomics should always be evaluated in independent, large clinical cohorts using 
specific methods such as ELISAs or MRM MS, which is a targeted MS approach to measure 
specific proteins or peptides of interest, and has shown promising results in CSF [456]. 
The preferred method to identify differentially expressed miRNAs in CSF is qPCR. To 
screen a large number of miRNAs, qPCR panels are available for approximately 800 known 
miRNAs, and in CSF it was possible to detect at least 86 miRNAs by using such a multipanel 
[124]. However, the number of known miRNAs is much higher and keeps increasing. 
Even using a qPCR panel, miRNAs that are potential biomarkers might be overlooked. A 
quite novel approach to profile small RNAs for biomarker discovery is next-generation 
sequencing (NGS). In the past, the amount of total RNA that was required for NGS (at least 
1 µg) could not be obtained from volumes of CSF samples that would be clinically relevant 
(< 1 ml). However, recently it was possible to apply sequencing protocols to CSF samples 
with volumes of 0.5 ml by comparing and improving RNA extraction methods with the 
aim to increase RNA yield [457]. In 2014, NGS was used for the first time for CSF of AD 
patients, however, CSF had been obtained postmortem [458]. Nonetheless, this study 
indicates that it might also be possible to measure miRNAs in antemortem CSF using NGS. 
The advantage over qPCR is that NGS targets all miRNAs, including variations in miRNA 
sequences (isomiRs) [457]. This method has thus the potential to identify novel miRNAs 
that have not been described previously. 
Exosomal miRNAs
Another novel approach to study miRNAs as biomarkers is the extraction of exosomes 
from body fluids and the subsequent quantification of the exosomal miRNA content. RNAs 
are prone to breakdown by endonucleases and RNAses, which are especially abundant in 
extracellular biofluids. Circulating miRNAs however appear to be very stable, which is 
ascribed to protection by argonaute proteins, lipoproteins and perhaps most importantly 
exosomes [127, 459, 460]. Exosomes (30-90 nm) are derived from multi-vesicular bodies 
(MVBs) that transport cargo between the plasma membrane, trans-Golgi network and 
lysosomes [461]. A great variety of cells, including neurons, produce exosomes for 
intercellular communication by transporting miRNAs or proteins between cells [462]. 
Exosomes and their content have been primarily investigated in cancers such as breast 
cancer [463], renal cancer [464] or gastric cancer [465], and these tumor-secreted 
exosomes have been shown to contain unique exosomal miRNA profiles compared to 
healthy controls which makes them interesting study objects for biomarker identification. 
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Importantly, exosomes also contain specific factors such as (membrane) proteins and 
lipids that can give information about their origin such as the cell type that produced 
them and that could serve as markers for exosome identity [466]. Furthermore, exosomes 
are found in various body fluids such as urine, amniotic fluid, saliva, blood and CSF [467]. 
In CSF, large starting volumes (200-500 ml) were initially used to isolate exosomes [468]. 
Recently, also 5-7 ml of CSF was sufficient to extract exosomes and subsequently identify 
differentially expressed miRNAs in glioblastoma [428]. In the future, exosomal miRNAs 
might also be studied in CSF of AD patients. If then exosomes could be specifically 
identified as for instance neuron-derived exosomes, this could overcome the problem of 
blood contamination in CSF on miRNA levels and miRNAs would become more specific 
and reliable biomarkers for a brain disease. However, methods to isolate and characterize 
exosomes and subsequently to determine their miRNA content need to be more sensitive 
for these purposes. 
Biomarker panel instead of an individual biomarker
In the past, numerous analytes have been tested for differential diagnosis. In general, 
not one analyte, but a combination of several analytes achieved the highest sensitivity 
and specificity in discriminating dementia subtypes. Most successful were panels that 
made use of a combination of traditional biomarkers and newly identified biomarkers. 
For	instance,	Aβ42, t-tau and p-tau in combination with the neurotransmitter 3-methoxy-
4-hydroxyphenylethyleneglycol (MHPG) could discriminate DLB from AD patients with a 
sensitivity of 97.6% and a specificity of 95% [469]. Or in discriminating AD from healthy 
controls, the panel in which NrCAM and five other novel markers were combined with 
traditional biomarkers achieved a sensitivity of 97% and a specificity of 93.9% [343]. A 
CSF signature of a panel of miRNAs for AD has not yet been established. However, miRNAs 
are abundantly present in blood and miRNAs have therefore also been studied in blood 
samples of AD patients. Recently, a signature with seven miRNAs measured in plasma was 
established that differentiated AD patients from controls in two independent cohorts with 
an accuracy up to 95% [470]. However, in this study both cohorts were rather small (< 20 
subjects per group). In a somewhat larger study (48 AD patients; 22 controls), a signature 
of 12 miRNAs was identified using NGS in whole blood samples [123]. Of note, the 12 
miRNAs were all different from the miRNAs that were identified in the 7-miRNA signature. 
Furthermore, the 12-miRNA signature was less useful in differentiating between AD and 
neurological disorders such as depression or schizophrenia, or neurological diseases such 
as Parkinson’s disease and multiple sclerosis [123]. It should also be noted that results 
of differential miRNA expression in blood may not specifically reflect changes in AD, but 
is likely to also indicate peripheral changes that possibly correlate to a systemic disease. 
However, the use of a panel of biomarkers of either proteins or miRNAs has proven to 
achieve higher accuracy than individual analytes and should be exploited further in the 
future. Possibly, even a combination of proteins and miRNAs, for instance both isolated 
from exosomes, might be a novel approach for biomarker discovery in AD. 
9.2.5 Other considerations in CSF biomarker studies
Studies for biomarker discovery in CSF rely on the use of well-diagnosed sample groups 
that are matched for parameters such as age, gender and sample treatment. Well-
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diagnosed would ideally imply not only an established clinical diagnosis according to 
published consensus criteria, but also neuropathological verification of this diagnosis or 
a long-term follow-up to affirm the clinical diagnosis. In practice however, samples from 
patients with a neuropathologically confirmed diagnosis are very scarce, and therefore 
are usually not used for biomarker discovery. Samples of patients with (long) clinical 
follow-up are a good alternative and usually more easily available.
Another issue is that CSF samples that are available in a clinical institution for scientific 
purposes often have been obtained from AD patients or patients with other dementias in 
an already advanced disease stage. Samples of patients with MCI or preclinical dementia 
are less often available.
Matching samples for age and gender is in our experience mainly an issue when testing 
biomarkers in less common dementia types than AD. For instance, FTD patients are 
generally younger than AD patients, since the age of onset of FTD is earlier than the 
age of onset for AD [471]. Some dementias such as AD are more prevalent in women 
and therefore more samples of women are available [472]. This is however not the case 
for DLB, which might be more prevalent in men than in women [473]. If the number of 
available patient samples is limited, it might be difficult to match different groups for age 
and gender. Furthermore, pre-analytical factors can have a major impact on biomarker 
outcomes (reviewed in [427, 474]). For instance, simple laboratory equipment such as the 
tube in which CSF is collected and stored can have an effect on biomarker levels, as has 
been	shown	for	Aβ	and	tau	proteins,	which	tend	to	stick	non-specifically	to	polystyrene	
or glass tubes, but much less to polypropylene tubes [475]. Centrifugation of CSF samples 
seems to not only affect miRNA measurements as we observed, but also the levels of 
various metabolites, amino acids and proteins [476]. Confounding factors caused by 
differences in sample collection, preparation and analysis methods should therefore not 
be underestimated, and standardization of these parameters is an important future goal 
in CSF biomarker studies.
Finally, many biomarker studies that are published today are small-scale pilot studies 
usually with a retrospective design, which often introduces bias in sample selection. 
As a result, many findings are not reproducible, which certainly accounts for many 
miRNA studies, as we already discussed in chapter 8. Therefore, studies with a much 
larger number of samples in each group, preferably with heterogeneous genetic 
and ethnic backgrounds of patients, are needed to confirm the results of small-scale pilot 
studies. 
9.2.6 Concluding Remarks
Novel biomarkers might be needed as much as more sensitive methods to measure them. 
A correct diagnosis of AD or the other dementias will not only benefit the patients in 
helping to choose the right treatment, but will also substantially contribute to set-up 
good, clinical trials, in which patients with early disease stages or different subtypes of 
dementias participate.
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In this thesis, several ways were described how to identify novel biomarkers in CSF and 
serum, for primarily AD, but also MCI-AD and for differential diagnosis between AD, VaD, 
DLB and FTD. We showed how we aimed to set-up a sensitive assay to be able to explore 
low-abundant analytes in CSF. Although we did not succeed, this may remain an important 
issue for future biomarker research and other sensitive techniques that are now available 
or in development may assist in improving the detection of low-abundant analytes. 
Serum	levels	of	Aβ/ApoE	complexes	and	NrCAM	levels	in	CSF	did	not	proof	to	be	suitable	
as biomarkers for AD and differential diagnosis. However, these studies are nonetheless 
important in directing future research. NrCAM could be studied in more detail as marker 
for	 disease	 severity	 in	AD.	 Since	Aβ/ApoE	 complexes	were	not	 useful	 as	 biomarkers	 in	
serum, future investigations might focus on measuring the complexes in antemortem 
CSF.	 We	 furthermore	 showed,	 how	 we	 developed	 a	 specific	 ELISA	 to	 detect	 Aβ/ApoE	
complexes. Our study therefore could also serve as an example for setting-up assays for 
other	Aβ-protein	complexes	that	could	serve	as	specific	AD	biomarkers.	
Finally, we studied miRNAs in CSF, and gained many insights on how they should be 
handled and what the pitfalls are. Our miRNA studies belong to the first explorative 
studies on miRNA expression in CSF. In the future, our insights might contribute to set-up 
new studies to measure miRNAs in CSF not only for AD, but also other neurodegenerative 
diseases such as Parkinson disease or Multiple sclerosis, or neurological disorders such as 
depression or schizophrenia. Since miRNAs are involved in many processes, in particular 
in the brain [115], and circulate in body fluids, they remain interesting biomarker 
candidates.
In the future, novel biomarkers might be discovered by using inductive methods such as 
proteomics and NGS in large sample cohorts. These methods are well-suited to identify 
a panel of biomarkers, which might be most specific in differentiation of AD from other 
types of dementia.
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Nederlandse samenvatting
Dementie
Het verlies van verstandelijke vermogens, met name het geheugen, word dementie 
genoemd. Hierbij zijn zenuwcellen in de hersenen aangetast en gaan uiteindelijk dood. 
Voor een patiënt betekent dit dat simpele, dagelijkse handelingen zoals bijvoorbeeld zich 
aankleden, eten bereiden of rekeningen betalen steeds minder goed kunnen worden 
uitgevoerd. Ook communicatie gaat steeds moeilijker totdat het vermogen te spreken 
helemaal verdwijnt. Er kunnen tevens veranderingen optreden in karakter en gedrag. 
Dementie komt vooral voor bij ouderen boven de 60; alleen in zeldzame gevallen, waarbij 
vaak een genetisch defect de oorzaak is, kan dementie al op jongere leeftijd optreden. 
Dementie kan niet worden genezen en uiteindelijk overlijdt de patiënt aan de gevolgen 
ervan. In Nederland is dementie na kanker en hart- en vaatziekten de meest voorkomende 
doodsoorzaak. Actuele cijfers laten zien dat wereldwijd ~5% van de mensen aan een vorm 
van dementie lijdt, een percentage die in de komende jaren na verwachting zal toenemen 
omdat mensen steeds ouder worden. In vergelijking met alle andere ziekten veroorzaakt 
dementie de hoogste ziektelast voor patiënten en de hoogste zorgkosten, en is voor 
mantelzorgers een zware last. Met dit vooruitzicht is het belang groot om effectieve 
medicijnen tegen dementie en de verschillende vormen ervan te ontwikkelen, waarbij 
het van essentieel belang is, de juiste vorm van dementie bij een patiënt te identificeren. 
Ruim vijftig verschillende ziektes worden door dementie gekenmerkt, waarvan de 
bekendste en vaak voorkomendste de ziekte van Alzheimer (60-80%) is (zie volgende 
paragraaf). Daarna volgt vasculaire dementie (20%), Lewy body dementie (10-15%) en 
frontotemporale dementie (5-20%).
Pathologie van de ziekte van Alzheimer
De stapeling van eiwitten is een cruciaal onderdeel in het ontstaan van vele dementieën, 
zo ook bij de ziekte van Alzheimer. Al in 1907 beschreef de Duitse psychiater en patholoog 
Alois Alzheimer een ophoping van eiwitten (plaques) in de hersenen van een overleden 
patiënte, die had geleden aan achteruitgang van haar geheugen en sterke beperkingen 
in spraak en gedrag liet zien. De ziekte van Alzheimer is dan ook naar hem vernoemd. 
Later	 werd	 ontdekt	 dat	 plaques	 vooral	 bestaan	 uit	 het	 eiwit	 amyloid-β	 (Aβ).	 Dit	 eiwit	
word aangemaakt door zenuwcellen in de hersenen en ontstaat tijdens het knippen door 
verschillende enzymen, die secretases genoemd worden. De gangbare hypothese, waarom 
Aβ	 in	 de	 hersenen	 van	 ouderen	 gaat	 ophopen	 is	 niet	 zo	 zeer	 dat	 dit	 productieproces	
verandert met leeftijd maar meer dat het eiwit niet meer efficiënt word afgevoerd 
en	 daarom	 toenemend	 aggregaten	 vormt,	 die	 toxisch	 zijn	 voor	 hersencellen.	 Dat	 Aβ	
hoofdverantwoordelijk is voor het ontstaan van Alzheimer word onderstreept door het 
voorkomen van genetische defecten (familiair Alzheimer), die wél het productieproces 
beïnvloeden	en	de	aanmaak	van	Aβ	verhogen.	Er	zijn	dan	veel	Aβ	eiwitten	in	de	hersenen	
al vroeg te vinden, waardoor de ziekte zich bij familiaire Alzheimer patiënten al op een 
veel	 jongere	 leeftijd	 kan	manifesteren.	Naast	Aβ	 spelen	ook	nog	 twee	andere	eiwitten	
een belangrijke rol in de pathologie van Alzheimer. Het tau eiwit, dat in de hersenen 
een steun-eiwit is voor hersencellen, kan door fosforylatie dusdanig worden veranderd, 
dat het zijn steun-functie verliest. Tau gaat dan ook ophopen en vormt de zogenoemde 
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tau tangles. En dan is er nog het eiwit apolipoprotein E (ApoE), dat voorkomt in drie 
verschillende varianten, waarvan het hebben van de ApoE4 variant als belangrijkste 
genetische risico factor geldt voor het ontwikkelen van Alzheimer. Zo verhoogd ApoE4 
niet alleen de kans op Alzheimer, maar kan ook de leeftijd vervroegen waarop Alzheimer 
begint en het proces van achteruitgang versnellen.
Alzheimer diagnose
Samen	 zijn	Aβ	plaques	 en	 tau	 tangles	 de	 belangrijkste	 pathologische	 kenmerken	 in	 de	
Alzheimer hersenen en worden door pathologen gebruikt om een definitieve diagnose te 
stellen na het overlijden van een patiënt. Om een diagnose tijdens het leven te kunnen 
stellen, maken artsen gebruik van verschillende tests en vragenlijsten, en methoden, 
die de achteruitgang van de hersenen ook visueel in kaart kunnen brengen. De klinische 
diagnose word tevens ondersteund door het meten van zogenoemde biochemische 
markers	 of	 biomarkers.	 Ook	 hier	 spelen	 de	 eiwitten	 Aβ	 en	 tau	 een	 belangrijke	 rol.	 De	
concentraties van deze eiwitten kunnen van een levende patiënt niet zomaar in de 
hersenen worden bepaald, maar wel in het hersenvocht dat door een ruggenprik wordt 
verkregen.	Een	verlaagde	concentratie	van	Aβ	en	een	verhoogde	concentratie	van	het	tau	
eiwit, al dan niet in zijn gefosforyleerde vorm, kunnen al met redelijke nauwkeurigheid 
bepalen of een patiënt aan Alzheimer lijdt of niet. De klinische diagnose samen met 
de biomarker-waarden geeft echter vooralsnog niet een 100% zekerheid of de patiënt 
daadwerkelijk Alzheimer heeft of de symptomen het gevolg zijn van een andere vorm van 
dementie.
Het doel van dit proefschrift was het onderzoeken van nieuwe biomarkers voor Alzheimer 
en een goede methode om deze te meten. Dit is op twee manieren aangepakt: 1) Het 
opzetten van een gevoelige methode om lage concentraties van nog niet eerder gemeten 
biomarkers te kunnen meten, 2) Het onderzoeken van het eiwit NrCAM, het eiwit-
complex	Aβ/ApoE	en	een	aantal	microRNAs	(miRNAs)	als	mogelijke	nieuwe	biomarkers	in	
hersenvocht of serum. 
Gevoelige methode (hoofdstuk 3)
De	eiwitten	Aβ	en	tau	worden	in	hersenvocht	gemeten	door	middel	van	een	immunologische	
techniek, die ELISA genoemd word. Juist in hersenvocht zijn, naar verwachting, echter 
ook veel eiwitten aanwezig, die niet met ELISA kunnen worden gemeten, omdat zij in te 
lage concentraties voorkomen. Voor dat soort eiwitten probeerden we een gevoeligere 
methode dan ELISA op te zetten. Enkele jaren geleden werd in een publicatie zo’n 
gevoelige methode beschreven, die Bio-barcode assay (BCA) werd genoemd. Deze assay is 
gebaseerd op een ELISA methode, maar maakt tevens gebruik van DNA oftewel barcodes, 
die het signaal aanzienlijk kunnen verhogen. De barcodes worden hiertoe gekoppeld aan 
minuscule goud bolletjes. Doordat er veel barcodes kunnen worden gekoppeld en doordat 
deze DNA stukjes vervolgens nog vermeerderd kunnen worden, wordt er ook een signaal 
verkregen in geval van lage concentraties van het eiwit. In de praktijk was het echter 
lastig om een dergelijke assay te ontwikkelen. Wij kwamen verschillende problemen 
tegen zoals aspecifiek binden van de goud bolletjes waardoor er hoge achtergrond 
signalen ontstonden. Uiteindelijk bleek de assay wel te werken, maar konden we niet 
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noemenswaardige lagere concentraties meten dan in een vergelijkbare ELISA. Vooralsnog 
is de BCA een methode die tot nu toe slechts door een kleine handvol onderzoekers is 
opgezet en nog lang niet als een standaard diagnostische methode kan worden gebruikt.
Zoektocht naar nieuwe biomarkers
Voor het tweede doel richtten wij ons op het vinden van een nieuwe effectieve biomarker. 
Naast	 Aβ	 en	 tau	 zijn	 er	 natuurlijk	 nog	 talrijke	 andere	 eiwitten,	 metabolieten	 of	 RNA-
moleculen zoals miRNAs, die een belangrijke rol spelen in de hersenen en bij het ontstaan 
van een dementie zoals de ziekte van Alzheimer. Elke vorm van dementie zou zo zijn 
eigen palet moleculen kunnen hebben, die in afwijkende concentraties voorkomen en de 
ziekte via dit uniek en afwijkende biochemische patroon kunnen aanwijzen. Hersenvocht 
word graag gebruikt als bron voor deze zoektocht, omdat het de hersenen omgeeft 
en biochemische moleculen uit de hersenen afvoert. Daarnaast wordt ook bloed, dat 
makkelijker te verkrijgen is, onderzocht. Het transport van moleculen uit de hersenen 
naar het bloed is mogelijk, maar word ook afgeremd door de zogenoemde bloed-hersen-
barrière, waardoor niet alle moleculen in het bloed terecht komen of slechts in geringe 
hoeveelheden	aanwezig	zijn.	Zo	is	bijvoorbeeld	van	Aβ,	dat	ook	in	bloed	voorkomt,	maar	
een kleine percentage afkomstig uit de hersenen en de concentraties van dit eiwit zijn 
dan ook niet verschillend in bloed van Alzheimer patiënten vergeleken bij mensen zonder 
dementie. Er zijn echter mogelijk andere moleculen, die wel in afwijkende concentraties 
voorkomen in het bloed, en gebruikt kunnen worden als een nieuwe biomarker voor 
Alzheimer.	Wij	hebben	ons	gericht	op	complexen	tussen	de	eiwitten	Aβ	en	ApoE	in	serum.
Aβ/ApoE complexen (hoofdstuk 4)
Zoals	al	beschreven,	spelen	Aβ	en	ApoE	allebei	een	belangrijke	 rol	 in	de	pathologie	van	
Alzheimer.	De	eiwitten	kunnen	echter	ook	elkaar	beïnvloeden.	Hoe	ze	dat	precies	doen,	
is	nog	steeds	niet	volledig	duidelijk,	maar	ApoE4	zou	een	efficiënte	afvoer	van	Aβ	uit	de	
hersenen tegen kunnen gaan, wat zou verklaren waarom dragerschap van deze ApoE 
variant het ontstaan van Alzheimer bevordert. Er is ook in de literatuur beschreven dat 
de	twee	eiwitten	aan	elkaar	kunnen	binden	en	complexen	vormen.	Zo	ontstond	het	idee	
om	 een	 complex	 van	 deze	 twee	 eiwitten	 als	 biomarker	 kandidaat	 te	 onderzoeken.	We	
ontwikkelden	speciaal	voor	dit	doel	een	specifieke	ELISA,	die	alleen	de	complexen	van	de	
beide	eiwitten	meet,	maar	niet	ApoE	of	Aβ	alleen.	Vervolgens	gingen	wij	met	deze	ELISA	
de	Aβ/ApoE	complexen	meten	in	serum	van	Alzheimer	patiënten,	patiënten	met	vasculaire	
dementie,	patiënten	met	Lewy	body	dementie,	patiënten	met	frontotemporale	dementie	
en	 in	 een	 groep	 met	 mensen	 zonder	 dementie.	 Wij	 wilden	 onderzoeken	 of	 Aβ/ApoE	
complexen onderscheid kunnen maken tussen deze verschillende groepen. Dit was echter 
niet het geval. Onze resultaten wijzen erop, dat de complexen in serum niet als biomarker 
kunnen dienen. Interessant zou het nog zijn om de complexen ook in hersenvocht te meten, 
maar met onze ELISA was het niet mogelijk om de complexen te detecteren. Wellicht is 
onze methode hiervoor niet gevoelig genoeg.
NrCAM (hoofdstuk 5)
In hersenvocht hebben we een ander eiwit als mogelijke biomarker voor het 
onderscheiden van verschillende vormen dementie onderzocht. NrCAM, een afkorting 
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van “Neuronal Cell Adhesion Molecule”, komt voor in de hersenen en is daar belangrijk 
om de verbindingen tussen hersencellen te ondersteunen. Dit is dan weer van belang 
voor een goede informatie-uitwisseling in de hersenen. In een eerdere studie werd een 
verlaagde concentratie van NrCAM gevonden in hersenvocht van Alzheimer patiënten ten 
opzichte van een controle groep. Wij probeerden deze bevindingen te herhalen en uit te 
breiden met groepen patiënten met frontotemporale dementie en Lewy body dementie. 
In onze studie waren NrCAM levels echter vergelijkbaar tussen de verschillende groepen. 
Wel zagen we dat de NrCAM concentratie afnam met de duur van de ziekte, wat erop zou 
kunnen wijzen dat NrCAM een biomarker voor ziekte progressie is. Dit werd ook in twee 
andere studies opgemerkt, maar zou nog uitgebreider moeten bestudeerd worden.
miRNAs
In dit proefschrift zijn meerdere studies (hoofdstuk 6, 7 en 8) gedaan om miRNAs als 
biomarkers voor de ziekte van Alzheimer te onderzoeken. Het onderzoeken van miRNAs 
als biomarker in hersenvocht is een relatief nieuwe aanpak en onze studies kunnen 
daarom bij de eerste verkennende studies worden geteld. 
MiRNAs zijn geen eiwitten, maar kleine stukjes RNA, die de expressie van eiwitten 
beïnvloeden. Dat doen ze door samen met enkele eiwitten specifiek aan de coderende 
sequentie RNA voor een eiwit te binden en zo de productie van het corresponderende 
eiwit te onderdrukken. Op die manier hebben miRNAs een belangrijke rol in ons lichaam en 
beïnvloeden ze vele processen. Ze zijn daardoor ook bij het ontstaan van vele ziektes min 
of meer betrokken. Er bestaan wel duizenden miRNAs, één miRNA kan meerdere eiwitten 
reguleren en één afzonderlijk eiwit kan door meerdere miRNAs gereguleerd worden. 
Dit maakt het miRNA systeem ook meteen erg complex. Bij de ziekte van Alzheimer zijn 
ook	al	miRNAs	gevonden	die	bijvoorbeeld	de	productie	van	Aβ	kunnen	beïnvloeden.	Uit	
eerdere studies is al gebleken dat de concentraties van enkele miRNAs sterk kunnen 
verschillen in de hersenen van Alzheimer patiënten vergeleken met een controle groep. 
Dit was aanleiding voor ons om de concentraties van enkele goed geselecteerde miRNAs 
als biomarker in hersenvocht van Alzheimer patiënten en controles te onderzoeken. 
In hoofdstuk 6 onderzochten we zeven miRNAs zowel in de hersenen als ook in hersenvocht. 
In de hersenen keken we naar een gebied dat betrokken is bij vorming van herinneringen: 
de hippocampus. Hiervoor gebruikten wij hippocampus weefsel van overleden controles 
en Alzheimer patiënten, die in een ver gevorderd en een minder ver gevorderd stadium 
waren overleden. Van de zeven miRNAs waren maar liefst vijf miRNAs verschillend, en 
vooral de Alzheimer patiënten in een ver gevorderd stadium hadden lagere concentraties 
van deze vijf miRNAs dan de controle groep of patiënten in een minder ver gevorderd 
stadium. In hersenvocht, dat was verkregen van nog levende patiënten, wilden we deze 
effecten graag terug zien, maar stootten we al snel op wat problemen. Ten eerste waren 
de meeste onderzochte miRNAs op twee miRNAs na, niet meetbaar. En ten tweede waren 
de hersenvocht samples, die kleine hoeveelheden bloed bevatten, niet betrouwbaar voor 
miRNA analyse. Bloed kan in het hersenvocht komen tijdens de afname en hoe meer 
bloed aanwezig was, hoe hoger de concentraties van de onderzochte miRNAs. Dit gaf dus 
een vertekend beeld van de daadwerkelijke situatie. Uiteindelijk konden wij twee miRNAs 
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in een aantal hersenvocht monsters meten, die (vrijwel) geen bloed bevatten. Eén van 
deze twee miRNAs (miR-146a) had een verlaagde concentratie in Alzheimer patiënten ten 
opzichte van controles. Dit miRNA is daarom een mogelijke biomarker kandidaat voor de 
ziekte van Alzheimer.
In hoofdstuk 7 onderzochten wij nog vier andere miRNAs in hersenvocht van Alzheimer 
patiënten en controles. Hierbij waren twee miRNAs (miR-29a en miR-125b) verhoogd 
in Alzheimer patiënten versus controles, waarvan miR-125b niet door de aanwezigheid 
van bloed in een hersenvocht sample werd beïnvloed. Echter, een keerzijde van de twee 
eerder genoemde studies en tevens vele andere miRNA studies in hersenvocht, is het 
relatief kleine aantal samples in een groep.
Daarom onderzochten wij in hoofdstuk 8 de miRNAs miR-146a, miR-29a en miR-125b in 
aanzienlijk grotere groepen met Alzheimer patiënten en controles, die afkomstig waren 
van drie verschillende Europese centra. Bovendien bestudeerden wij deze miRNAs ook 
in een groep met patiënten in een vroeg stadium van Alzheimer en in groepen met 
patiënten met frontotemporale dementie en dementie met Lewy bodies. De verlaagde 
expressie van miR-146a in Alzheimer patiënten werd bevestigd in samples die afkomstig 
waren van ons eigen ziekenhuis. Toen echter alle samples gecombineerd werden, konden 
wij de resultaten van de eerdere studies niet herhalen, wat verschillende oorzaken kan 
hebben. Zo vonden wij bijvoorbeeld verschillen in miRNA levels tussen de drie centra, wat 
zou kunnen komen doordat samples niet op precies dezelfde manier waren behandeld. Bij 
het meten van miRNAs in hersenvocht kunnen vele factoren komen kijken, en gebaseerd 
op onze ervaringen kunnen wij enkele aanbevelingen meegeven om vervolgstudies op te 
zetten.
Conclusie
Nieuwe, betere biomarkers die een onderscheid kunnen maken tussen patiënten met de 
ziekte van Alzheimer en patiënten met andere vormen van dementie zijn nog steeds hard 
nodig. Niet alleen om een goede diagnose te stellen, maar ook om nieuw ontwikkelde 
therapieën optimaal te kunnen testen.
De hier beschreven studies dragen bij tot de zoektocht naar biomarkers voor de ziekte van 
Alzheimer.	Ook	al	vonden	wij	in	Aβ/ApoE	complexen	in	serum	en	NrCAM	in	hersenvocht	
geen nieuwe specifieke biomarkers, zo kunnen deze studies toch de weg wijzen naar 
vervolgstudies. Het onderzoek van miRNAs als biomarkers in hersenvocht staat nog in de 
kinderschoenen en wij hebben uit onze studies nieuwe inzichten verkregen die andere 
onderzoekers op weg kunnen helpen en aanleiding geven tot vervolgonderzoek. Een van 
de bestudeerde miRNAs (miR-146a) verdient zeker nog nader onderzocht te worden, 
omdat het in twee onafhankelijke studies verlaagd was in Alzheimer patiënten. 
In de toekomst zal de zoektocht naar betere, specifiekere biomarkers dan diegene die 
al beschikbaar zijn, nog zeker doorgaan. Het ontwikkelen van sensitieve methoden zal 
hierbij wellicht net zo belangrijk zijn als het vinden van nieuwe biomarkers.
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Deutsche Zusammenfassung
Demenz
Der Verlust der kognitiven Leistung, vor allem der Erinnerung, wird Demenz genannt. 
Zellen im Gehirn verlieren ihre Funktion und sterben ab. Für einen Patienten bedeutet 
dies, dass einfache, alltägliche Handlungen, wie zum Beispiel sich selbst anzuziehen, 
Essen zuzubereiten oder Rechnungen zu bezahlen immer beschwerlicher ausgeführt 
werden können. Auch die Kommunikation wird für den Patienten immer schwieriger bis 
hin zum vollkommenen Verlust des Sprachvermögens. Darüber hinaus können sich der 
Charakter und das Verhalten eines Patienten verändern. An Demenz leiden vor allem 
ältere Menschen, die über 60 sind. Nur in seltenen Fällen, meist stellt ein genetischer 
Defekt die Ursache dar, kann Demenz auch schon in jüngerem Alter auftreten. Für Demenz 
gibt es kein Heilmittel und am Ende stirbt der Patient an den Folgen der Krankheit. In den 
Niederlanden ist Demenz die dritthäufigste Krankheit. Nur Krebs und Gefäßkrankheiten 
treten noch häufiger auf. Aktuellen Studien zufolge leiden etwa 5% der Menschen 
weltweit an einer der spezifischen Demenzformen. Aufgrund des zunehmenden 
Lebensalters der Menschen, ist zu erwarten, dass diese Prozentzahl in den kommenden 
Jahren steigen wird. Verglichen mit allen anderen Krankheiten verursacht Demenz mit 
ihren verschiedenen Formen die größte Belastung, sowohl für den Patienten, als auch 
für Pfleger, und die höchsten Kosten im Gesundheitswesen. Aufgrund der erwarteten 
Entwicklungen in der Zukunft ist es wichtig, wirksame Arzneimittel gegen Demenz und 
ihre verschiedenen Formen zu entwickeln. Hierbei ist es besonders von Bedeutung, die 
richtige Demenzform bei einem Patienten festzustellen. Es existieren ungefähr fünfzig 
verschiedene Demenzformen, von welchen Alzheimer (60-80%) die am häufigsten 
vorkommende Demenzform ist (siehe folgenden Paragraph). , gefolgt von Vaskulärer 
Demenz (20%), Lewy-Body-Demenz (10-15%) und Frontotemporaler Demenz (5-20%).
Pathologie der Alzheimer-Krankheit
Die Anhäufung von Proteinen stellt eine wichtige Gegebenheit in vielen Demenzformen, so 
auch bei der Alzheimer-Demenz, dar. Schon 1907 beschrieb der deutsche Psychiater und 
Pathologe Alois Alzheimer eine Ansammlung von Proteinen („plaques“) im Gehirn einer 
verstorbenen Patientin, die an mangelndem Erinnerungsvermögen, eingeschränktem 
Sprachvermögen und Verhaltensauffälligkeiten litt. Alzheimer-Demenz wurde nach diesem 
Psychiater benannt. Später wurde entdeckt, dass „plaques“ vor allem aus dem Protein 
Amyloid-β	 (Aβ)	 bestehen.	 Dieses	 Protein	wird	 in	 Gehirnzellen	 produziert	 und	 entsteht	
beim Zusammenwirken verschiedener Enzyme, den Sekretasen. Eine häufig vertretene 
Hypothese	über	die	Ansammlung	von	Aβ	im	Gehirn	älterer	Menschen	besagt,	dass	sich	die	
Aβ	Produktion	im	Alter	nicht	zwingend	verändert.	Man	geht	hingegen	davon	aus,	dass	das	
Protein im Gehirn nicht mehr effizient abgebaut wird und darum zunehmend Aggregate 
formt,	 die	 dann	 toxisch	 für	 Gehirnzellen	 sind.	 Dass	 Aβ	 hauptverantwortlich	 für	 das	
Entstehen von Alzheimer ist, kann in Fällen, in denen Alzheimer durch genetische Defekte 
entstand, gezeigt werden (familiär bedingtes Alzheimer). Hier ist der Produktionsprozess 
von	Aβ	beeinflusst	und	die	Produktion	erhöht.	Schon	früh	sind	viele	Aβ	Proteine	im	Gehirn	
vorhanden, die dafür sorgen, dass sich die Krankheit in jüngeren Jahren manifestiert. 
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Außer	Aβ	spielen	auch	noch	zwei	andere	Proteine	eine	wichtige	Rolle	 in	der	Pathologie	
von Alzheimer. Das Tau Protein gilt im Gehirn als Stützprotein für Gehirnzellen, kann 
sich aber durch Phosphorylierung so verändern, dass es seine Stützfunktion verliert. 
Tau Proteine können sich dann ebenfalls ansammeln und formen die sogenannten 
„Tau tangles“. Darüber hinaus existiert ein Protein, Apolipoprotein E (ApoE), welches in 
drei verschiedenen Varianten auftritt. Die ApoE4-Variante gilt als größter genetischer 
Risikofaktor für die Entstehung der Alzheimer-Demenz. ApoE4 erhöht nicht nur das Risiko, 
Alzheimer zu bekommen, sondern verfrüht auch den Beginn der Krankheit und kann den 
degenerativen Prozess beschleunigen.
Alzheimer Diagnose
Gemeinsam	sind	„Aβ	plaques“	und	„tau	tangles“	die	wichtigsten	pathologischen	Merkmale	
im Gehirn eines Alzheimer-Patienten und helfen den Pathologen, eine treffsichere 
Diagnose nach dem Tod eines Patienten stellen zu können. Um eine Diagnose bei lebenden 
Patienten zu stellen, werden verschiedene Tests und Fragebögen eingesetzt. Auch 
Methoden, die das Absterben von Zellen und Gewebe im Gehirn visuell veranschaulichen, 
werden durchgeführt. Darüber hinaus wird die klinische Diagnose durch das Messen von 
sogenannten biochemischen Markern oder Biomarkern unterstützt. Auch hier spielen die 
Proteine	Aβ	und	tau	eine	wichtige	Rolle.	Eine	Messung	ihrer	Konzentration	im	Gehirn	des	
Menschen ist nicht möglich. Die Messung kann jedoch mit Hilfe einer Lumbalpunktion 
durchgeführt	werden.	 Eine	niedrigere	Konzentration	des	Aβ	Proteins	und	eine	erhöhte	
Konzentration des tau Proteins, in seiner normalen und der phosphorylierten Form, 
können schon mit relativer Genauigkeit bestimmen, ob ein Patient Alzheimer hat oder 
nicht. Die klinische Diagnose zusammen mit den Biomarkerwerten geben dennoch nicht 
100%ige Sicherheit, ob ein Patient wirklich Alzheimer hat oder ob die Symptome von 
einer anderen Demenzform verursacht werden.
Das Ziel dieser Doktorarbeit war, neue Biomarker für Alzheimer zu untersuchen und 
eine Methode für deren Messung zu entwickeln. Konkret bedeutet das: 1) Eine sensitive 
Methode zu entwickeln, um niedrige Konzentrationen von Biomarkern messen zu 
können, die bisher noch nicht gemessen werden konnten. 2) Das Protein NrCAM, den 
Proteinkomplex	 Aβ/ApoE	 und	 einige	 microRNAs	 (miRNAs)	 als	 mögliche	 Biomarker	 in	
Gehirnflüssigkeit und Serum zu untersuchen.
Sensitive Methode (Kapitel 3)
Die	 Proteine	 Aβ	 und	 tau	 werden	 mit	 einer	 immunologischen	 Methode	 in	 der	
Gehirnflüssigkeit gemessen. Diese Technik wird ELISA genannt. Es wird jedoch vermutet, 
dass gerade in der Gehirnflüssigkeit einige Proteine in sehr niedrigen Konzentrationen 
vorhanden sind, die nicht mit einem ELISA gemessen werden können. Das Ziel sollte sein, 
für solche Proteine eine sensitivere Methode zu entwickeln. Vor einigen Jahren wurde 
eine solche Methode, Bio-barcode assay (BCA) genannt, in einer Publikation beschrieben. 
Dieser Assay basiert auf einem ELISA, aber auch DNA oder Barcodes werden eingesetzt, die 
das Signal, das beim Ausführen eines ELISAs erzeugt wird, beträchtlich erhöhen können. 
Die Barcodes werden dazu an kleine Goldkügelchen gekoppelt. Weil viele Barcodes 
gekoppelt werden können und weil diese Barcodes auch noch vermehrt werden können, 
wird bereits bei einer niedrigen Proteinkonzentration ein Signal erzeugt. Die praktische 
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Entwicklung eines solchen Assays stellte sich jedoch als schwierig dar. Wir trafen auf 
verschiedene Probleme, wie zum Beispiel unspezifische Bindungen der Goldkügelchen, 
was dann wiederum hohe Hintergrundwerte verursachte. Letztendlich funktionierte der 
Assay in seiner Ausführung, konnte aber keine nennenswert niedrigere Konzentrationen 
messen als ein vergleichbarer ELISA. Der BCA ist eine Methode, die bisher nur wenig 
Anwendung gefunden hat und noch nicht als standardisiertes diagnostisches Verfahren 
betrachtet werden kann.
Suche nach neuen Biomarkern
Unser	zweites	Ziel	war	das	Finden	von	neuen	effektiven	Biomarkern.	Neben	Aβ	und	tau	
existieren noch zahlreiche andere Proteine, Metaboliten oder RNA Moleküle, wie z.B. 
miRNAs, die alle eine wichtige Rolle im Gehirn spielen, ebenso beim Entstehen einer 
Demenz, so auch der Alzheimer- Demenz. Jede Demenzform könnte so eine eigene 
Molekülpalette haben, deren Moleküle in abweichenden Konzentrationen vorhanden 
sind und eine Krankheit so über ein spezifisches, abweichend biochemisches Muster 
identifizieren. Gehirnflüssigkeit wird gerne als Quelle für die Suche genutzt, weil das 
Gehirn von dieser Flüssigkeit umgeben wird und sie biochemische Stoffe aus dem Gehirn 
abtransportiert. Darüber hinaus wird auch Blut, das etwas einfacher entnommen werden 
kann, untersucht. Der Transport von Molekülen aus dem Gehirn ins Blut ist möglich, 
kann aber auch ausgebremst werden von der sogenannten Blut-Hirn-Schranke, was dazu 
führt, dass nicht alle Moleküle ins Blut übergehen oder nur geringe Konzentrationen zu 
finden	sind.	So	ist	z.B.	Aβ	auch	in	Blut	vorhanden,	aber	davon	wird	nur	ein	kleiner	Teil	im	
Gehirn	produziert.	Die	Aβ	Konzentrationen	können	 im	Blut	keinen	Unterschied	machen	
zwischen Patienten mit Alzheimer und Menschen ohne Demenz. Möglicherweise gibt es 
aber andere Moleküle, die in abweichenden Konzentrationen im Blut vorhanden sind, 
welche dann als neue Biomarker für Alzheimer eingesetzt werden können. Wir haben 
darum	Komplexe	von	den	Proteinen	Aβ	und	ApoE	im	Serum	untersucht.
Aβ/ApoE Komplexe (Kapitel 4)
Wie	schon	erwähnt,	spielen	Aβ	und	ApoE	beide	eine	wichtige	Rolle	in	der	Alzheimerpathologie.	
Die	 Proteine	 können	 auch	 einander	 beeinflussen.	 Der	 genaue	 Ablauf	 ist	 noch	 nicht	
vollständig	erforscht	ApoE4	könnte	einen	effizienten	Abbau	von	Aβ	im	Gehirn	unterbinden,	
was erklären könnte, weshalb ein ApoE4-Träger eine erhöhte Wahrscheinlichkeit hat, an 
Alzheimer zu erkranken. In der Literatur wurde auch beschrieben, dass die beiden Proteine 
aneinander binden können und Komplexe formen. So entstand unsere Idee, den Komplex 
der beiden Proteine als Biomarkerkandidat zu untersuchen. Zu diesem Zweck entwickelten 
wir	 einen	 spezifischen	 ELISA,	 der	 nur	 die	 Komplexe	 der	 beiden	 Proteine	 erkennt,	 nicht	
aber	ApoE	oder	Aβ	als	Einzelnes.	Daraufhin	erfassten	wir	mit	diesem	ELISA	die	Aβ/ApoE-
Komplexkonzentration	im	Serum	von	Alzheimer	Patienten,	Patienten	mit	Vaskulärer	Demenz,	
Lewy-Body-Demenz und Frontotemporaler Demenz und in einer Gruppe mit Menschen ohne 
Demenz.	So	sollte	untersucht	werden,	ob	die	Aβ/ApoE-Komplexe	eine	Unterscheidung	der	
verschiedenen Gruppen möglich machen. Dies war jedoch nicht der Fall. Unsere Resultate 
zeigen, dass die Komplexe im Serum nicht als Biomarker dienen können. Interessant könnte 
darüber	hinaus	sein,	die	Komplexe	 in	Gehirnflüssigkeit	zu	untersuchen,	was	mit	unserem	
ELISA	jedoch	nicht	möglich	war.	Unsere	Methode	erschien	dazu	nicht	ausreichend	sensitiv.
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NrCAM (Kapitel 5)
In der Gehirnflüssigkeit haben wir ein anderes Protein als möglichen Biomarker zum 
Unterscheiden von verschiedenen Demenzformen untersucht. NrCAM (Neuronal Cell 
Adhesion Molecule) kommt im Gehirn vor, wo es die Verbindungen zwischen Gehirnzellen 
unterstützt. Dies ist wichtig für einen guten Informationsaustausch im Gehirn. In einer 
früheren Studie wurde in der Gehirnflüssigkeit von Alzheimer-Patienten eine niedrigere 
Konzentration von NrCAM gefunden als bei einer Kontrollgruppe. Wir versuchten diese 
Befunde zu replizieren und zu erweitern durch Patientengruppen mit Frontotemporaler 
Demenz und Lewy-Body-Demenz. In unserer Studie waren die NrCAM-Werte jedoch 
vergleichbar in den verschiedenen Gruppen. Wir bemerkten jedoch eine Reduktion der 
NrCAM-Werte mit fortschreitender Krankheit. Dies könnte auf NrCAM als Biomarker für 
das Krankheitsfortschreiten verweisen, was auch in zwei anderen Studien angedeutet 
wurde. Diese Gegebenheit müsste aber noch weiterführend untersucht werden.
miRNAs
In der vorliegenden Doktorarbeit sind mehrere Studien (Kapitel 6, 7 und 8) beschrieben, 
in denen miRNAs als Biomarker für Alzheimer untersucht wurden. MiRNAs als Biomarker 
in Gehirnflüssigkeit zu untersuchen ist relativ neu und unsere Studien können darum zu 
den ersten Erkundungsstudien in diesem Gebiet gerechnet werden. MiRNAs sind keine 
Proteine, sondern kleine Teile RNA, die die Proteinproduktion beeinflussen. Hierbei binden 
sie zusammen mit einigen Proteinen an die kodierende RNA Sequenz eines Proteins und 
unterdrücken so die Produktion des korrespondierenden Proteins. Auf diese Weise spielen 
miRNAs eine wichtige Rolle in unserem Körper und beeinflussen viele Prozesse. Dadurch 
sind sie auch beim Entstehen von vielen Krankheiten mehr oder weniger beteiligt. Es 
gibt Tausende miRNAs, eine miRNA kann mehrere Proteine regulieren und ein einzelnes 
Protein kann wiederum von mehreren miRNAs reguliert werden. Diese Gegebenheit 
macht das miRNA-System sehr komplex. Bei Alzheimer wurden miRNAs gefunden, die 
z.B.	die	Produktion	von	Aβ	beeinflussen	können.	 In	 früheren	Studien	 fand	man	bereits	
heraus, dass die Konzentrationen von miRNAs stark unterschiedlich ausfallen können, 
wenn man das Gehirn von Alzheimer Patienten mit einer Kontrollgruppe vergleicht. Aus 
diesem Grund wollten wir eine Auswahl an miRNAs als Biomarker in der Gehirnflüssigkeit 
von Alzheimer Patienten und einer Kontrollgruppe untersuchen.
In Kapitel 6 untersuchten wir sieben miRNAs sowohl im Gehirn als auch in der 
Gehirnflüssigkeit. Im Gehirn untersuchten wir einen Bereich, der zuständig für die Entstehung 
von Erinnerungen ist, den Hippocampus. Hierfür benutzten wir Hippocampusgewebe von 
verstorbenen Menschen für die Kontrollgruppe und von verstorbenen Alzheimer-Patienten 
in einem weit und einem weniger weit fortgeschrittenem Stadium. In Gehirnflüssigkeit, 
die lebenden Menschen entnommen wurde, erwarteten wir gleiche Effekte wie in dem 
entnommenen Gehirngewebe, begegneten hier jedoch einigen Problemen. Erstens waren 
die meisten untersuchten miRNAs nicht messbar in der Gehirnflüssigkeit. Zweitens stellte 
sich mit Blut verunreinigte Gehirnflüssigkeit als unbrauchbar dar für die miRNA Analyse. 
Während der Entnahme kann Blut in die entnommene Gehirnflüssigkeit eintreten. Je mehr 
Blut eintritt umso höher ist die Konzentration einiger miRNAs. So wird das Bild verfälscht. 
Letztendlich konnten wir zwei miRNAs in einigen Gehirnflüssigkeitsproben, die mit (fast) 
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keinem Blut verunreinigt waren, identifizieren. Eine dieser beiden miRNAs (miR-146a) 
hatte eine niedrigere Konzentration bei Alzheimer-Patienten als in der Kontrollgruppe. 
Diese miRNA stellt möglicherweise ein Biomarkerkandidat für Alzheimer dar. 
In Kapitel 7 untersuchten wir vier weitere miRNAs in der Gehirnflüssigkeit von einer 
Alzheimer- und einer Kontrollgruppe. Zwei dieser miRNAs (miR-29a und miR-125b) zeigten 
eine erhöhte Konzentration bei Alzheimer-Patienten. Die Werte der miR-125b wurden bei 
der Messung nicht durch Blut beeinflusst.
Ein Nachteil der beiden beschriebenen Studien und vieler anderer miRNA-Studien in 
Gehirnflüssigkeit ist jedoch die relativ kleine Anzahl Proben in jeder Gruppe. Darum 
untersuchten wir in Kapitel 8 miRNAs miR-146a, miR-29a und miR-125b in beträchtlich 
größeren Gruppen mit Alzheimer-Patienten und Kontrollpatienten, welche wir von 
drei verschiedenen europäischen Zentren erhielten. Darüber hinaus untersuchten wir 
diese miRNAs auch bei einer Patientengruppe mit einem frühen Alzheimer-Stadium 
und in Patientengruppen mit Lewy-Body-Demenz und Frontotemporaler Demenz. Die 
niedrigeren Werte von miR-146a konnten bei Alzheimer Patienten, von welchen wir 
Proben aus unserem eigenen Krankenhaus erhalten hatten, bestätigt werden. Beim 
Kombinieren von allen Proben, konnten wir die Resultate unserer früheren Studien nicht 
replizieren, was verschiedene Gründe haben kann. So entdeckten wir unterschiedliche 
miRNA Werte zwischen den drei Zentren, was darauf weisen könnte, dass die Proben 
nicht in der gleichen Weise behandelt wurden. Beim Messen von miRNAs mit Hilfe 
von Gehirnflüssigkeit können viele Faktoren eine Rolle spielen. Basierend auf unseren 
Erfahrungen konnten wir einige Empfehlungen für weitere Studien in der Zukunft geben.
Fazit
Noch immer brauchen wir neue, bessere Biomarker, welche die Unterscheidung zwischen 
Alzheimer-Demenz und anderen Demenzformen ermöglichen. Sie werden nicht nur für 
die optimale Diagnostik, sondern auch für die Entwicklung besserer Therapien benötigt. 
Die hier beschriebenen Studien liefern einen Beitrag zur Suche nach Biomarkern für die 
Alzheimer-Krankheit.	Obwohl	wir	in	Aβ/ApoE-Komplexen	im	Serum	und	in	NrCAM	in	der	
Gehirnflüssigkeit keine neuen spezifischen Biomarker fanden, können unsere Studien 
wegweisend sein für weitere Studien. Die Erforschung von miRNAs als Biomarker steht 
noch am Anfang und mit unseren Studien konnten wir neue Einsichten gewinnen, die 
anderen Forschern bei der Entwicklung weiterer Studiendesigns hilfreich sein können. 
Eine der untersuchten miRNAs (miR-146a), für die wir niedrigere Konzentrationen bei 
Alzheimer-Patienten fanden, verdient es, noch weiter untersucht zu werden.
In der Zukunft wird die Suche nach besseren, spezifischeren Biomarkern als die bereits 
bekannten, fortgesetzt werden. Das Entwickeln von sensitiven Methoden wird dabei eine 
genau so große Rolle spielen wie das Finden von neuen Biomarkern.
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Met dit dankwoord ben ik aan het eind aangekomen van mijn proefschrift en mijn 
promotie onderzoek. Soms had ik het zelf niet voor mogelijk gehouden, maar uiteindelijk 
heb ik dit punt toch bereikt. Ik had dit natuurlijk nooit alleen voor elkaar gekregen en 
maak nu van de gelegenheid gebruik om alle mensen te bedanken, die mij hierbij hebben 
geholpen.
Marcel en Bea, jullie als mijn copromotoren wil ik als allereerste bedanken. Jullie hebben 
mij van het begin af aan begeleid en in jullie had ik begeleiders, die elkaar perfect 
aanvulden. Marcel, jou wil ik bedanken voor het faciliteren van mijn promotie en in het 
bijzonder dat je voor een verlenging van het traject zorgde, die het mij mogelijk maakte 
om alle projecten af te ronden. Jij stond altijd open voor mijn voorstellen en ideeën en 
gaf me vaak de vrije hand om nieuwe dingen uit te proberen. Ook reageerde je altijd 
snel met je commentaar, zelfs als ik een manuscript op vrijdag middag of nog snel voor 
de Kerst bij jou ging “dumpen”. Jouw opmerkingen, vaak gepaard met een dosis typisch 
“Marcelaanse” humor, vergden in het begin enige gewenning van mijn kant, maar leerde 
ik erg waarderen bij het herzien van mijn manuscripten. Jij was ook altijd geinteresseerd 
in Duitse eigenheden of het nu om een politiek onderwerp of culinaire tradities ging. 
Gelukkig was er altijd nog Udo die hielp met het uitleggen.
Bij jou, Bea, kon ik altijd met alle vragen terecht. Of het nou ging om het bespreken van 
experimenten, het invullen van formulieren, statistiek vraagstukken of het indienen van 
een artikel bij een journal, jij wist altijd raad. Met jouw onophoudend optimisme liet jij 
me toch weer mijn resultaten vanuit een net iets ander perspectief bekijken en kwam 
jij met goede ideeën voor vervolg experimenten. Met jouw oog voor detail slaagde jij 
steevast erin de laatste onvolkomenheden in mijn manuscripten te ontdekken. 
Samen stonden jullie altijd voor me klaar, kon ik altijd nog een extra overleg met jullie 
inplannen en zochten jullie nieuwe projecten voor mij als het nodig was. Ik maak daarom 
nu van de kans gebruik om het een keer goed te zeggen: Bedankt voor alles!
Michél, jij bent als mijn promotor pas in de laatste fase van mijn traject erbij gehaald en 
was inhoudelijk minder betrokken. Ik wil jou bedanken, dat jij deze taak op jou nam en 
mij in de laatste fase begeleidde door hier en daar na te vragen hoe het ging en je steun 
aan te bieden.
Als volgende wil ik al mijn oud-collega’s bedanken uit de Neurochemie onderzoeksgroep: 
Kim, Nienke, Ilona, Elisanne, Linda, Alexandra, Megan, Marijke, Anja, Tainá en Lieke. Kim 
en Alexandra, jullie heb ik gevraagd om als paranimfen op te treden tijdens mijn promotie. 
Met jou Kim ben ik zo’n beetje tegelijk begonnen aan onze promotieonderzoeken en 
hebben	 wij	 samen	 onze	 eerste	 artikel,	 een	 review	 over	 methoden	 om	 Aβ	 aggregaten	
te meten, gepubliceerd. Op alle nationale en internationale congressen, die ik bezocht 
en natuurlijk de CTMM meetings, was jij ook van de partij en uiteindelijk hielden onze 
contracten ook tegelijk op. Vaak was jij mij net iets voor, of het nou om het insturen ging 
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van het proefschrift of om het krijgen van kinderen, waardoor ik je altijd om advies kon 
vragen. 
Alexandra, jij legde de basis voor de experimenten voor de ontwikkeling van de Bio-
barcode assay. En mijn laatste project, het meten van verschillende microRNAs in een 
grote hoeveelheid samples had ik nooit tot een goed eind kunnen brengen zonder jouw 
hulp en inzet. Vanzelfsprekend ben jij daarom co-auteur voor hoofdstuk 8, dat binnen 
afzienbare tijd hopelijk gepubliceerd gaat worden. Als onze research analist kon ik altijd 
bij jou met technische vragen terecht en kwam je vaak met goede praktische suggesties 
over het opzetten en uitvoeren van een experiment. Ook hebben we samen met Linda 
nog heel wat kilometers afgelegd tijdens onze lunch-wandelingen en altijd verfrissende 
gesprekken gehad.
Kim, Megan, Elisanne en Linda, met jullie als mijn mede PhDs kon ik altijd lief en leed 
delen omtrent een promotietraject. Megan, jij bent al gepromoveerd en kon net een baan 
bemachtigen in Oxford. Veel succes daarzo! Linda en Elisanne, ik wens jullie nog veel 
succes bij het afronden van jullie promoties, het komt uiteindelijk allemaal goed!
Ilona en Nienke, de laatste fases van jullie promotie onderzoeken heb ik nog mee mogen 
maken. Fijn dat jullie ook daarna nog als postdocs bij ons op de afdeling bleven en de 
werk- en literatuurbesprekingen verrijkten met jullie ervaringen. Met jou, Ilona, kon ik 
regelmatig over microRNAs van gedachte wisselen en jij Nienke hebt me ingeleid in de 
kunst van het vriescoupe snijden en cellen kweken. Jullie waren altijd een goed voorbeeld 
voor mij. Succes in jullie (inmiddels al niet meer zo nieuwe) functies! Marijke en Anja, 
jullie waren allebei research analisten bij de neurochemie groep en werken inmiddels al 
een tijdje nu bij andere bedrijven. Ik heb aanvankelijk nog heel wat tijd met de Luminex 
doorgebracht en kon bij jou, Marijke altijd met vragen terecht. Bedankt hiervoor!
Samen hebben jullie als mijn collega’s het promotietraject gezellig een luchtig gehouden. 
De gesprekken en grapjes tijdens de pauzes en de talrijke leuke activiteiten zoals 
bijvoorbeeld de etentjes, of hier en daar een pubquiz, bowling avond, diner rouler of BBQ 
had ik nooit willen missen.
Guus, jou mag ik niet vergeten in dit lijstje te noemen. Toen jij de enige promovendus bij 
de Ijzergroep was, hebben wij jou zo’n beetje geadopteerd in onze kring en jij deed vrolijk 
bij alle activiteiten mee. 
Inge, jij bent op dezelfde dag als ik begonnen aan een promotie onderzoek in de 
Neurochemie research groep. Jammer, dat je na het eerste jaar al weer stopte en verder 
ging met een baan als research analist. Toch bedankt voor de korte maar gezellige tijd die 
we als collega’s hadden, en tevens als bestuursleden van de DCN PhD council.
Ik wil ook even alle andere (oud)leden van de DCN PhD council bedanken. Moniek L en 
Moniek M, Lu Xu, Josien, Linsey, Janita en Ruben, jullie hebben niet direct bijgedragen aan 
mijn promotietraject, maar toch was de council, onze vergaderingen en activiteiten goede 
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gelegenheden om ervaringen uit te wisselen met andere promovendi. De etentjes bij de 
Serre in Nijmegen waren altijd erg gezellig!
Bedankt ook aan mijn studenten Giovanni, Dick, Deborah en Lieke, die ik mocht begeleiden 
en die een hoop werk voor mij hebben verzet. Dick en Deborah, jullie hebben allebei aan 
de opzet van de Bio-barcode assay gewerkt. Dit vereiste nauwkeurig, tijdsintensief werk 
en volharding, die jullie wisten op te brengen en dat zo’n acht maanden lang. Uiteindelijk 
is er helaas geen assay uitgekomen die bijzonder lage concentraties eiwitten kon meten. 
Jullie werk was echter niet voor niets en jullie gecombineerde resultaten zijn terug te 
vinden in hoofdstuk 3 van dit proefschrift. Jullie zijn allebei inmiddels begonnen aan een 
promotie onderzoek en ik wens jullie hierbij nog veel succes. Lieke, jij werkte als student 
met microRNAs, en ging als een trein door jouw stage heen. Jouw bevindingen over 
microRNA expressie in CSF zijn al gepubliceerd en terug te vinden in hoofdstuk 7. Ook bij 
het opschrijven van de resultaten heb jij een grote bijdrage geleverd. In de Neurochemie 
research groep ben jij inmiddels begonnen aan jouw promotietraject en twee weken lang 
waren wij nog collega’s. Ik ben er vast van overtuigd dat je jouw promotietraject tot een 
goed einde gaat brengen.
Ook wil ik hier van de gelegenheid gebruik maken om Jan-Hendrik en Rianne te bedanken. 
Hoewel ik jullie als studenten niet direct begeleid heb, hebben jullie toch een belangrijke 
bijdrage	geleverd	in	het	experimenteel	werk	voor	de	Aβ/ApoE	ELISA	en	voor	het	ontstaan	
van hoofdstuk 4.
Next, I want to thank all co-authors on my manuscripts whom I have not mentioned yet. 
Some of them are from abroad, which is why this part is in English. I thank the co-authors 
from Italy: Lucilla Parnetti, Davide Chiasserini, Lucia Farotti and Francesca Baschieri, the 
co-authors from Belgium: Sebastiaan Engelborghs, Hanne Struyfs, Naomi De Roeck and 
Jill Luyckx and co-authors Jurgen Claassen and Benno Küsters. Thank you all for providing 
samples and the information about the samples and this way enabling my studies. Thank 
you also for all your helpful suggestions during the writing process of the manuscripts.
Naast de Neurochemie research groep wil ik natuurlijk ook de Neurochemie diagnostiek 
groep bedanken: Ria, Ben, Jacqueline en Irma. Jullie stonden altijd klaar met een 
antilichaam of een ander onderdeel voor de ELISA’s, dat ik even mocht lenen. En toen 
ik	voor	een	aantal	 samples	nog	snel	Aβ-	en	tau-metingen	nodig	had,	pasten	 jullie	deze	
meteen in jullie toch al drukke agenda’s. 
Ook wil ik alle andere medewerkers van het TML lab bedanken. De meeste tijd heb ik op 
de Q-kant doorgebracht. Mijn dank gaat naar alle analisten, stafleden en de secretaresses 
van de Q-kant voor hun hulp en uitleg als ik weer eens op zoek was naar iets of uitleg 
nodig had over de apparatuur. Op de P-kant kwam ik nog weleens voor RNA isolaties, 
qPCRs of cell-kweek experimenten. Bedankt voor alle vriendelijke hulp aldaar, in het 
bijzonder Annalies en Edwin, die mij in het begin met het opzetten van het RNA werk 
en het gebruik van de qPCR hielpen. Bijzonder bedankt ook voor de gezelligheid en alle 
leuke gesprekjes in de koffiekamer van Q, de keek-van-de-week vrijdag middagen, het 
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bespreken van films en series en het fanatiek volgen van “Boer zoekt vrouw” of “Wie 
is de mol?”. Ook de paardrij-uitjes georganiseerd door Gwendolyn waren altijd leuk. En 
met jou, Danuta, had ik vaak interessante gesprekken, waarin we de Poolse, Duitse en 
Nederlandse tradities vergeleken.
Ik wil ook de medewerkers van pathologie bedanken. Jullie hadden altijd behulpzame 
adviezen of het nu ging om cellen kweken, de Odyssey of ELISA reader gebruiken of 
weefsel snijden. Riki, jij had altijd snel toegang voor mij en mijn studenten geregeld. 
Nu wil ik nog enkele vrienden bedanken. Anthonieke, jij kwam als research analist werken 
op de afdeling, waar ik toen mijn tweede masterstage heb gedaan. Met jou bleef ik ook na 
deze stage nog veel contact houden en gingen we regelmatig wandelen in de lunch pauze. 
Bedankt voor alle fijne gesprekken. 
Nikkie, jou als mijn oud-huisgenote, maar tevens mede promovendus in het Radboudumc 
wil ik bedanken. Toen ik nog nauwelijks ervaring had met het werken met microRNAs, 
maakte jij een paar dagen vrij en liet jij me zien, hoe jullie microRNAs gingen meten. 
Ook mijn andere oud-huisgenoten, Kelly, Pleun en Laila, Matthijs en Lobke wil ik bedanken. 
Een groot deel van mijn tijd als promovendus heb ik met jullie onder een dak gewoond en 
hebben jullie mijn ups- en downs gedeeld. Bedankt voor alle gesprekken, leuke etentjes 
en de spelletjesavonden. Sinds ik met Geert naar Arnhem ben verhuisd zien we elkaar wat 
minder, maar als we weer een keer bij elkaar komen is het altijd nog even gezellig.
Ook enkele bevriende stellen wil ik bedanken: Frank en Ellen, Maus en Willeke, Michiel 
en Leonie, Jochem en Evi, Peter en Julia, Chris en Anneloes, Joris en Lizzy. Met Geert zijn 
ook jullie allemaal in mijn leven gekomen. Het is altijd supergezellig bij de verjaardagen, 
oudejaarsfeestjes, concerten, en alle andere samenkomsten. Jullie hebben altijd interesse 
getoond in wat ik doe en vragen gesteld, of zelfs een keer om “zo’n artikel” gevraagd 
(Lizzy). 
Ten slotte wil ik mijn familie bedanken, eerst in het Duits. Mama und Papa, ihr habt 
mich immer unterstützt bei wirklich allem. Ihr habt schon früh eine kleine Entdeckerin 
in mir gesehen und mir einen Chemiekasten gegeben mit dem ich meinen Forscherdrang 
ausleben konnte. Für meine Heilkräuter habt ihr mir Platz gemacht, damit ich sie im 
Garten anbauen konnte und zum Trocknen aufhängen konnte. Auch hier und da musstet 
ihr herhalten, damit ich eines meiner selbstgemachten Kräuterpräparate testen konnte. 
Mama, Gesundheit und Wohlbefinden waren auch immer schon Themen mit denen du 
dich gerne auseinander setzt. Ich kann dich dazu immer um Rat fragen. Papa, ich hätte 
dich so gerne dabei gehabt bei meiner Disputation, aber es sollte nicht sein. Du bist viel 
zu früh von uns gegangen. Doch will ich vor allem auch dir bedanken für deine Weisheit, 
dein Vertrauen und deine Ratschläge, die mich mein ganzes Leben begleitet haben und 
immer noch begleiten. 
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Susan, Katja und Jürgen, danke für euer Interesse in meine Arbeit und alle Fragen, die 
ihr gestellt habt. Susan, du hast mir bei der Arbeit auch mal über die Schulter geschaut 
um dir ein genaueres Bild zu machen, was ein Forscher den ganzen Tag lang so treibt. 
Und besonderen Dank, dass du dein künstlerisches Talent beim Gestalten des Umschlags 
eingesetzt hast. Katja, mit dir als Psychologin konnte ich mich ab und zu austauschen. 
Danke auch für das Überprüfen all meiner deutschen Texte, die dich hoffentlich nicht 
zu viel zum Schmunzeln gebracht haben (Immerhin weiss ich jetzt auch, dass man “CSF-
samples” besser nicht mit “Gehirnflüssigkeitsmonster” übersetzen sollte). Jürgen, danke 
auch, dass ich dir meine Fragen über Statistik vorlegen durfte. 
Ook mijn Nederlandse familie wil ik bedanken. Bedankt, Ans en Jan, dat jullie elke week 
van Merselo naar Arnhem kwamen om op jullie kleinzoon te passen. Vooral ook in die tijd, 
waarin ik alleen nog aan het schrijven van mijn proefschrift was, hebben jullie mij zo de 
handen vrij gehouden. Ik ben blij dat jullie mijn schoonouders zijn.
Geert en Jorre, als allerlaatste wil ik jullie bedanken. Geert, bedankt voor je 
onvoorwaardelijke liefde, je begrip en je absolute steun. Met mijn computer-frustraties 
kan ik altijd bij jou terecht en jij hebt ze zo opgelost. Tijdens mijn promotie onderzoek 
en vooral tijdens het schrijven hebben jij en Jorre altijd voor de nodige afleiding gezorgd. 
Jorre, jij bent mijn zonnetje, jij maakt me elke dag honderd keer aan het lachen en jij geeft 
mijn werk een heel nieuwe zin. Jullie maken mijn leven compleet.
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